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ABSTRACT 
 This thesis is divided into two sections.  The first section focuses on 
developing a better method for the detection of C - reactive protein (CRP) from whole 
blood.  CRP plays a key role in determining the risks associated with various 
cardiovascular diseases.  However, detecting this protein is a challenge since it 
accounts for < 1% of all known blood proteins.  This protein can be detected by using 
a sandwich ELISA inside of a microfluidic chip made from Polydimethyl Siloxane 
(PDMS).  PDMS chips are created that will first remove blood cells and platelets from 
whole blood.   For the removal of blood cells, different filter papers that specialize in 
blood separation are tested based on the volume of filtrate recovered, amount of blood 
cells filtered out and whether the cells rupture or not.  From these tests, it was 
determined that the Vivid Plasma Membranes GX and GR from the Pall Company was 
the most suitable filter based on blood cell removal and quality of filtrate.   
 To further compliment this, these chips need to extract high abundance plasma 
proteins (HAP) including human IgG antibody and human serum albumin.  These 
experiments focused on using protein A as a method for the removal of IgG due to its 
high affinity with the antibody.  This will be then coupled with IgG that has been pre-
attached to Protein A specifically modified to attach to Human Albumin.  Experiments 
were conducted in order to obtain the appropriate incubation time needed for removal 
of antibody/protein as well as the effects on surface concentration and amount of 
incubation reservoirs.  The final step was to combine these two aspects in order to 
create a microfluidic chip that accurately detects CRP by filtering out blood cells and 
removing high abundance proteins.  This resulted in a microfluidic chip that was able 
  
to detect CRP from whole blood while filtering out blood cells and removing the bulk 
of the high abundant plasma proteins in order to obtain a high signal.  This was 
performed by the addition of multiple incubation areas for high abundance protein 
removal embedded on the chip.  Detection was carried out via fiber optic cables and a 
standard curve was created that associated a specific CRP blood concentration to an 
intensity found via fiber optics.  By use of this method, a correlation between the 
concentration of CRP in a sample of blood, as well as a limit of detection for the 
system could be obtained. 
 The second section focuses on identifying an antibody fragment as a bio-
marker against tau protein.  Tau protein is a known to play a role in the development 
of Alzheimer's disease.  This is due to the rapid addition of multiple phosphate groups 
attaching to the protein.  This section focuses on the identification of antibody 
fragments that detect a normal form of tau and one affected by the addition of 
phosphate groups.  These fragments are recombinant antibody fragments created via 
phage display.  Antibody phage is inserted into a well, in which the phage that is able 
to bind to tau will bind to it.  These phages are then injected into an E. coli culture 
which will produce antibodies known as single-chain variable fragments (scFvs). 
These antibodies are extracted and tested on whether or not they attach to the specific 
tau antigens.  After performing these experiments, two scFvs have been found that 
attach to both forms of tau: one with phosphate groups and one without.  Titration 
curves and DNA sequences for both antibodies were also created.  With these 
antibodies, they can be used as an effective biomarker into the early treatment of 
Alzheimer's disease.
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SECTION 1 
 
DETECTION OF C REACTIVE PROTEIN IN WHOLE BLOOD 
 
CHAPTER 1 
 
INTRODUCTION 
 
In previous years, in order to effectively detect a disease or a serious condition, 
a large sample would have to be extracted and sent into a laboratory.  From there, 
numerous experiments that would take days, even weeks to complete would have to be 
performed.  Not only was this work time consuming, but it also could mean the 
difference between life and death to a certain individual.  Today, testing can be 
performed with small chips and paper-based cartridges with little fluids required.  This 
is a breakthrough in detecting and treating certain diseases and ailments.  This is what 
is known as Lab-on-a-Chip (LOC).  In LOC experiments, large scale experiments are 
performed on the small scale with small volumes of sample and reagent, is not only 
found in current research, but used in practical applications
[1,2]
.  This can be beneficial 
in rapid detection and care of various ailments.  One such ailment is heart disease
[3]
. 
There are various factors that can cause heart disease which include high cholesterol
[4]
. 
However, one important compound is C - reactive protein (CRP).  CRP is found in the 
blood and is a factor in determining whether or not an individual can be affected by 
heart problems
[5]
.  If a certain sample has a level of CRP that is over a certain amount, 
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then this individual would be susceptible to heart disease.  Currently, those same 
laboratory methods are used to detect CRP, which include extraction of a good amount 
of blood and waiting at least a few days for results
[6]
.  The following project will focus 
on these aspects of LOC’s in order to better detect CRP. 
1.1.  Lab on a Chip 
In the previous decade, there has been an effort to make the detection and 
treatment of diseases and ailments easier and faster. Currently, the best methods to 
detect diseases are in laboratories with expensive equipment
[6]
. There are various 
issues that do come up when performing these experiments.  First of all, bulky 
equipment is used and a lot of it can be pretty expensive to buy and/or repair. Second, 
with this large equipment, it can be certain that large amounts of sample and or 
reagent have to be used. This amount can be in the area of a few milliliters. The third 
issue is the time needed to perform each experiment. These tests can last for a few 
weeks if needed. Because of these issues, a new method needs to be addressed. 
Basically, a system for detection has to be designed, that not only is light and portable, 
but must also be fast in detection and must take as little fluid as possible. 
Currently, there is a new method of detecting ailments with all of these points 
in mind called Lab-on-a-Chip, or LOC for short. LOC essentially takes experiments 
that can only be done in labs and miniaturizes them onto a small chip
[1,2]
. Because of 
this, all the reagents used would have to be enough to be present in the chip, 
preferably in the microliter range. In addition to all of this, because of the smaller 
volumes of liquid, the time needed to perform these experiments is greatly reduced. 
This allows for better detection that most people can do in a relatively short amount of 
3 
 
time. This is beneficial not only for home testing, but also for allowing testing to be 
performed in under-developed countries, where access to top of the line health care is 
all but non-existent
[7]
.  
Because LOC devices are relatively new, there are a limited amount of 
technological advances that are widely known. The most known system to use all 
three of these properties (miniaturization laboratory equipment, small sample and 
reagent size and quicker reaction times) are glucose meters. These meters measure the 
amount of glucose that is found in the blood
[8,9]
. Other examples of these include 
pregnancy tests
[10]
 and disease testing kits that range from strep throat
[10]
 all the way to 
HIV
[11]
. These devices prove to be beneficial in the determination of something that 
does not need a large scale laboratory or a large amount of time to complete. 
How can each of those three aspects create a better system for detecting 
diseases and ailments?  Here, each aspect can be looked at one at a time. The first 
aspect is the amount of equipment. As stated previously, the detection of most 
antigens are performed in huge laboratories with numerous large and expensive 
equipment
[6]
. With LOC, chips are created using inexpensive materials (polymers and 
paper, as a few examples)
[3]
. These chips include all of the reagents and detection 
areas that are needed for the experiment to be performed
[8]
. Also, platforms can be 
made that are either portable or hand held, eliminating the need for a laboratory
[8]
. 
The second aspect involves using as little reagent and sample as possible. In 
laboratories, it is common to use milliliters of sample and reagent to perform 
experiments
[6]
. But in LOC applications, the amount of fluid used is in the microliter 
range
[8]
. Even in ELISA (enzyme linked immunosorbent assay) experiments, which 
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will be explained later, the total amount of liquid used in each experiment could be 
upwards to around 1 liter
[12]
. But in LOC experiments, with the exception of a sample, 
the majority of the fluid is in the chip. And with the chip being as small as possible, 
the amount of fluid can amount to less than 10 milliliters
[1,8]
. The third aspect involves 
time. In normal laboratory settings, with the previous two aspects, these experiments 
can take upwards to a few days to complete. With LOC processes, these same 
experiments can be done in the matter of an hour or less with comparable results. For 
these reasons, it can be seen that LOC technology is a novel idea as a better way to 
detect diseases and ailments. 
One source of interest with LOC devices is the method of detection of various 
pathogens in blood. Since there are about 4.7 – 5.5 liters of blood in the body and it 
reaches virtually every place in the body carrying oxygen, carbon dioxide and 
nutrients, it is one of the body's most essential fluids
[13]
. There are thousands upon 
thousands of different proteins and pathogens that can be found in blood, some of 
which can be dangerous for people. There have been numerous methods to use LOC to 
detect these antigens, but one of the problems with using LOC devices with blood is 
that the makeup of blood is very complex
[14]
. Plus, with the small amount of liquid 
used in LOC, it becomes difficult to separate the antigen that is desired from all the 
other components in blood
[14]
. In order to see how complex blood is and the problem 
associated with it, the upcoming sections will explain the composition of blood with 
comparison to C-reactive protein. 
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1.2. Detection of C-Reactive Protein in Blood 
Since CRP is normally found in blood, one of the issues concerning the 
detection of CRP on LOC is the amount of interference caused by other components in 
the blood. These components not only include large particles, including blood cells 
(both red and white) and platelets, but also smaller particles, including various blood 
proteins and antibodies
[14]
. Because LOC applications require the use of minute 
amounts of reagents (up to 1 mL), traditional blood plasma separation, which include 
centrifugation is not applicable. Also, it should also be noted that because of the need 
to these applications to be portable and compact, an on-site separator also has to be 
incorporated onto the chip. Because of these reasons, a direct blood plasma separator 
has to be integrated onto the chip
[15-17]
.  In the upcoming sections, different methods of 
blood separation will be explained and checked in order to see if it is feasible to 
integrate these systems onto an LOC device. 
One other issue is in the plasma itself. CRP is only one of thousands of 
proteins found in blood and these proteins can cause interference with detecting 
CRP
[18]
. Because of this, a method to extract a good amount of proteins before 
detection has to be implemented inside of the chip.  This can be performed by 
incorporating the various channels that transfer the plasma from the cell separator to 
the detection site
[14]
. Using the channels, these proteins have to be removed before 
they enter the detection area. There are different methods which can be performed to 
accomplish this. These will be explained in the upcoming sections.  
One other point to get across is that there are many methods to detect CRP in 
blood, including different methods based on LOC concepts
[19,20]
. This project will take 
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a look at these different concepts and compare them to how well they can be 
performed. With all of these concepts, a newer and better method to detect CRP in 
blood on a chip will be tested. 
1.3. Removal of Cells and High Abundance Proteins 
As previously stated in section 1.2, one of the issues that surround the 
capturing of CRP is because of the fact that it is normally found in blood
[6]
.  This 
causes a lot of issues because of the amount of other abundant objects in blood
[18]
.  
These objects of important not only are of concern on the micro scale (red and white 
blood cells, platelets), but also on the nanoscale (plasma proteins).  These objects are 
able to cause all types of obstruction when they are placed in a detection area that 
would be used to capture CRP.  Because of this problem, it is essential to remove 
these aspects in order to obtain a reliable result. 
Starting from whole blood, it is ideal to remove the blood cells and the 
platelets first
[17]
.  The reason for this being that it is easier to remove larger objects, 
(cells, platelets), compared to the proteins.  Since the cells are noticeably larger, they 
do tend to interfere with the signal the most.  This can be done either by intentionally 
blocking the receptors, or by accidental removing of whatever is supposed to bind to 
CRP, or whatever antigen is being detected.  There are numerous methods to separate 
blood cells from plasma, but most involve using large devices and sample amounts
[21]
.  
In terms with LOC applications, especially if it is being used in a non-laboratory 
setting, it would be ideal to use only a minute amount of blood and basically separate 
it on a chip.  There have been projects in the past that have focused on using filter 
paper as that medium because of its flexibility to be in any shape and size, its low cost 
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and with most papers, its effectiveness in separating blood cells from plasma
[16,17]
.  
This project will integrate this method of using filter paper for blood plasma 
separation. 
The other obstacle in this project is the amount of proteins found in plasma
[18]
.  
There are hundreds of plasma proteins at varying concentrations.  One of the issues 
surrounding this is that like blood cells, these proteins are still able to cause 
interference within the detection area.  Because of this, like the blood cells, they have 
to be removed in order for CRP to be fully detected.  However, because of their small 
size and that this has to be performed in the chip before detection and after blood cell 
separation, current methods of protein removal, which can include centrifugation
[21]
, 
cannot be applicable.  Instead, there have been studies, including former 
investigations
[22-24]
, which use antibodies on surfaces, like an ELISA
[12]
 (Enzyme-
Linked Immunosorbent Assay) that can capture these various proteins.  This project 
will focus on these principles in order to effectively remove these high abundance 
proteins (HAP). 
1.4. Objective 
 The objective of this investigation is to create and improve on a LOC process 
that would better detect C - reactive protein in blood.  This project will be in 
cooperation with previous projects that have been used to begin to detect CRP
[22-24]
.  
These projects include a better method to filter blood cells, capture HAPs in 
blood/serum that can cause interference and use these two methods to implement a 
system to detect CRP onto a chip design that was previously used in a few other 
projects. 
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 The first part of the project is to find a better way to filter blood cells.  This is 
important since they consist of the largest objects in blood and take up the largest 
amount of space.  There have been previous methods in which to extract plasma from 
blood into a microchip
[23,24]
, but a lot of projects do not go into a lot of detail that 
explains the need to better filter blood.  These reasons include the amount of force it 
takes to extract blood into a channel, how much plasma can be extracted from filter 
papers and if the paper is sturdy enough to withstand not only the amount of blood 
cells on it, but also the force required to effectively extract plasma without ruining the 
filter.  For this, there will be research performed that will determine the quality of the 
filter paper that will be used for the microchip. 
 The second part of the project is to find a better method of HAP removal.  Like 
the above section, there have been attempts to effectively remove these proteins
[23,24]
.  
However, as will be explained in Chapter 2, there are flaws with these methods.  This 
is based on the amount of proteins in plasma and how they can affect the detection 
area.  This is not only because of the amount of the different types of proteins, but 
rather the amount the most abundant proteins in blood plasma: human serum albumin, 
and human immunoglobulin antibody G.  These two proteins account for more than 
75% of all the total proteins in blood
[18,28]
.  Because of this, which will be explained in 
the upcoming sections, a better method of antibody removal must be performed. 
 The final part will be to put both parts together in order to better a currently 
proposed method for CRP detection in whole blood.  With these two parts formed into 
one, actual CRP tests in blood can be performed.  In the previous projects, most 
experiments were not performed with whole blood because of special procedures and 
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the uncertainty of the amount of proteins in a certain sample.  Most projects either 
relied on a buffer solution with CRP in it, or serum with CRP.  Because of this, one 
could not say whether or not it could be performed with blood.  One reason is that 
serum does not contain fibrinogen, a protein known for clotting, whereas plasma does.  
Also, the previous filter effects have to come into play.  It has to be certain that only 
plasma can go into the channel, and not either blood cells or hemoglobin, caused by 
hemolysis, or blood cell rupturing.  These factors have to come into play, in order for 
this project to be successful. 
 Lab-on-a-Chip is a novel idea, where a person can perform diagnostic checks 
without the use of a laboratory and a large amount of sample and/or reagent.  But the 
above topics have to be addressed in order to make certain that it can be justified that 
blood can be used for LOC applications.  Due to the amount of blood cells and the 
amount of plasma proteins, these have to be removed first hand in order to be able to 
detect CRP, a known protein that is linked to cardiovascular disease.  With this in 
place, a better method of detecting CRP on a microfluidic chip can be performed. 
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CHAPTER 2 
 
REVIEW OF LITERATURE 
 
 2.1. Types of Lab on a Chip Applications 
The first known instance of Lab-on-a-Chip (LOC) was in the December 1979 
issue of Electron Devices, where a miniature gas analysis system was implemented on 
silicon using photolithography and chemical etching
[1]
.  This was a system used for 
gas chromatography and used to detect and separate various hydrocarbon mixtures
[1]
.  
However, there has been an increased interest in microfluidics starting in the mid to 
late 1990’s[2].  One of the earliest known examples of LOC technology was a project 
between the years 1999-2003 at Delft University in the Netherlands where a microchip 
was created that allowed for the analysis of different bioprocesses (i.e. 
fermentation)
[2]
.  These microchips was created by using glass and used silicon and 
glass etching in order to create the channels to allow fluid inside the chip. 
One other application for LOC systems is for testing the quality of certain 
fluids (urine, semen, blood, water, etc…).  By allowing these measurements, one 
could find out how healthy a certain environment is.  For example, a biochip has been 
developed by Siemens that would be able to test the quality of water
[25]
.  This test 
would be able to detect certain hormones, antibiotics, bacteria and pesticides.  The unit 
is roughly the size of a laptop computer and can be able to identify up to 25 known 
substances in a 30 minute timespan.  This biochip is covered with surface antibodies 
that react to corresponding substances contained in the sample liquid.  This is followed 
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by an electrochemical reaction which emits a signal.  With this technology, it would 
be beneficial to any industry that handles wastewater on a regular basis (water 
treatment plants, hospitals, and even living conditions with horrible drinking water)
[25]
. 
However, the most common application of LOCs is in the use of medical 
diagnostics.  In recent years, there has been a rise in the amount of the need of portable 
diagnostic equipment that is easy to use with accurate results.  One option that helps 
with LOC devices is the integration with point of care testing (POCT).  POCT is 
testing that is performed at or near the site of where a patient is located.  These tests 
are important as that they can give direct results to the patient at his or her precise 
location
[26]
.  This is both beneficial to the doctor and the patient where that the results 
for any diagnostic test can be fast and immediate.  Also, since the tests are performed 
with the patient at the doctor’s side, there is no need of a laboratory in order to obtain 
results.  There are many types of POCTs that are currently in use.  Some of the most 
common tests that require POCTs include testing for pregnancy, the amount of blood 
glucose, testing for strep throat and influenza via the throat
[10,26]
.  These are only a few 
of the tests that POCTs can deliver. 
However, with the advances in medical diagnostics, there is a greater need to 
deliver POCT as a method of detecting different conditions and diseases.  This is 
extremely beneficial in home care, doctors working on site and in places where 
modern medical facilities are not readily available.  One such use for POCT that has 
been on the rise is the use of analyzing blood.  Blood contains numerous amounts of 
proteins, viruses and compounds that that serve a specific function within the human 
body
[27,28]
.  One of the first POCT devices that incorporate LOC technology are 
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glucose meters.  Here, a small amount of blood is drawn from the body and sent up a 
wick coated in glucose oxidase, which is an enzyme that reacts to the glucose found in 
the blood sample
[8,29]
.  An electrical current then interacts with the glucose reaction, 
which then generates a signal.  This signal then is read as a value that corresponds to a 
glucose concentration in blood.  The higher the signal, the higher the number
[29]
.   This 
allows clear, quick and accurate results for people who suffer from diabetes, in order 
to make sure that their glucose levels are either healthy or not
[8,29]
.  This is only one 
example of an LOC device which is a good POCT tool for blood testing. 
Other examples of POCT for LOC devices that uses blood include various 
chips that are able to detect a whole plethora of proteins and ailments
[30-33]
.  These 
include a device that uses an LED to detect proteins and viruses fixed to a gold 
plate
[30,31]
 and a device that could detect conditions that include HIV and diabetes
[32]
.  
In the example of the LED and nanoparticles, proteins and antibodies are fixed on an 
array and a blood sample is passed over it.  After incubation, a gold plate with holes 
on it goes over the sample and light is emitted from an LED through the holes and 
onto the sample.  An imager detects the emitted and reconstruct the image of the 
detected chip into intensity values
[31]
.  One final example is a chip which separates 
blood cells and analyses the properties of the separated cells
[33]
.  These examples of 
POCT chips which use LOC technology are useful in that different viruses and 
proteins and can be extracted and analyzed.  With this technology, it will not be long 
until these detection values will have a correlation to how much of an extent a person 
has a certain ailment.  However, one thing in common with these LOC devices is not 
only that blood is used, but also that blood cells have to be separated from plasma in 
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order to obtain accurate results.  The next section will explain the makeup of whole 
blood, why separation is an issue and what types of separation are there. 
 2.2. Whole Blood Makeup 
 
Figure 2-1: Makeup of whole blood
[27] 
In the human body, there are many factions that contribute to the makeup of 
whole blood. The first includes red and white blood cells and platelets. These three 
components are the biggest objects that can be found in blood. Red blood cells 
transport nutrients and oxygen to the muscles of the body, while also transporting 
carbon dioxide to the lungs and waste to the kidneys. They account for 45% of the 
total volume of blood. White blood cells are part of the body's immune system, which 
fight off foreign pathogens and platelets are used for blood clotting when the blood 
canal is ruptured in order to prevent blood from escaping the canal. Both of them 
account for < 1% consists of the volume of blood. The remaining 55% is known as 
plasma. Plasma consists of water and all the proteins that are common in blood. With 
the absence of the protein fibrinogen, which aides platelets with clotting, this fluid is 
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called serum
[18,27,44]
.  Figure 2-1 shows a comparison as to how the makeup of whole 
blood is constructed. 
The issue with blood in an LOC process is that these three components can 
interfere with any detection signal when a certain antigen is to be obtained. This is due 
to the large size and abundance of the cells. Most proteins have an average diameter 
size of 200-400 µm, while blood cells as a comparison have a diameter of 6-8 
µm
[18,44]
.  In any experiment in which blood is used, it will cause interference in any 
type of detection because of its size. These cells could both act as a barrier and block 
certain antigens from being detected or if there is a method of detection already in 
place in the chip, it could effectively remove that area of detection. Either way, 
because of this disruption, it will be necessary to remove said blood cells and platelets 
before the blood goes into the chip.  The following section will explain the various 
methods of blood filtration and plasma separation. 
2.3. Methods of Blood Cell Separation 
2.3.1. Blood Centrifugation 
The most common method for blood cell removal and plasma separation is 
centrifugation. This involves taking a vile of blood and placing it inside of a 
centrifuge. Using centripetal force, the centrifuge spins around at a high RPM and the 
cells head towards the bottom of the vial. After about 20 to 30 minutes, a vial that 
appears to be red now has three visible layers: a bottom red layer showing the cells, a 
small middle layer containing platelets and a clear, almost tan layer containing plasma 
or with EDTA, serum
[21]
.  Figure 2-2 on the next page shows two vials with blood 
inside of them.  The right vial is normal blood without any separation of blood cells 
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occurring.  The left vial is blood that has underwent centrifugation.  Notice the two 
distinct layers; while the third layer, the platelets, are not shown due to the amount and 
size of them in blood.  The bottom of the vial contains all of the blood cells, both red 
and white, while the top tannish translucent liquid is blood plasma after the removal of 
blood cells.  
 
Figure 2-2:  Blood separation via centrifugation (left vial) compared to whole blood 
without separation (right vial) 
 
While centrifugation is an ideal method to separate blood cells effectively, it is not an 
ideal method of blood separation to use in POCT with an emphasis on LOC 
technology.  The main reason for this being that external equipment has to be used.  In 
this case, a centrifuge has to be used.   With LOCs and POCTs, it is imperative that all 
experiments are performed on the chip.  This should include any blood separation 
processes where the testing can be performed outside of the laboratory.  Since a 
16 
 
centrifuge is normally not included on or in an application involving LOC and that 
most centrifuges can be big and bulky, this method is not applicable with this type of 
process.  Also, the amount blood required to be separated is greater than what is 
required in LOC applications.  In order to effectively see any separation, at least 1 mL 
of blood has to be sufficient in order to see this separation of plasma and cells.  One 
could use less blood, however for most experiments that use blood centrifugation; at 
least 1 mL is required in order to effectively separate blood.  The most effective 
method to separate plasma from blood would be to perform this inside of the chip 
itself. 
2.3.2.  Lab on a Chip Methods 
Currently, there are numerous methods for the separation of plasma from 
whole blood with volumes less than 1 mL on LOC devices. One of these methods 
involves a process known as dielectrophoresis.  “Dielectrophoresis (DEP) is a 
technique to handle neutral particles in liquid medium using polarization of particles 
and medium in an inhomogeneous electric field,” according to Nahashima[34].   This 
means that a force is placed upon a particle, in this case blood cells, and moves them 
when exposed to an electric field.  In this article, blood is inserted inside of the chip 
and an electric current is run through the chip, which separates the cells from the 
plasma.  This is performed by placing electrodes on one side of the chip and 
connecting it to an electric current.  As soon as a voltage is applied, the cells move 
towards the electrodes and plasma is extracted through small channels into a small 
reservoir. The result of this being fully separated plasma without the rupturing of 
blood cells
[34]
.  Even though this is a good system for LOC applications, it cannot be 
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useful for POCT diagnostics.  For one reason, this system relies on an outside electric 
current in order to separate the cells.  This defeats the purpose of having the system 
portable and helpful in on site diagnosis.  Also, because of the electrodes, it is rather 
difficult to integrate it with a system that also accounts for CRP detection.  There are 
too many electrical parts this can cause interference with the detection system due to 
the electric field.  One other constraint is that during the fabrication of the chip, the 
electrodes have to be fabricated inside of the chip.  These are gold electrodes that must 
be between glass and epoxy before blood is inserted
[34]
.  This creates a problem in that 
the chips are more expensive to make because of the electrodes.  For this reason, other 
methods for blood plasma separation have to be considered.   
One other method that can be considered when trying to filter blood in a 
microchip is by building tiny micro structures embedded inside of the chip that can 
help separate the blood cells
[35]
. Based on the research performed by Shim, a 
microfluidic chip was created in order to separate blood cells from plasma using tiny 
microstructures and packed beads in the chip
[35]
.  Like the previous example, small 
channels were etched inside of the chip, but this example does not require the use of 
electrodes to separate the chip.  Instead, small channels were created inside of the chip 
complete with fluid beds to hold the blood in the chip for filtering.  These beds were 
filled with packed beads which created spacing just large enough for plasma to travel 
through, but not the blood cells.  Movement throughout the chip was performed by 
capillary action in the chip, where the plasma would seek and fill the open spaces 
caused by the beads.  Plasma was then extracted by way of an opening where air could 
be pumped into the chip and forces the plasma out of the chip
[35]
.    
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Even though this is a possible method of blood cell removal, in terms of this 
project, it is not a viable method to remove blood cells.  The reasoning for this is the 
fabrication, or building, of the microchip.  According to Shim, a nickel plate had to be 
coated with a photoresist in order to create the molds.  These molds were formed by 
exposing the photoresist under UV light and then developing the molds
[35]
.  One of the 
experiments on mold creation involves this method, but the technology provided by 
the laboratory does not allow the formation of these particular channels.  This is due to 
the fact that in order to create narrow channels, the UV light source in this experiment 
has to be focused and direct in creating these channels.  A broad UV light source can 
cause errors in creating the channel shape by making the channel widths wider than 
what it should be
[22]
.  This will be explained in further detail in chapter 3.  Also, 
because of the extra step in that beads have to be used; there still can be gaps in which 
blood cells can escape.  Because of these reasons, this method of blood filtration is not 
feasible for this thesis project. 
Other methods of blood cell separation include hydrophoretic filtration, in 
which high structures inside of the chip inhibit blood cells from passing through
[36]
, 
planar microfilters
[37]
, microfilters with agarose gel
[38]
, which does not use external 
forces to remove blood, devices that require cross-flow filtration
[39]
 and ones that 
utilize the Zweifach-Fung effect, (where particles tend to migrate to an area of a 
higher flow rate when approaching a fork in the channel)
[40,41]
, which uses more 
external forces upon the blood.  Again some of the problems with these devices are the 
amount of time, energy and cost to create and the issues of implementation onto a 
LOC system.  However, with the examples that do not require external forces to 
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separate blood cells, this becomes more difficult as a way to extract plasma is needed.  
Because of this, there has to be a simpler way to not only remove blood cells, but also 
extract plasma into the microchip. 
In order to incorporate blood filtration in a microfluidic chip for use in a POCT 
device, it not only has to be cost effective in monetary value and labor, but it also must 
be easy to set up and integrate without external factors.  For this reason, one of the 
most effective methods is to use blood filters or membranes that can effectively 
separate blood cells from plasma. Filters/membranes are a more logical solution 
because of its availability, ease of use and cost. In addition, since the filtration is to be 
included in the microchip, the filters can be altered so that it is small enough to either 
fit inside or on top of the microchip. However, one does have to look out for the 
possibility of potential blockage in the filter paper based on the size of the blood cells 
compared to the pores embedded on the paper
[42]
.  Despite this disadvantage, the 
restructuring of the chip to encompass the filter will be minimal. Because of the idea 
of filter paper, the user will be able to handle smaller quantities of blood (up to 100 
µL) and eliminates the need for a centrifuge. Unlike previous Lab-on-Chip methods 
that involve small microchannels which filter blood, to include that and have the 
experiments on the same chip will require a larger chip altogether. This would require 
a redesign of the device that performs the immunoassay in order to adapt to the 
changes in the chip design. Because of these reasons, it would be beneficial in 
incorporate filter paper as part of the blood – separation process. 
Since there are numerous blood filters, it would be essential to test as to how 
well each one will fair. While some filters are just a simple filter, others are more 
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complex based on its mechanics and how effectively it can filter out blood cells. For 
this reason, two separate tests will be conducted for the effectiveness of the filters: a 
filtrate volume test, a blood cell characterization test. 
2.4. Plasma Makeup and Protein Removal 
One other concern deals with what happens after the plasma fully separates 
from the blood cells. This concern deals with the makeup of the plasma. Currently, 
there are thousands of known proteins and antibodies in plasma
[45]
, most of which 
again interfere with whatever the method of detection system is used. The amount of 
these proteins in blood is usually around 8% of the volume of plasma, while the 
remaining 92% is water, with dissolved materials which include glucose, vitamins, 
minerals, carbon dioxide and urea
[43]
.  While there are hundreds upon hundreds of 
proteins that are known to cause interference, three main proteins usually cause the 
most interference. The first important protein is fibrinogen, which explained in the 
previous section, is the cause of blood clotting along with platelets
[18,44]
. It is a long 
protein that has an approximate length of 45 nm and it is composed of multiple peptide 
chains which link together and form this long protein
[44]
.  Compared to the other 
proteins that will be mentioned later on, fibrinogen can cause interference with 
detecting antigens in blood.  Even though the amount of fibrinogen in blood is low 
compared to other proteins (4-7% of total plasma proteins)
[44,45]
, they could still be a 
factor in obstruction due to their size and ability to form clots.   However, most of the 
LOC experiments rely more on blood serum. Serum is essentially blood plasma but 
without any fibrinogen. Because it does not contain fibrinogen, serum will not easily 
coagulate when outside of the blood canal. Despite this, there is still an issue with 
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serum due to two other proteins, known as high abundance proteins (HAP): human 
albumin and human immunoglobulin antibody. 
Albumin makes up roughly 50 - 60% of the total amount of proteins in plasma, 
making it the most abundant protein in blood
[28,45]
. Because of the abundance of 
albumin, it does not allow the majority specific proteins to be easily detectable. In 
short, albumin acts as a barrier that does not allow antigens to be detected easily. 
Natural occurring antibodies, known as immunoglobulin, which comprise of a group 
of proteins known as the globulins, which account for 20 – 30% of the total proteins in 
the body
[28,45]
. These antibodies come in various forms including immunoglobulin A 
(IgA). Immunoglobulin B (IgB), immunoglobulin E (IgE), immunoglobulin G (IgG) 
and immunoglobulin M (IgM). The most abundant of these antibodies would be 
human IgG
[45]
. There are two factors that rise with IgG is a factor when dealing with 
assays that require blood. The first of which is their size. Antibodies are normally 
larger in size than most proteins, which, like albumin and fibrinogen, represent a 
barrier against and sort of detection. The second factor arises in that in many assay, 
other known antibodies are used to detect specific antigens.  This will be explained 
later, but in short, human IgG can force these antibodies out of position, causing a 
false signal in the detection area. Because of these two aspects, it would be ideal to 
remove them before any detection happens. But since the aforementioned blood cells 
also have to be removed and are bigger, it would be easier to remove these proteins 
after the removal of the cells.  Table 2-2 explains the three different types of HAPs 
and the average amounts in plasma. 
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Table 2-1: Ranges of the amount of high abundance proteins in blood
[28,44,45] 
In laboratory applications, there are various methods to fully separate and 
remove these proteins.  The most common methods are via precipitation
[46]
 and 
ultracentrifugation
[47]
.  Precipitation involves the use of a chemical (trichloroacetic 
acid, acetone, ethanol, etc) in order to aggregate certain proteins can clump them 
together
[46]
.  This process requires the use of a centrifuge in order to force this 
sediment down to the bottom.  Another method, known as ultracentrifugation, requires 
no chemicals, but still relies on a high-powered centrifuge in order to effectively 
separate and remove proteins
[47]
.  These proteins can be extracted via drying of the 
precipitate, or extraction of the supernatant (liquid).  While this method is shown to 
work, there are two drawbacks to these methods.  First, with a centrifuge, the use of 
performing all the experiments on a chip would be useless, since protein extraction 
must be performed before the serum is in the chip.  Also, with precipitation, some 
chemicals are not as selective in the precipitation of proteins.  This means that all 
available proteins could be in the precipitate, which can cause problems which 
detection.  Because of this, a method of HAP removal has to be utilized inside of the 
chip and is selective only to those HAPs. 
To help further explain the reasoning behind the removal of blood cells and 
these abundant proteins, it would be helpful to talk about a protein that is normally 
found in the bloodstream. This protein is far less abundant in blood than that of 
Type of Protein Concentration in Blood 
(mg/mL) 
Percentage of Plasma 
Proteins 
Albumin 40 - 45  50 – 60% 
Globulins  20 - 25 20 - 35% 
Fibrinogen  2 - 4 4 - 7% 
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albumin and human IgG. Also, this protein is regarded to have a link to various 
cardiovascular diseases, diabetes and liver failure. This essential protein is known 
commonly as C - reactive protein
[6,48]
. 
2.5.   About C-Reactive Protein 
C - reactive protein (CRP) is a ring-shaped protein that is found in the blood 
stream. This is a protein that is used in immune system of the human body. Its role is 
to bind to the surface of infarcted, or dead, cells and bacteria and alert components in 
the immune system, including macrophages, which in turn, clear these cells. Because 
of this property and their role in the body, CRP is normally used as an inflammation 
marker
[49]
. CRP is synthesized in the liver and travels down the blood stream in search 
of inflamed areas
[49,50]
. The first mention of CRP came from William Tillett and 
Thomas Francis in 1930 as a pathogen because of its appearance in various 
cancers
[49,50]
.  The CRP protein structure consists is of pentagonal shape consisting of 
5 monomers with an average weight of 25.106 kDa per monomer (total weight: 125.53 
kDa) and has 224 amino acids in its monomer structure
[49]
. 
In a laboratory setting, CRP is used as inflammation marker for the 
determination of patients that are susceptible of different ailments. For a long time, it 
was determined that there was a link between CRP and various cancers, including 
colon cancer. However, many studies have shown that CRP is only known to 
determine whether a patient has a risk of developing cancer, rather than whether a 
patient is at risk of cancer
[50]
. In recent years however, a link has been found between 
CRP and cardiovascular disease. This was shown with patients with high blood 
cholesterol content in blood, which can lead to coronary heart disease
[49,50]
. However, 
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since CRP levels can increase with any type of inflammation, it is not very specific in 
terms on the immediate risks of cardiovascular disease.  However, it can be shown that 
there is a link between the two based on sample size and amount of tests performed. 
In blood serum, the amount of CRP varies with the individual; however there 
are CRP levels that exhibit whether or not due to age, inflammation or heart risk. 
Normal CRP concentration in serum is usually between 5 and 10 µg/mL. However, 
higher levels can be found in older patients and mild inflammations. This is usually 
between 10 and 40 µg/mL concentration of CRP. Over a concentration of 40 µg/mL 
CRP is where more active and severe cases of inflammation can occur
[6,49]
.  In the case 
of determining a risk of heart disease, the American Heart Association has developed 
a quick reference guide.  According to them, a CRP level under 1.0 µg/mL correlates 
into a low risk category, 1.0 – 3.0 µg/mL correlates into an average risk category and 
over 3.0 µg/mL correlates into a high risk category
[6]
. However, this is based on the 
concentration in blood. Since there is a 11:9 ratio of serum to blood cells (54% serum, 
45% cells)
[27]
, this scale can be modified to mean that low risk is less than 1.85 µg/mL 
CRP concentration of serum and high risk is greater than 5.56 µg/mL CRP 
concentration of serum. However, multiple tests have to be confirmed, including a 
second CRP test and a cholesterol test to better determine one's own risk
[6]
. 
2.6.    CRP Detection 
 2.6.1. Current Detection Methods 
Currently, there are numerous methods in which CRP can be detected. 
However most of these do not involve LOC technology. Perhaps the most common 
method used is using a blood analyzer
[6]
. A blood analyzer takes a sample of blood 
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and analyzes the sample. The most common method of analyzing is by use of a 
nephelometer. A nephelometer measures the particles in a solution by shining a light 
into the solution and reflecting the light onto a light detector. Each protein can be 
found by either emitting a different wavelength or by seeing the how much or the 
angle of light is reflected back
[51]
. For measuring CRP, there are two types of tests. 
The first being a normal CRP test which measures the amount of total CRP in a 
sample and the second being a hs-CRP (high sensitivity CRP) test which is more 
useful in determining the risk or cardiopulmonary disease
[6]
.  
While this is an effect method to measure CRP, it does not work well for LOC 
applications. The first of which is its size. This is a machine than can weigh anywhere 
up to a couple of hundred kilograms, so most of them are not portable. Second, all of 
the experiments are performed on the machine and not on a small chip. The blood 
goes into a vial and then into the machine for screening. This brings up the third 
drawback. Most of these blood analyzers up to, if not more than, 1 mL of blood. Most 
LOC devices use far less fluid than what a blood analyzer uses. Fourth, most of these 
analyzers only use plasma or serum. This means that the blood cells cannot be in the 
detection area. While all experiments require this, blood must be pre-separated before 
it can be placed in the analyzer. This usually involves centrifugation, hence the large 
volume required. Finally, time is always a factor. From blood extraction to results, the 
time elapsed could be as long as a few days, which does not take into consideration 
logging data and bookkeeping. Based on the type of machine, it can take anytime from 
a few minute to a couple of hours
[4,51]
. Even though it is a well-known system, it is not 
ideal for LOC applications based on the preceding. 
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Other large machines include liquid chromatography, for example, high 
performance liquid chromatography (HPLC). Liquid chromatography allows a user to 
determine what types of proteins are in a sample by mixing a sample with a solvent 
and sending through a column with packing material that separates the proteins in 
solution
[52]
. The detection of specific proteins is good, but there are also drawbacks to 
this. Mostly, it can detect proteins, but not the concentration of certain proteins. Also, 
all the samples are diluted before they are measured so an accurate measurement 
cannot be found. Furthermore, one test run can last up to a day
[52]
. Because of these 
reasons, any liquid chromatography experiments cannot be performed to detect and 
measure CRP. 
However, in terms of LOC experiments, there have been different platforms 
that have been created in order to detect CRP. One platform uses immunoglobulin Y 
(IgY) as a method to capture CRP in not only serum, but also in blood. The time taken 
to perform this test has been reduced significantly to only a couple of minutes and has 
a high detection range
[53,54]
. Other LOC applications use nanoparticles coated with 
anti-CRP antibodies that would attach and allow for accurate detection
[19,20]
. These are 
only a few examples on how far LOC has developed into a well-known method for 
detecting CRP in whole blood. 
However, while reviewing a few of these products, it is worth noting a few 
limitations to them. First, some of the reagents can either be expensive in cost, as in 
the case with gold nanoparticles
[19]
, or expensive in time in which to engineer the 
reagents
[54]
. In the case with IgY, there is a stark contrast with it compared to IgG.  
IgG is a mammalian antibody that is used cooperatively with the immune system. IgY 
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is similar, but it is found in reptilian and avian (bird) blood. This means that is cannot 
bind either well or at all to mammalian proteins or antigens
[55]
. Because of this, these 
antibodies need time to be effectively engineered in order to make them more useful 
for mammalian experiments. There is one other limitation to these experiments: the 
type of fluid used in the experiments.  
A number of LOC systems can either use serum or whole blood for analysis. 
But this whole blood needs a certain anti-coagulant to be present before it is dropped 
onto the chip, for example, with the ABX Micros CRP 200 by Horiba
[56]
 and the CRP 
analyzer by Labcompare
[57]
. The most common anti-coagulant is EDTA 
(Ethylenediaminetetraacetic Acid). EDTA is commonly found in laboratories and is 
mixed with blood as soon as the blood is extracted
[56]
. The need for an anti-coagulant 
in experiment is that the blood does not curdle during experiments. Over time, due to 
platelets and fibrinogen, blood can become more gel-like and solidify
[58]
. Anti-
coagulants slow down and occasionally stop this process in order to preserve blood. 
This method is still great for laboratory work, but in field work, or a home setting, 
where EDTA is not readily available, this can cause some problems. Because of this, a 
better method for detecting CRP from a drop of blood directly from the body has to be 
considered. 
2.6.2. CRP Detection with ELISA 
One of the most common methods in detecting CRP is what is known as an 
enzyme-linked immunoassay (ELISA). In a basic ELISA, the antigens are attached to 
a certain surface, in most cases, the bottom of a micro-titer plate. Afterward, a specific 
antibody is attached to the antigen followed by a substrate to detect the antibodies 
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attached to the antigen. This is a simple method to be able to detect certain antigens
[12]
. 
A full detailed example will be discussed in the upcoming sections. For this part 
however, it is essential to know the basics of an ELISA. 
There are multiple types of ELISA that can be used for experiments. The first 
type, explained above, is known as a direct ELISA. This ELISA is beneficial because 
a certain antigen can be detected by the use of antibodies specifically designed to 
attach to that antigen
[59]
. The second type is known as an indirect ELISA. This ELISA 
is used to detect an antibody, rather than an antigen. To perform this experiment, a 
known antigen is attached to the bottom of a well.  An unknown solution that may 
possibly contain an antibody that can attach to that antigen is placed into the well.  
From there, antibodies designed to attach to that antigen will attach.  This antibody is 
what is known as a primary antibody.  Later, a secondary antibody is used to detect 
that first antibody, in which the substrate can detect these secondary antibodies
[59]
.  
The third type is what is known as a sandwich ELISA.  This type can either be direct, 
or indirect, but the main difference being that instead of an antigen binding to a well, 
an antibody specific to that antigen binds to the well. Then a solution with many 
antigens or proteins (blood serum) is sent though, allowing the antigens that are 
specific to the antibody already attached to attach. A second, and sometimes a third is 
used to detect that antigen again and also be used to activate the substrate once it 
comes into contact
[59]
. A final type of ELISA is known as a competitive ELISA. 
Unlike the first three examples, this type of ELISA uses competing proteins or 
antibodies to either detect changes in detection, or to remove/narrow down possible 
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choices for unknown proteins or antibodies
[59]
. Below is a diagram highlighting the 
main differences between the first three ELISA types. 
 
Figure 2-3: Diagrams highlighting the differences between a direct ELISA (left), an 
indirect ELISA (center) and a sandwich ELISA (right)
[59] 
 
Because of the fact that a certain antigen is being detected, it would be better to use a 
sandwich ELISA in order to capture and detect CRP. Also, since this project is also 
concerned about the concentration of CRP, it would also be helpful to use a 
competition ELISA, where more than one concentration of CRP. With these two types 
of ELISAs, it would be the most optimal method to detect and calculate the 
concentration of CRP in blood. Previous lab projects have combined to obtain a 
working microchip that envelops this concept
[22-24]
.  Based on this, work from these 
previous models will be brought together in order to create a more modern version of a 
CRP detection chip that incorporates blood cell removal and ELISA detection. 
2.7. Previous Lab Work 
 Over the past few years, there have been systems developed by the URI 
microfluidics laboratory that used LOC technology in order to capture and detect CRP.  
The first system was developed by Peng Li in order to detect CRP on a microchip.  
This system implemented an ELISA detection system and was one of the first systems 
30 
 
to integrate sequential loading, where all the reagents were inside the chip and the 
reagents were fed through the detection area by way of a micropump
[22]
.  This system 
accurately detected CRP in buffer.  The second system was developed by Michael 
Godfrin in order to find a method of detecting CRP in blood serum with the removal 
of albumin and human IgG
[23]
.  The third system was developed by Michael Franzblau 
as an updated version of the system developed by Peng Li with incorporated both 
sequential loading and CRP detection in blood.  This system was also novel in that the 
detection was automated, rather than relying on human interaction.  An example of 
this system is found in figure 2-4
[24]
.   Pictures displaying this system is shown below 
in figure 2-4.  Other projects developed include a hand-held CRP detector developed 
by John Jones
[60]
 and an ongoing project in detection of CRP and other reagents on 
paper
[61,62]
.  This project encompasses the first three projects mentioned and uses this 
to develop a better method to detect CRP.  The reason for this is explained below. 
 
Figure 2-4: Prototype of CRP detection POC device created by Michael Franzblau 
2.8. Reasoning for a Modified CRP Lab-on-a-Chip System 
 In order to better develop this goal of detecting CRP in whole blood, it would 
be beneficial to incorporate the projects developed by Li, Godfrin and Franzblau into 
an updated and more reliable system.  In order to see if there needs to be any 
improvements on these systems, a simple experiment combining the chip developed 
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by Franzblau
[24]
, the protein removal developed by Godfrin
[23]
 and the detection 
system developed by Li
[22]
 to see if this experiment was feasible.  Further explanations 
of each of the three experiments will be clarified in the next chapter.   
 In a brief synopsis of the experiments, the chips were first functionalized with 
BSA (bovine serum albumin) protein, glutaraldehyde and protein A
[22]
.  This allowed 
the removal of the high abundance proteins and the detection of CRP.  The chip was 
divided into three sections: a top section for removal of IgG, a middle section for 
removal of albumin and a bottom section for CRP detection
[24]
.  Anti-albumin IgG in 
the middle and Anti-CRP IgG in the bottom were added and incubated for 5 
minutes
[22-24]
.  The chip was washed with PBS (phosphate buffer saline) and serum 
with CRP was added to the chip.  It first incubated in the IgG removal area for 5 
minutes, then in the albumin removal area for 5 minutes and finally in the detection 
area for 5 minutes.  After a PBS wash, anti-CRP antibodies labeled with FIT-C were 
added and incubated for 5 minutes.  After a PBST wash, PBS was added and detected 
using fiber optics
[22-24]
.  A negative control with serum but no protein removal and a 
positive control with CRP in PBS buffer were also used in conjunction.  This 
experiment was performed with 5 and 10 µg/mL concentration of CRP in serum (2.6 
and 5.2 µg/mL concentration of CRP in blood)
[48-50]
. 
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Figure 2-5: Comparison of CRP detection in previous projects 
 
 Figure 2-4 depicts the detection of CRP in serum using the previous methods 
designed.  The center bars show the result given when the experiment was performed.  
The values of the signal are based on the intensity, or how much light was adsorbed by 
the fiber optics used in detection.  To the left are the signal values for the same 
experiment with no removal of albumin and IgG.  The signal of the tests are 
noticeably higher than that of the buffer, but in comparison to the signal of just CRP in 
buffer (right bars), it tells a completely different story.  The values of the tests were 
half that of the buffer experiments.  This relates that there was a noticeable presence of 
IgG and albumin in the detection area.  The probable cause of this would be the 
incubation of the removal of IgG and albumin.  Five minutes for the removal of the 
two most abundant proteins in blood is not an ideal amount of time if there is still a 
large amount of antibodies.  Also, there was not a significant change in signal as 
concentration increased in the experiment as compared to CRP in buffer.  One other 
thing is that even though it was implied that blood could be used in the experiment, 
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there were not enough tests in order to see if this was functional.  Because of these 
reasons, this method of high abundant protein removal has to be dealt with. 
 In order to go about fixing this system, each of the aspects from getting from 
separating blood cells to detection of CRP has to be looked at.  This includes seeing 
how well blood cells get filtered out of the chip to seeing as to what is the most 
efficient method of IgG and albumin removal.  This project will take a look as to how 
well IgG attaches to protein A and how it can be bettered.  This will help in the 
removal of albumin from serum as well.  With these aspects, a newer more efficient 
method of removing CRP from whole blood can be obtained. 
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CHAPTER 3 
 
METHODOLOGY 
 
In order to explain the process behind this project, this section will be broken 
up into three different sections. The first section will be about the process of making 
the chips. The second section focuses on blood separation. The third section focuses 
on the removal of high abundance proteins in order to detect C – reactive protein. 
3.1. Microchip Fabrication 
One of the main issues is deciding what type of chip to work with. Different 
chips can be constructed by using different materials. Based on the material being 
used, these chips can be divided into two categories. This is based on how fluid travels 
through the chip. The first category is known as passive flow chips. These chips use 
capillary forces to move a liquid down a channel without the need of an external force 
to move the chip. The second type is known as active flow chips. These chips use an 
external source, such as a pump, in order to move the liquid towards its potential 
area
[63-65]
. The upcoming paragraphs will examine both processes and determine which 
process would be better suited. 
The first process mentioned is passive flow. This method does not require the 
use of a pump, but rather forces in the material, either through diffusion or capillary 
forces, drive the fluid to a destination
[65]
. In most cases, this is performed by wetting 
an area for the fluid to go through with a hydrophilic solution, while wetting the 
boundary in a hydrophobic solution
[64]
. The most common materials that are used to 
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make the chips are any material that can easily draw water, including paper, twine and 
fabric
[64]
. The advantages to using a passive system are that the materials needed to 
make the chip are inexpensive and the design and printing of the chips can easily be 
performed on the computer. The disadvantages to using passive systems are that there 
is no optimal fluid control since there is no external source other than the chip to guide 
and control the flow of the fluid. 
The other process mentioned is active flow. This method requires the use of an 
external source for the fluid to flow. These sources include pumps, electrical impulses 
and magnetic impulses
[65]
. Basically, if an external force is needed to drive the fluid, 
then it is an active flow system. Unlike a passive flow system, where the material acts 
as channel for the fluid to flow, in active flow, the channels are formed inside of the 
chip, by way of a mold
[22-24]
. This allows the fluid to easily flow inside the chip and 
keep intact and not leave much of a streak or residue behind. These chips are usually 
made out of glass, plastic or nay polymer. The advantages for using active flow is that 
the user has full control over the liquid in the channel, they are easy to make and fluid 
can be easily placed in and taken out of the chip. The disadvantages are that it is more 
costly to make, based on the making of one mold, and numerous amounts of polymer 
or glass, the process to create the chips usually takes longer than that of a passive 
system and external equipment is needed to perform the experiments. 
Based on the reasons listed above, it was more beneficial to go with an active 
system than a passive system. The reason for this being that the fluid is easier to 
control in an active system. The fluid is allowed to stay in one place, which would be 
ideal for allowing more CRP to be detected. Also, with a pump or a syringe, the user is 
36 
 
allowed to move the fluid to all the different parts of the channel. With a passive 
system, the best way to move liquid would be to add more liquid to the chip. In the 
case of adding blood to the paper, some aspects of the experiments include the 
removal of blood cells and high abundance proteins. The issue is that with using a 
passive system, if the plasma is in constant flow, then it would be a lot more difficult 
to contain it in order to remove all of the high abundance proteins. This will be 
explained in full detail later on in the removal of high abundance protein section. 
Because of the ability to better control the fluid in the chip, the method of active flow 
to detect CRP will be investigated. 
3.1.1. Mold Creation 
The first part on creating the chip is creating the mold. The mold acts as a 
template in order to create the microchannels. Each mold will have an etched side, 
where indents will be formed in order to create the channels that the substrate will be 
set upon. For this project, the molds were made based on two methods: an older 
method using silicon wafers and SU-8 photoresists via soft lithography developed by 
Peng Li
[22]
 and a newer method by using aluminum molds via hard lithography 
developed by Michael Franzblau
[24]
. 
3.1.2. Silicon Molds 
To prepare the molds using the first method, the silicon wafers (SI-Tech, Inc., 
Topsfield, MA) have to be pre-treated. This is performed by placing the wafers in a 
piranha solution. This removes any debris and organic material on the chip. This 
solution consists of a 50/50 mixture of hydrogen peroxide (H2O2) (Ricca Chemical 
Company, Arlington, TX) and sulfuric acid (H2SO4) (Acros Organics, Geel, Belgium) 
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and is an oxidizer against organic material. These wafers are placed in the solution on 
an Orbit Shaker (Lab-Line Instruments, Melrose Park, IL) for about 15 minutes or 
until no bubbles are present on the wafer. The wafer is then soaked in distilled water 
three times for five minutes per soak. The wafer is then dried using compressed 
nitrogen and stored until adhesion of the photo resist. 
Once the wafers have been cleaned and dried, the photo resist is then applied to 
the wafer. The wafer is first cleaned with compressed nitrogen and placed on the spin 
coater (Laurell Technologies, Corp., North Wales, PA). 2 – 3 mL of AP300 adhesion 
promoter (Silicon Resources, Inc., Chandler, AZ) is added to the wafer. The wafer is 
spun for 25 seconds at 300 rpm and then for 30 seconds at 3000 RPM once to spread 
the resist and twice to dry it. Nitrogen gas is blown gently onto the wafer to dry the 
wafer. Then, SU-8 2050 photo resist (MicroChem Corp., Newton, MA) is added to the 
center of the wafer. The wafer is spun a second time first at 300 RPM for 45 seconds 
and then at 600 RPM for 50 seconds. The wafer is removed and placed on a leveling 
tray, resist side up and allowed to level off for 1 hour. Finally, the wafer is placed on a 
hot plate (HS40A, Torrey Pines Scientific Inc., Carlsbad, CA) in order for the photo 
resist to harden. The baking consists of a three part sequence. First, the hot plate must 
be at 50°C before the wafer can be on the hot plate. Once the wafer is on, the 
temperature will rise from 50°C to 95°C for 23 minutes at a rate of 2°C/min. At 95°C, 
the wafer will continue baking for 3 hours. Finally, the temperature is lowered at a rate 
of 1°C/min until the plate is at room temperature. These wafers are then stored until a 
pattern for them will be etched. 
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The next step is to create a pattern to be placed on the chip. This is done by 
using Adobe Acrobat. A sheet is made with four black boxes, with white etchings that 
relate to the dimensions of each wafer the channels are drawn using white lines, along 
with openings for the fluid to enter and a detection area for the immunoassays. Each 
document can hold up to four stencils, or photo masks.  Examples of the photomasks 
used can be found in the Appendix (A.1 & A.2).  Once the making of the photo mask 
is complete, the document is saved and sent via e-mail to CAD/Art Services, Inc. in 
Bandon, OR, which would print the masks on transparent plastic to be used for 
etching, with the clear sides being the areas where the channels will be etched.  These 
examples are shown on the below in figure 3-1. 
 
Figure 3-1: Transparent masks for silicon wafer molds for the channel side (left) and 
filter holder (right) 
 
The last step will be to etch the pattern on the wafer. To do this, the photo 
mask is placed over the resist, making sure that there is no gap in between them. They 
are then placed in a UV-light source (i-line, Karl Suss MJB-3, Suss Microtech, 
Garching, Germany), where UV light at 365 nm wavelength will harden the exposed 
photo resist, while the covered sections will remain untouched. This exposure will last 
approximately 6 minutes for resist thickness of 400 µm. This does not include two 1 
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minute rest times in between. In total, for a 400 µm resist thickness, there is a 2.5 
minute exposure, followed by a 1 minute break, then a 2 minute exposure, a 1 minute 
break and finally a 2.5 minute exposure. The wafer is then placed on a hotplate at 
45°C and then ramped up to 85°C at a rate of 2°C/min. It is then baked at 85°C for 40 
minutes, before coming back down to room temperature at 1°C/min. Finally, the 
molds have to be developed. For this, three solutions have to be used. First, the wafer 
is placed in a series of two SU-8 developers (MicroChem Corp., Newton, MA), on an 
Orbit Shaker and shaken until the non-exposed photo resist comes off (approx. 10-20 
minutes).  Finally the wafer is placed in a container of isopropyl alcohol (Fisher 
Scientific, Fair Lawn, NJ) for 1 minute and then blown dry. The last step would be to 
bake the chip at 150°C for 30 minutes, with a 1°C/min heat up and cool down before 
and after
[22]
.  A full protocol can be found in appendix A.3.  Figure 3-2 shows the 
process and figure 3-3 shows the final molds. 
40 
 
 
Figure 3-2: Example of microchip fabrication using soft litography
[66] 
 
 
Figure 3-3: Completed silicon wafer molds used for LOC chip production for multi-
fluid assays (left) and single fluid assays (right) 
 
Even though this is a known and good way to create the molds, there are 
drawbacks to this method. The first drawback is the UV light. The light source used in 
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the experiment is very broad and dim when etching. This is problematic because the 
dimensions of the channels will be larger than what they should be and due to the lack 
of intensity, not too high. In the case of more elaborate channels, where this light 
source would not create better channels, the wafers and masks had to be sent to the 
laboratories at the Massachusetts Institute of Technology in Cambridge, where a 
better, more direct light source was used.  The second drawback is the repeated use of 
the wafers. On average, the wafers are used about a dozen times until they either break 
due to the heat and negligence, the photoresists peels off or the wafers become 
warped. The third drawback is the various chemicals being used, which are known to 
be not only toxic, but can cause skin corrosion. The fourth drawback is that one of the 
necessary components, the AP300, was discontinued.  The final drawback was that 
from designing the mask to finishing the molds, the process took approximately 
between 2 to 3 weeks to complete.  Because of these issues, a more ethical procedure 
in order to create better molds had to be established. 
3.1.3.  Aluminum and Polymer Molds 
In this method of mold fabrication, the channels were all etched out on a small 
block of either aluminum or a polymer material. The first step in creating the molds 
was to create a design by use of a CAD program (in this case, SolidWorks was used). 
The finished program was then translated into a programming language via 
MasterCam, which was then relayed to a computer numerical control (CNC) milling 
machine where the mold was carved out of either aluminum or a polyetherimide 
known as Ultem, which was developed by SABIC. The end result revealed a durable, 
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etched block that consisted of the etched channels that would be implemented in the 
chips
[24]
. 
There were a few things to look out for when creating these molds.  First was 
that the molds had to have raised structures which indicated where the channels were 
supposed to be.  Second, the molds had to be designed within the parameters of how 
the milling machine could create them.  The bits that were used to sculpt the channels 
were McMaster-Carr end mills (part# 8832A008) that had a diameter of 203 µm and a 
depth cut of 350 µm.  Because of this, all the channel heights hat to be at the most 300 
µm and the thickness between any two raised structures to 205 µm, in order to stay 
within the parameters of the device
[24]
.   
However, there are many advantages to using aluminum molds as compared to 
silicon molds.  One advantage is that the time which the entire process is performed is 
cut by, on average, a week.  One of the reasons why the silicon wafers take longer is 
that the photo masks take up to a week or two to be fully completed.  Without that step 
and the fact that the chip designs are only converted into code, it takes less time to 
make these molds.  Second, these molds are more durable than the previous silicon 
ones.  With silicon molds, there is always the possibility that the molds can shatter and 
warp, the photo resists can break off and the molds could easily get lost.  This means 
that a new mold is usually created after only a couple of months.  With aluminum and 
polymer molds, on the other hand, there is no need to worry about any of this because 
the molds are usually between 0.25” and 1” thick.  And since the raised channel 
structures are part of the chip, there is no fear in that these structures would break off 
from the mold.  Finally, unlike the previous molds, these molds can withstand higher 
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temperatures.  With silicon molds, there is always the chance that warping can happen 
on the molds due to heat.  Because of this, the chips have to be cooked at 95°C in 
order to prevent this.  Aluminum molds are more thermal resistant, especially since 
they are thicker, so they can withstand temperatures greater than 150°C
[24]
.  Because 
of these reasons, it is safe to say that these aluminum molds are an improvement over 
the previous silicon molds. 
 
Figure 3-4: Aluminum molds used for LOC chip production for single fluid assays 
(left) and multi-fluid assays (right)  
 
 
Figure 3-5: Aluminum and polymer molds used for LOC chip production for multi-
fluid assays.  Clockwise from top: bottom of chip, channel sides (2), blood filter 
holder 
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3.1.4.  Fabrication of the Chips 
Regardless as to how the molds were created, the method of making the chips 
remained constant. There are many substrates in which chips can be made, based on 
the different properties. Etching chips from glass is a common method that is used 
because glass can be durable, is transparent and does not react when in the proximity 
of biological substances
[34]
. However, glass is brittle and can shatter, is expensive to 
obtain and etching usually requires hydrofluoric acid, which is extremely corrosive. 
The best method would be to use polymers as a chip substrate because they are usually 
nontoxic, inexpensive, can withstand high temperatures and can be easily liquefied 
and solidified. One of the best known polymers is polydimethylsiloxane (PDMS). 
PDMS is a transparent silicon polymer that is usually inert under chemical and thermal 
changes. It is relatively inexpensive to use PDMS and the fact that it starts as a liquid 
with a high viscosity and low surface tension means that the polymer can flow over 
the mold in order to make sure all the nooks on the mold are covered. 
To make the actual chips a mixture of liquid PDMS (Slygard 184, Dow 
Corning, Midland, MI)  and curing agent are added in a 8:1 – 10:1 PDMS : Curing 
Agent ratio. Depending on the size of the mold and the thickness of the final chip 
(between 0.4 and 0.6 mm thickness), the mass of the PDMS mixture varies between 30 
and 50 grams. This was found by taking the approximate volume (cross-sectional area 
X slab height for one side) and multiplying it by the PDMS density (0.965 g/mL) and 
doubling it.  The reason for this mass is that this is the total mass for the top side 
(channel side) and bottom side (flat side). The liquid mixture is poured onto each mold 
in equal proportions. During the mixing and the pouring of the PDMS, air bubbles 
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form in the mixture. It is essential that these bubbles are removed as that they cause 
irregularities in the channel formation and cause interference in the detection signal. 
For this, the molds are placed in a vacuum chamber (Sybron – Nalge, Braunschweig, 
Germany) for 1 hour to remove all bubbles from the molds. This process can be 
performed quicker by leaving it in the chamber for 15 minutes until all the bubbles 
reach the surface and then leaving it outside the chamber for another 15 minutes. Once 
all the bubbles are gone from the mold, the mold is placed on a hot plate at 95°C to 
bake for 2 hours. 
After the PDMS has hardened, they are removed from their respective molds 
and trimmed of excess PDMS using a 4” razor blade scrapper (McMaster-Carr catalog 
#26765A31). Holes are punched at the channel openings using a 1.5 mm biopsy punch 
(Miltex catalog #33-31A) to allow fluid into the chip and tubing to latch into the holes 
created. The next step will be to bind both sides of the chip together. This will be 
performed by using the plasma asher (Femto, Diener Electronic, Reading, PA). To use 
the plasma asher, both sides of the chip are placed on a tray that is then inserted the 
asher. The chips are inserted mold side up because they tend to be the clean side free 
from air bubbles and in the case of the channel mold, it is where the channels are 
located. The process consists of four steps. First, the chips are inserted, the window 
between the chips and the outside sealed and air is pumped out the chamber. This 
process takes about 3 minutes, in order to make sure no air is in the chamber. Second, 
oxygen gas is pumped into the chamber. This step takes approximately one minute. 
Third, the chamber is activated, which plasmas a thin layer of oxygen onto the surface 
of the chip. This process takes 3 minutes to perform. Finally, once the 3 minutes are 
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up, the gas and pump are turned off and air is added to re-pressurize the chamber. The 
chips are then taken out and are bonded together with the two sides facing up being in 
contact. The chips are pressed together and are placed on a hot plate at 95°C to bake 
for 1 hour in order to facilitate binding. If the chip requires a paper pad to be used as a 
waste area, the paper is fitted onto the channel chip with the flat chip brought in to seal 
them. If a filter is needed, the top of the chip is placed in the asher with the filter 
holder and the process continues. The filter is placed on top of the holder, with the 
smooth side facing up, then the chip is pressed onto the holder and placed on the hot 
plate
[24]
.  The full protocol can be found in appendix A.3.  Since there are multiple 
chip designs that will be implemented, each upcoming section will explain the 
geometries of each chip.  Figure 3-6 below highlights the process of making the chips 
and 3-7 on the next page shows the equipment used in the creation of the chips. 
 
Figure 3-6: Sample assembly of PDMS Chips
[65]
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Figure 3-7: Equipment used to create PDMS chips including vacuum chamber (top 
left), hot plate (top right), plasma asher (bottom left) and vacuum oven (bottom right) 
 
3.2. Blood Separation 
In the previous chapter, it was determined that because of the cost, 
functionality and easier integration, it was determined that the preferred method of 
blood separation would be to use filter paper and membranes.  However, since there is 
a large selection of filter papers, there has to be a way to sort and narrow down the 
search for a proper filter paper.  There are numerous tests that one can perform that 
include measuring the amount of filtrate and seeing how well they keep blood cells 
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out.  These methods will be implemented in determining a suitable filter for blood cell 
separation. 
One of the companies that produce blood filtration membranes is the Pall 
Corporation.  Pall has a line of membranes known as the Vivid Plasma and the 
Cytosep Membranes
[68,69]
.  These are two types of membranes that not only are able to 
separate a large amount of plasma, but also show no sign of blood cells rupturing or 
escaping the membrane.  This is based on the characteristics of the membrane.  The 
membrane consists of two different sides: a rough upper side and a smooth lower side.  
Blood is placed upon the upper side and the liquid migrates to the smoother side.  
There are pores in the paper that allow the blood to flow through, but the roughness of 
the sides depends on the size of the pores.  The rough side has larger pores, making it 
ideal for cells to be captured, while the smooth side has pores small enough for the 
plasma to seep through, while keeping the cells inside of the membrane
[68,69]
. 
It is a highly hydrophilic membrane and unlike some papers which are fibrous, 
or made from paper, these membranes are made from a polymer known as polysulfone 
in the case of the Vivid Plasma Membrane
[68]
 and of a blend of natural and synthetic 
fibers in the case of the Cytosep Membrane
[69]
.  Because of this, it actually can 
withstand higher temperatures and pressure forces exerted onto it.  Plus, since it is 
hydrophilic, the blood can travel readily throughout and stay in the membrane until an 
external pressure is applied.  This allows for an adequate amount of plasma to remain 
on the filter until it is needed to be exerted onto the chip and the amount of plasma can 
be high enough to be necessary without fear that blood cells and hemoglobin can enter 
the chip
[68,69]
. 
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Since these are a few examples of blood filters, it would be essential to test as 
to how well each one will fair.  There are two main tests that will be used to determine 
how effective these filters are.  The first will be a test based the amount of filtrate has 
been filtered out.  This will be performed by just directly measuring the filtrate volume 
by using a syringe pump to extract the filtrate until the filter does not allow any more 
filtrate to pass through.  The second test will be to see how well the filters separate the 
blood cells from the plasma.  This can be performed with multiple tests including 
blood staining and microscopy.  An additional test can be performed to see if either 
plasma or serum is obtained from the filtrate.  From these tests, a suitable filter will be 
found that can be used to separate blood cells from whole blood. 
3.2.1.  Filtrate Volume Tests 
The first test involves the volume of the filtrate. The main filtrate that will be 
going through the chip should be plasma. As stated previously, plasma accounts for 
approximately 55% of the total blood volume. This means that for every 100 µL of 
blood, there will be approximately 55 µL of plasma to go along with it. In experiments 
that require only a small amount of plasma, it is not a big issue that 100 µL of blood is 
used. The issue occurs when for example 15 µL of blood is filtered to yield 
approximately 8 µL pf plasma. The reasoning for this that the filter can adsorb a good 
amount of plasma and that red and white blood cells, known as the filter cake in this 
experiment, can ultimately block off the channel so that no more filtrate can be pulled 
into the channel. With this knowledge, it is important to find out if these filters are 
even functional to begin with. 
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Tests will be performed with the filter to make sure that these filters are 
functional. In each experiment, a syringe will be connected via tubing to a PDMS slab. 
The tubing will be marked at 1 µL intervals, which will be used to measure the filtrate 
volume. A small piece of filter paper will be placed in the slab, where a drop of blood 
will be placed. The filter papers being used in these experiments were the Vivid 
Plasma Membranes GX and GR from the Pall Corporation (Ann Arbor, MI). 
According to Pall, these filter papers are some of the top of the line papers because of 
their double-sided nature. The top side has rough openings that can entrap blood cells, 
while the bottom has a smooth, yet finely holed surface that allows plasma to escape. 
By use of active transport, fluid motion with the aid of an outside influence, in this 
case, a syringe pump, the blood would flow through the filter and into the tubing. The 
remaining plasma will then be collected, measured and analyzed based on techniques 
that are used to characterize and determine the quality of the plasma. 
The syringe pump that is used is from the company SyringePump.com from 
New Era Pump Systems. The model number of this pump is NE-1010. A picture of 
this pump is shown on the next page as well as the setup of the experiment in figure 3-
8. The reason this experiment focuses on active transport is because it is the easiest 
method to collect and isolate blood filtrate. The filtrate is collected inside the tubing 
due to the movement of the syringe and the vacuum pressure created inside of the 
tubing. This forces the plasma through the membrane into the tubing at a steady rate. 
The one issue concerning this would be the filter cake that builds up. The cake is 
defined as the items that did not effectively flow through the filter (RBC, WBC, 
Platelets). This causes a slowdown in filtrate extraction and a buildup in vacuum 
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pressure. In addition to this, membrane rupturing and hemolysis can occur. This 
causes a problem mainly in the antibody-antigen assay, where hemoglobin can 
interfere with the interactions between antigen and antibody. 
  
Figure 3-8: Apparatus of syringe pump (left) and PDMS chip (right) used for plasma 
extraction 
 
During each experiment, the main focus would be not only how much plasma 
can be extracted, but also if 5-7 µL can be extracted from a blood volume between 25 
and 45 µL. This is important because the reservoir for the antigen has a volume of 5-7 
µL and through experiments, it will be shown that it is the ideal volume for the 
amount of plasma that can be collected, where the risk of hemolysis, or rupturing of 
the blood cells is minimal. These values will be graphed and compared with each other 
in order to determine which filter is the most ideal filter to use in the system. 
3.2.2. Blood Cell Analysis 
The second factor with blood filtration involves the clarity of the filters. For 
this segment, two aspects are taken into account. The first is whether or not red blood 
cells are filtered from the plasma. This is important because in the immunoassay, only 
the proteins in blood are important in detection. Since RBC’s have an average 
diameter of 6-8 microns
[18,44]
, they can interfere with the proteins while performing the 
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immunoassay.  Because there cannot be any trace of blood cells in the channels as the 
filtrate is added to the serum, it is necessary to see if cells were able to penetrate 
through the membrane and into the channel.  In order to perform this, microscopy has 
to be used.  There are two different methods that can be utilized in order to perform 
the microscopy.  One method is by use of what is known as a Giemsa Blood Staining.  
In this method Giemsa Stain is applied to a dried sample and by using microscopy, the 
different specimens can be identified based on the color given.  One example 
performed in the lab used this testing to find the effectiveness of the Pall Membranes. 
   
 
  
Figure 3-9: Giemsa Staining of filtrate from different membranes (top, left to right: 
whole blood, filtrate from Vivid Plasma Membrane GX, filtrate from Vivid Plasma 
Membrane GR; bottom, left to right, filtrate from Cytosep 63, filtrate from Cytosep 
62)
[70] 
 
As shown in figure 3-9 above, this test was performed on both the Vivid 
Plasma and the Cytosep Membranes.  Both sets of the Vivid Plasma Membranes 
performed well and did not filter through any blood cells.  The Cytosep Membranes on 
the other hand not only allowed more blood cells to seep through, but some of the 
filter paper broke apart in the filtrate.  From these tests, it was shown that the Vivid 
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Plasma Membranes performed better than the Cytosep Membranes
[70]
.  However, one 
of the main issues with using Giemsa stain is that it is very oxidative, meaning that if 
not carefully performed, a stock solution of Giemsa Stain can be ruined with a small 
amount of oxygen in air and water.  Because of this, an alternative method of direct 
microscopy of filtrate samples will be performed for this project.  This involves 
creating chips that hold the filtrate and place them directly under a microscope.  Keep 
in mind that because of these previous results with the Giemsa staining; only the Vivid 
Plasma Membranes will be in use for this experiment. 
Another factor is based on whether or not hemolysis has occurred. Hemolysis 
is the process where RBC membranes rupture and hemoglobin is released in the 
plasma. This can occur either in the filtration process due to a bad filter or a high 
pressure caused by the syringe pump, or by using old blood. Normally, if there is 
redness in the filtrate, it is either caused by RBC’s or hemolysis. Normally, it can be 
seen with the naked eye whether or not it occurs, but it is better to check using a 
microscope if there is noticeable redness.  This can involve seeing whether or not 
blood cells remain in a “reddened” filtrate.  This would show whether or not 
hemolysis has occurred in the blood and the amount can tell whether it was the filter 
or that old blood was used in the system. 
To perform the microscopy aspect of this project, slides will be prepared by 
using a PDMS chip with 5 microchannels. One microchannel will contain whole blood 
as a control and to see the relative RBC size. The other microchannels will contain a 
filtrate based on a specific type of filter paper, the dimensions and area of it and 
because a syringe pump is used to withdraw the plasma, the rate of extraction. Each 
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blood sample will be of the same volume based on the average drop size and because 
the drop needs to soak into the filter paper completely, a common time between 
dropping the blood onto the paper and the start of the pump. This method will help 
determine what the ideal method is for blood filtration. During each experiment, 
various observations will be noted, including total plasma volume, plasma color upon 
initial inspection, and volume before possible hemolysis. These observations will play 
a vital role in characterizing the filters and help determining the aforementioned 
qualities if the filter paper.  Microscopy will be performed on a Leica DMLB 
microscope (Buffalo Grove, IL).  This microscope has the ability to vary in resolution 
size, from 5X to 20X and is able to take a snapshot of the channels by way of a 
mounted camera connected to the computer.  With this camera, pictures can be taken 
of the microchip to be used for further processing. 
  
Figure 3-10: Microscope and chip used for blood cell analysis 
 
3.2.3. Clotting Factors: Plasma vs. Serum 
One other factor that has to be taken into account is whether or not the filtrate 
is plasma or serum. The difference between these two is based on fibrinogen, or 
clotting proteins present in the filtrate. Serum contains no amounts of fibrinogen, 
which means that even if there is a small amount of fibrinogen in the filtrate, it will 
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still be identified as plasma. Since there is not an ideal method to locate fibrinogen 
under a microscope, the best method to characterize the filtrate will be to precipitate 
the fibrinogen out of solution. This is performed by coagulating the fibrinogen, which 
is soluble, into fibrin, which is not soluble. There are different reagents that are able to 
perform this, such as thrombin and certain aqueous salts
[71]
. This project however will 
focus on using ethanol for fibrinogen aggregation
[71]
. By adding ethanol into plasma, 
fibrin will precipitate out of solution, leaving only serum in liquid form. If this 
experiment does not perform, then it will be clear that fibrinogen is left behind in the 
filter and serum is yield in the filtrate. However, if even only a small amount of fibrin 
is recovered in the filtrate, then the only possible way to classify it is to say that these 
filters will filter out plasma. If this happens, then further research will have to be 
conducted as to how serum can be extracted using these filter papers. 
3.2.4.  Design of a Microchip that Incorporates Blood Filtration 
Ultimately, this new chip design will incorporate a one-touch system, where 
the user will use a drop of blood onto the filter and the micropump will draw the 
plasma into the chip and perform the immunoassay with only the touch of a button. 
The filter will be embedded inside the microchip to allow for filtration without the 
need for an external source. Because filters come in all shapes and have different 
microstructures and properties, they have to be taken into account. From all of this, a 
microchip that enables both sequential loading and blood microfiltration will be used 
to perform immunoassays in order to detect various diseases found in the blood.  
This chip will encompass the idea of sequential loading, where a reagent is 
transported into a detection area one at a time by use of a micropump. Along the way, 
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different projects will encompass the focus of the main project. These projects include 
finding a suitable method for microfiltration, finding out how much plasma or serum 
can be extracted by using this method of filtration and checking the quality of the 
plasma based on the number of blood cells filtered out. From these results, a suitable 
design for the sequential loading microchip that encompasses microfiltration will be 
designed. 
However, in order to make sure that blood filtration and sequential loading can 
be easily combined into one chip, a prototype filtering chip has to be introduced. This 
chip would only involve the direct separation of plasma from blood. This is just to 
make sure that not only the filter can be embedded inside the microchip, but the 
plasma can easily flow into the microchannel without the risk of hemolysis or a 
sudden increase in the vacuum pressure. In order to perform this, a PDMS slab will be 
used to hold the filter in place. This slab will have an indent, which will act as a 
mechanism to hold the filter in place. To make sure that this procedure works each 
time, the filter has to be cut at precisely the exact dimensions to fit in the chamber 
properly. If the filter is too small, the blood would run over the sides. However, if the 
filter is too big, the PDMS slabs will not stick together properly. In order to figure out 
the appropriate size of the filter paper, tests will be performed by dropping different 
amounts of blood onto different filter paper sizes. This will be based on the design 
specifications of the filter paper, which was given by the manufacturer. By knowing 
this and that a drop of blood should be in the volume range of 40 – 50 µL, the 
appropriate size filter will be found based on these characteristics. 
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From these specifications, moldings of the filter will be made in order to place 
it between two slabs. Ultimately, the new chip will have multiple layers, instead of the 
two layers that were on it previously. Before the new design, the chip had only two 
layers: a channel layer and a blank slab. This new design will include one additional 
layer: to hold the filter in place. In total, the new chip will comprise of three layers, 
which is shown below. 
3.3.  CRP Detection and HAP Removal 
3.3.1. Surface Functionalization 
Surface functionalization or modification is when a surface has to be coated in 
order to change its properties
[22]
. This can mean by changing the surface of the 
channels by either making them either more hydrophilic or hydrophobic, or by 
allowing proteins or other antigens to bind more easily to the surface. For these 
experiments, because of the surface structure and the hydrophobicity of the PDMS, the 
antibodies used in the ELISA cannot bind to the surface of the channels well. 
However, there are certain known proteins that can readily bind to IgG antibodies. 
One certain protein is known as Protein A, which has a high affinity to IgG 
antibodies
[72]
. However, this protein cannot be stand alone in the channel. The reason 
for this being that even though the antibody would still bind to the protein, the protein 
could bind to other impurities in the chip or that the antibody would bind to the 
channel in a way that is not beneficial to the experiment. This type of binding is called 
non-specific binding. To circumvent this, a blocking agent has to be placed on the 
surface beforehand. One known protein that is able to do this is bovine serum albumin 
(BSA). BSA is a non-reactive protein that can be used in order to coat the surface 
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before protein A can be inserted into the chip. However, since BSA does not react and 
proteins usually do not bind with each other, there has to be a linker that can be able to 
connect both proteins. One known linker is glutaraldehyde (C5H8O2). Glutaraldehyde 
is a 5 carbon single chain with two aldehyde (one carbon attached a hydrogen and a 
double-bonded oxygen). With these two aldehyde groups, it is used as an amine-
reactive crosslinker, in which it can easily link two proteins together. This would 
enable a tight link between the blocking agent BSA and the capturing agent protein A. 
3.3.2. Method of Surface Functionalization 
To functionalize the PDMS, each chip is first checked to make sure that no 
leaks occur in the chip due to improper sealing. PBS (phosphate buffer saline) (Fisher 
Scientific) is inserted into the channel to clean out the channels and to make sure 
leaking does not occur. Once the PBS is removed from the channel, a mixture of BSA 
(Sigma Aldrich, St. Louis, MO) and PBS (1.5 mg/mL) is inserted in the chip. The 
chips incubate at room temperature for 4 hours in order for the BSA to attach to the 
channel. The BSA is removed from the chip and PBS is inserted and removed to wash 
the chips and remove excess BSA. The channels are aerated in order to remove excess 
liquid. A mixture of glutaraldehyde (Sigma Aldrich) and water (0.4% v/v) is inserted 
into the chip. The chip is then incubated at room temperature for 1 hour. The 
glutaraldehyde is removed and the chip is washed with PBS and aerated a second time. 
Protein A (Sigma Aldrich) in PBS (50 µg/mL) is added in the chip and incubated at 
room temperature for 1 hour. The protein A is removed and the chip is washed with 
PBS and aerated a third time. A storage buffer consisting of 10 mM Tris in distilled 
water, 0.05% BSA (w/v), 0.05% Proclin 300 (v/v) and 5% Glycerol (v/v) is inserted 
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into the chip and the chip is stored at 4°C until the chip is ready to be used
[22-24]
.  
Below is the finished schematic of the functionalization process.  The protocol for this 
procedure can be found in appendix A.4.  A completed functionalization diagram is 
found on the below in figure 3-11 
 
Figure 3-11: Diagram of protein A functionalization on the channel surface 
 
3.3.3.  CRP ELISA and Detection 
This section will explain the process of performing the ELISA inside the 
PDMS chip. This process will be exclusively for the detection of CRP. Later 
modifications, including the addition of the filter and the antibodies for albumin 
removal will be explained the upcoming sections. This section will only focus on the 
detection area. To begin, the storage buffer is removed from the microchip. PBS is 
then inserted inside the chip, which will remove the excess buffer. In the case where 
the chip only includes the detection area and not any other channels for protein 
removal, an additional aeration step will be required after every wash in order to 
remove any excess fluid. In the case of multiple liquids, the fluid will be moving slow 
enough so that there is no accumulation of excess fluid on the surface of the channel.  
After the PBS has been removed, the captured antibodies are inserted into the 
detection area. The capture antibodies being used are Mouse monoclonal anti-human 
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CRP IgG antibody (Abcam, Cambridge, UK) at a concentration of 200 µg/mL in 
Protein A/IgG binding buffer (Thermo Scientific, Rockford, IL).  These antibodies are 
incubated in the channel for 7 minutes. The antibodies are removed from the chip and 
PBS is inserted to wash the channels. The CRP (Fitzgerald Industries, Acton, MA) is 
then inserted into the chip.  In terms of the type of protein, it is unclear on whether or 
not the CRP is in the pentagonal form, or the monomer based on the Fitzgerald 
website
[73]
, but it can be assumed it is the pentagonal form because it is the most native 
form and the CRP has to go through a dissociation process in order break into 
monomers
[74]
.  The protein is mixed with either a solution of PBS or serum that does 
not contain any CRP (Fitzgerald). Because of this, different concentrations will have 
to be added to the solution. For these experiments, the CRP concentration in either 
PBS or serum will be between 0.7 and 100 µg/mL.  Also, depending on the type of 
experiment, the protein will have various incubation times associated with it. 
However, for normal detection of CRP, an incubation time of 5 minutes will be used 
for each experiment. This will not have an effect on whether or not buffer or serum is 
used. 
Once the incubation of the protein has completed, it is removed and washed for 
a third time with PBS. A mixture of the detection antibodies in PBS (50 µg/mL) is 
then inserted into the chip. The detection antibodies used are Goat polyclonal anti-
human CRP IgG antibody labeled with FIT-C (Abcam).  The antibodies will then 
incubate for 5 minutes. After the incubation, the antibodies are removed and a final 
was step is required. This time, instead of PBS being used for the wash, PBST (1X 
PBS + 0.5 µL Tween 20 per 1mL PBS) will be used. This is a stronger wash than PBS 
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and it will remove more of the improperly bound antigens. After 5 minutes of 
incubation, the PBST is removed from the chip and PBS is then inserted in order to aid 
in detection.   This is also shown in the protocol in appendix A.4.  A diagram of the 
sandwich ELISA is pictured below in figure 3-12
[22-24]
. 
 
Figure 3-12: Diagram of completed sandwich ELISA for CRP detection 
 
Detection is performed by using fiber-optics.   The detection area consists of a 
spectrometer (Ocean Optics, USB4000, Dunedin, FL), which is hooked up to a 
computer.  To perform the detection, the fiber-optic cables are inserted into the 
openings of the chip next to the detection area. The chip with the fiber-optics is placed 
inside the detection box. To activate the antibodies, the power is turned on, which 
activates an LED (light emitting diode) (Quadica Developments, Brantford, ON, 
Canada) in order to excite the FIT-C. The light will travel through a series of bandpass 
filters that will filter the incoming light to give off a wavelength of 470 nm (Edmund 
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Optics, Barrington, NJ).  This filter that was used has a bandwidth of 10 nm, a 
minimum transmission of 45% and an optical density (OD) of 3.  This enabled the 
filter to block excess light that would interfere with the detection area and eliminate 
most of the background noise in the system.  Detection and readings are performed by 
using the Ocean Optics program Overture. The wavelength is adjusted to 200 nm and 
the reading will be read at 493 Hz. This is where the spike will appear on the screen. 
The higher the spike, the more “full” the detection area will be.  The absorbance level 
will be recorded and then plotted using Excel against the concentration of the IgG
[22-
24]
.  The experiment setup is shown below in figure 3-13 and example plots for the 
experiments will be available in appendix A.5. 
 
 
Figure 3-13: Front view (top) and top view (bottom) of fiber optic test are for CRP 
detection 
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3.3.4.  High Abundance Protein Removal 
One of the main issues with performing a LOC with using blood plasma or 
serum is the abundance of proteins in the blood. There are numerous proteins that can 
be found in plasma that are known to cause interference in an ELISA-type assay. 
These proteins not only can block the attachment areas in the assay, but also can 
remove the antibodies that are used to capture CRP. The best way to overcome this 
would be to remove the high abundance proteins already after the blood cell filtration. 
In order to do this, it would have to come after the blood cell filtration site and the 
detection site, since the blood cells can cause havoc with the detection for the same 
reasons stated above. 
Since there are many abundant proteins in serum, it would be most beneficial 
to focus more on the most abundant proteins: human serum albumin and human IgG. 
The reason for this being that they are the two most abundant proteins in plasma and 
serum, they tend to cause the most interference when trying to perform experiments 
that deal with plasma. There are other proteins that can cause interference, but these 
two proteins are by far the most abundant and since there are multiple proteins, the 
chip would have to be restructured in order to integrate multiple protein areas.  
The preferable method to remove these proteins would be before the detection 
area, but after the blood cell filtration. This means that there has to be a method of 
protein removal in the microchannels inside the chip. There are different methods to 
remove the proteins, but they involve using different outside sources and expensive 
methods. These methods include electrophoresis
[75]
, which was explained in the 
removal of blood cells
[34]
, a mixture of trichloroacetic acid and acetone
[76]
 and 
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different kits that are designed to remove albumin from serum
[77]
.  While these 
processes are effective, in terms of use on a microfluidic scale, it is rather difficult to 
integrate due to the size limitations on the LOC system.  However, one easy method is 
utilized already in the chip: protein A. Protein A already has a high IgG affinity, which 
is why it is already used in the detection area as a method to capture the capture 
antibody. The same principle can be used in order to effectively capture IgG already in 
a mixture like plasma. The channels of the chip can be coated by way of the same 
method that was used in the ELISA. Also, since there are also anti-albumin IgG 
antibodies on the market, they can be developed the same way as the capture 
antibodies are used in the detection area.  Except these antibodies will be used to 
remove the albumin that is in serum.  The antibodies used in these experiments are 
Goat polyclonal anti-human albumin IgG antibody (Pierce-Antibodies, Thermo, # 
PA1-29338).  Two diagrams showing highlighting these methods are demonstrated 
below in figure 3-14 and on the next page in figure 3-15. 
 
Figure 3-14: Schematic of Human IgG removal from Blood with by way of protein A 
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Figure 3-15: Schematic of Human Serum Albumin removal from Blood with by way 
of protein A and anti-albumin IgG 
 
There have been various methods to test in order to see how the removal of 
albumin and IgG will help in CRP detection and there have been designs and 
experiments performed that test this theory. However, most tests come to a conclusion 
of having the serum flow into a removal site, allow IgG to leave the solution, move to 
an albumin detection site, allow albumin to leave, and then flow to the detection site. 
While this theory may work well, there is one flaw to this theory: the amount of IgG 
and albumin is much greater than that of CRP. This creates the problem that even if 
there is one removal area for each protein, there would still be too much in solution so 
that it will cause interference. Because of this, a false reading can be taken and it 
would incorrectly portray the CRP in a solution. 
3.3.4.1. Indirect Measurement of HAP Removal 
To see how this method can be better develop, one has to look as to how well 
the protein – antibody interaction is. This can be demonstrated by measuring the 
concentration before and after each removal process.  This is what is known as an 
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indirect measurement.  During an indirect measurement, the serum is sent into the 
functionalized channel incubated to remove the high abundance proteins, removed 
from the chip and collected for concentration sampling.  This will help determine not 
only how much of the HAP still remains in solution, but also with basic subtraction, 
how much was taken by the protein.  To perform this experiment, a nanodrop 
specrtrophotometer was used to record the concentration.  The nanodrop used was a 
NanoDrop 1000 from Thermo Scientific.  This was performed at the INBRE 
Laboratory, URI College of Pharmacy.  A drop of the reagent (~2 µL) was placed on 
the center of the sample area.  This works similar to the fiber optic detection system, 
in which a light of a specific wavelength detects the particles in solution
[22]
.  The 
experiments will first focus on the removal of a pre-determined amount of IgG in PBS 
buffer and if that is successful, the removal of albumin in buffer. 
3.3.4.2. Direct Measurement of HAP Removal 
The other method will be a direct measurement of HAP removal.  This 
involves the same procedure as the indirect measurement, but instead of measuring the 
amount of HAPs still remaining in solution, it will measure the amount of HAP 
captured on the channel.  This method will be performed by using the same fiber optic 
detection method as with the ELISA.  The solution that will be used is a mixture of 
IgG labeled with FIT-C (detection antibodies) in PBS buffer.  With this method, it will 
be easy to see how well the IgG will attach to the protein A and come to a conclusion 
as to how well this process is. 
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3.3.5. Chip Designs for Protein Removal 
 In terms of what type of chips will be implemented, there are four main chip 
designs that will be implemented.  The first design is a one channel chip with two 
ports and a hexagonal detection area.  This design will be used to implement not only 
how well blood can enter the chip, but also how can IgG attach directly to protein A.  
This will both be performed with the indirect and direct IgG detections.  Also, this 
chip will be used to measure the CRP detection based on the positive (CRP in PBS 
buffer) and negative (CRP in serum without protein removal) controls. 
 The second design is a modified first design, where there is a longer end of the 
channel between the two ports.  It still will encompass the detection area, but on the 
bottom part of the chip.  This design is for the tests that will implement the IgG 
removal.  The whole chip will be functionalized in the same manner as in the previous 
chip, only the upper channels will be used as the IgG removal areas, and the hexagonal 
area will incorporate the detection area. 
 The third design will incorporate multiple IgG removal areas.  This design 
expands on the premise of the first design.  In this design, there are three separate 
chambers above the detection area that will incorporate more of the capturing of the 
IgG antibodies.  The bottom area below the detection area incorporates a waste area.  
No detection / IgG capturing will be performed in this area.  All this area serves is that 
the fluid will just enter this area after it passes through the detection area.  All of the 
channels of the chip will be coated with BSA, while the detection area on up will 
include the protein A on the channels. 
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 The final design comes from the Franzblau design of the final microchip, since 
this would eventually be integrated in this system
[24]
.  In this design, the same concept 
as the third design will be encompassed, but there are noticeable changes.  Starting at 
the top, there are holes that will lead to a channel which head towards the main 
channels.  This is where the inlet for where the blood / plasma / serum will enter the 
chip.  This is due to the fact that all the reagents will be present on the chip before 
blood plasma is introduced to the chip.  Above that junction where the two channels 
meet will be the storage for the reagents used after the plasma enters the detection 
zone.  In order are, from bottom to top, PBS, detection antibody, PBST, PBS.  Below 
this are the reagents used before the plasma enters the channel.  They are, from top to 
bottom, PBS, anti-albumin capture IgG, anti-CRP capture IgG.  Notice that the 
detection area now is the width of the channel.  This is to allow a better signal within 
the confines of the chip.  Below this is the waste area, where channels have been 
replaces by paper.  This is to better the movement of the fluid in the chip, without 
adding a delay in starting and stopping.  Full pictures of the chips will be presented in 
the figure on the next page. 
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Figure 3-16: Chips used in serum/blood experiments.  Clockwise from top left: 
single-channel detection area, single channel with IgG depletion area, multichannel 
with IgG and albumin depletion areas, multichannel with multiple IgG depletion areas. 
 
3.3.6. Combination of Cell and Protein Removal 
Using all of the methods described above the final steps will be to combine all 
of this into a LOC device that is able to detect CRP from whole blood more 
effectively. All three aspects, blood filtration, high abundant protein removal, and 
CRP detection will be implemented in this new chip. With many methods of detecting 
CRP in laboratories and with LOC processes, this new chip would not only have a 
simple to use design, but also detect CRP with the upmost accuracy. The experiments 
will show the most ideal method of removing blood cells, remove the majority of the 
high abundance proteins and be able to detect real-world levels of CRP from any 
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person. With this, testing for the risk of heart disease will be faster, easier to use, more 
available outside of the lab and more accurate. 
3.3.7. Limits of Detection and Quantification 
Based on the results of the experiments with serum and blood, titration curves 
will be created which display the comparison between CRP concentration in blood 
/serum and intensity detected by the fiber optics.  This diagram will be useful in that at 
a specific intensity value, a CRP concentration value can be founded.  This is useful in 
testing and in homecare use, but it would be ideal to find how well this system can 
effectively detect CRP, especially at low concentrations.  In order to see the 
effectiveness of the system, the limit of detection has to be implied.  The limit of 
detection (LoD) is the amount of, for example CRP, that can be effectively be detected 
in which there is a distinct signal (in which background noise is not a factor)
[78,79]
.  
With the LoD, one can find out the minimum CRP concentration that is allowable for 
accurate detection. 
There are different ways to find the LoD.  This project will focus on 3 methods 
to calculate LoD.  The first is what is known as a visual evaluation.  This involves 
creating a titration curve and checking to see where at low concentrations the graph 
begins to level off to where a constant signal occurs.  This is usually good for 
estimation, but there are two other methods in which LoD can be easily detected.  
The second method is what is known as a signal-to-noise calculation
[78]
.  This 
is a comparison between the amounts of the desired signal compared to the 
background noise.  This means that for a certain amount of signal that is produced, 
there is an amount of noise that goes along with it.  In any detection experiment the 
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amount of signal detected should be greater than the amount of noise detected.  
However, in order to obtain an accurate signal, the signal must be significantly higher 
that then background noise.  In most cases, a 3:1 ratio of signal to noise would be 
adequate in order to obtain an optimal reading.  However, there is a limit known as the 
limit of quantification (LoQ) in which the obtained signal is adequate without any 
objection.  This is usually a 10:1 ratio.  Both of these measurements can be easily 
calculated using the titration curves
[78]
. 
In order to calculate the LoD and LoQ, one has to plot the concentrations and 
signals for the lower end of the curve, usually near or past the point when the signal is 
concentrated at the zero point.  This plot is ideally linear and will give a slope (SL).  
The next step will be to obtain the standard deviations (SD) for each signal omitted.  
This is to see how far from a signal can the reader emit.  This is usually about 95% of 
the mean signal.  In Microsoft Excel, the STEYX formula is useful for this because it 
relates the standard deviations at each intensity for a given concentration and predicts 
the standard error of all values.  With the slope and standard deviation, the following 
two equations can be used to calculate the LoD and the LoQ respectfully
[78]
: 
      
       
  
                         (1) 
     
      
  
                 (2) 
The third method, based from Armbruster and Pry, calculates LoD based on 
the limit of blank (LoB)
[79]
.  The LoB is the highest expected amount that can be 
obtained where no antigen (CRP) is present in the system.  Even though there is no 
CRP in the detection area, a signal can still be obtainable.  For this, reason, a blank 
sample has to be taken into account.  To calculate the LoB, separate measurements of 
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the blank have to be measured.  From these measurements, the mean blank 
measurement and the blank standard deviation has to be calculated.  The LoB can be 
found using the following equation: 
                                     (3) 
Once the LoB is found, a sample with a low amount of analyte is measured and 
the standard deviation is recorded.  The LoD can then be found using the following 
equation
[79]
: 
                                                                                  (4) 
The LoQ can also be calculated based on the following method by rearranging 
and combining the standard deviation / slope ratio
[78]
: 
                                                 
  
  
  
   
   
  
   
  
     (5) 
Rearranging the right side obtains the approximation: 
                                                                (6) 
For this project, the limits of detection and quantification will be examined 
using these three methods and compared against each other. 
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CHAPTER 4 
 
FINDINGS 
 
4.1. Blood Cell Filtration 
After many tests with the vivid plasma membranes, it was shown that they 
were effective on removing RBC’s from whole blood. During each run, the syringe 
withdrew the plasma at a constant flow rate into the tubing until either an air gap was 
present, or the filters became clogged. Plasma was then collected in separate vials and 
analyzed using a microscope. This provided the basis for the removal of blood cells.  
Since the pores of the filters effectively allowed plasma to flow through, it was 
assumed that the proteins also flowed through the filter as well.  This was further 
exemplified during the experiments for fibrinogen detection. 
4.1.1.  Evidence of Blood Filtration 
In order to make sure that the following experiments can even be performed it is 
important that plasma can even be filtered out of solution.  The following pictures give 
an example as to if this process can even work.  For each test, piece of filter paper was 
placed on a slab of PDMS connected to tubing which connected to a syringe.  In this 
example below, a piece of filter paper was sandwiched in between the channeled chip 
and a PDMS slab designed to hold the filter paper. 45 µL of blood was inserted in an 
opening that allowed filtration.  A syringe pump was enabled at a pull flow rate of 100 
µL/min.  The filter paper used in this example is the Vivid Plasma Membrane GX 
from the Pall Corporation. 
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Figure 4-1: PDMS chip with Vivid Plasma Membrane GX with blood first inserted 
onto the paper (top left), spreading throughout the paper (top center), the underside 
after the blood spreading (top right), plasma extracted into the chip (bottom left) and 
filtrate inside of the tubing (bottom right) 
 
As seen in figure 4-1, the blood is added onto the chip and is able to migrate 
through the filter paper.  Note that the inlet into the channels is on the opposite side 
from the inlet to the paper, as to avoid tearing of the paper due to the force of the 
syringe pulling. After two minutes, the paper is concentrated with blood and there is 
noticeable separation in the membrane.  This is given off by that there is a tannish 
color on the paper between the edge and the area of red blood cells.  Normally, this 
paper is white as seen in the top left of figure 4-1, but because this area is darker, it is 
assumed that this would be the filtrate.  The top right shows the underside of the chip.  
Here, the blood has covered the entire area of the filter with it being red, in order to 
show that there are blood cells that are attached to all points of the filter paper.  It is at 
this point that the syringe pump is turned on in order to effectively draw the filtrate 
into the chip. 
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The bottom left shows that chip with the filtrate already extracted into the chip.  
The filtrate is the light tan fluid in the channels of the chip.  It might be a little difficult 
to see the filtrate inside of the chip, so bottom right includes the filtrate inside of the 
tubing that is connected to the syringe.  It is here that one is able to see very clearly 
that the filtrate is being pulled into the tubing, which means that the filter paper is very 
effective in obtaining a good amount of filtrate.  Also, it is worth noting that the 
filtrate has no red in it at all.  This means that the filter has both effectively separated 
the cells not allowed hemolysis to occur.  Because of this, it can be stated that the 
Vivid Plasma Membrane GX is an appropriate filter for separating cells from plasma 
in small quantities of blood.  The analysis of the blood will be investigated in section 
4.1.3.  The next section will explain how much filtrate can be exacted with the 
Membranes GX as well as the GR. 
4.1.2.  Filtrate Volume 
The two filter papers that this project is concerned with are the Vivid Plasma 
Membranes GR and GX.  The main difference between the two, according to the Pall 
website, were the amounts of whole blood it can filter out per one square centimeter of 
paper.  The GX can handle roughly 20 – 30 µL of blood, while the GR can handle 40 
– 50 µL of blood[66].  This is due to the void volume of the filters, where the GR has a 
larger pore space than that of the GX.  Based on this information, the following graphs 
detailing the average filtrate volume are shown below (Figure 4-2 for the GX and 
figure 4-3 for the GR).  Each initial blood sample was set at 45 µL.  Each test was run 
until the filtrate stopped moving due to the blockage caused by the blood cells.  Four 
tests were compiled based on the rate of extraction (50 – 100 µL/min) and by shape of 
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the filter (100 mm
2
 square vs 96 mm
2
 rectangle, based on whether or not the paper 
would break during extraction) 
 
Figure 4-2: Average Filtrate Volume from the Vivid Plasma Membrane GX with 45 
µL of blood 
 
Based on figure 4-2, the average filtrate volume did not vary significantly.  The values 
stayed around 13 – 16 µL filtrate, regardless of the filter shape and flow rate.  
However, in figure 4-3 below, a different story applies. 
 
Figure 4-3: Average Filtrate Volume from the Vivid Plasma Membrane GR with 45 
µL of blood 
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With the GR filter in place, there is a noticeable 5 µL increase with the higher 
flow rate.  This is mainly due to the fact that more filtrate can be extracted without 
environmental factors that include evaporation and the drying of the filter cake.  This 
did not show up in the GX due to the fact that the GR can handle 25% more liquid 
than the GX.  But other than this, there is no difference in the filter papers at the lower 
end of the flow rate.  With both types of filter papers, and both dimensions, it was 
apparent that up to 15 µL of filtrate can be extracted, or up to 35% (rounding) 
extracted from the original amount of blood.  Based on the estimation that 55% of 
whole blood is plasma, this amounts to an estimation of up to 68 – 70% of plasma 
recovered.  A table of values showing each volume extracted as well as percentages 
for total blood and plasma volume recovered for both papers is show below. 
Blood Vol. (µL)  Dim. (mm x mm) Average Vol. (µL) Blood % 
Recovered 
Plasma % 
Recovered 
50 10 x 10 16.5 36.37 67.90 
50 12 x 8 13.25 29.44 54.52 
100 10 x 10 15.5 34.44 63.79 
100 12 x 8 17.17 38.15 70.64 
Table 4-1: Values of filtrate volumes from Vivid Plasma Membrane GX 
Blood Vol. (µL)  Dim. (mm x mm) Average Vol. (µL) Blood % 
Recovered 
Plasma % 
Recovered 
50 10 x 10 15.13 33.61 62.24 
50 12 x 8 14.56 32.36 59.93 
100 10 x 10 20.88 46.39 85.91 
100 12 x 8 18.94 42.08 77.93 
Table 4-2: Values of filtrate volumes from Vivid Plasma Membrane GR 
Based on these findings and the fact that only about 5 - 7 µL is to be extracted, 
either the Vivid Plasma Membrane GX or GR is acceptable.  However, for the 
upcoming experiments, based on the amount of blood that can be withstood, a few 
tests will be conducted with the GX membrane. Even though the GR membrane could 
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handle more blood, it should be noted that the final chip design calls for two inlets: 
one for blood and one for the reagents.  Because of this, the blood inlet has to be 
sealed in order for the reagents to flow through the chip.  Because only a few 
microliters of blood are need and that the blood cells have to plug up the filter, it 
makes more sense to use the GX membranes.   
However, it is crucial to find the limit of what these filters can take.  The first 
test that demonstrated this was performed was with a larger sample size of blood (75 
µL).  Based on the previous experiments, it was assumed that the results would be the 
most plasma that could be extracted from that size of filter paper, since it was 
dependent on the recommended size for that specific blood volume.  For this 
experiment, since the amount of blood being used was about 1.5X the original amount, 
it would be best to use a filter area 1.5X that as well (150 mm
2
).  Also, the opening 
into the chip was on the opposite end of where the majority of blood cells would be 
filtered.  Based on this experiment, it was shown that a large amount of filtrate was 
extracted, with more extracted at a higher flow rate.  This satisfied the findings on the 
proportionality of the paper, where about 35 - 37% of the total blood volume was 
extracted (compared to 33 – 35%), which resulted in an overall percentage of filtrate 
extracted being between 68 and 70%.  The figure and table for this experiment is 
shown on the next page. 
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Figure 4-4: Average Filtrate Volume from the Vivid Plasma Membrane GX with 75 
µL of blood with a filter area of 150 mm
2
 
 
Blood Vol. (µL)  Dim. (mm x mm) Average Vol. (µL) Blood % Plasma % 
50 10 x 15 27.00 36.00 66.67 
100 10 x 15 30.17 40.22 74.49 
Table 4-3: Values of filtrate volumes from Vivid Plasma Membrane GX with 75 µL 
of blood with a filter area of 150 mm
2
 
 
However, with the same filter dimensions, but with the original starting 
amount of blood, it was shown that less filtrate could be extracted.  In the first 
experiments with the GX membrane, about 15 µL out of a total of 45 µL could be 
extracted.  Here on the other hand, only an average between 8 µL at 50 µL/min and 12 
µL at 100 µL/min could be extracted.  This relates to 30% of the total blood yield and 
about 58% of the total plasma yield.  It was possible to extract 15 µL, but only at a 
rate of 150 µL/min.  It should also come to be known that at 10 µL/min, only 4 µL of 
plasma could be extracted.  The graph and table explaining this is located on the next 
page. 
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Figure 4-5: Average Filtrate Volume from the Vivid Plasma Membrane GX with 45 
µL of blood with a filter area of 150 mm
2 
 
Blood Vol. (µL)  Dim. (mm x mm) Average Vol. (µL) Blood % Plasma % 
10 10 x 15 4.00 8.89 16.46 
50 10 x 15 8.54 18.98 35.15 
100 10 x 15 12.75 28.33 52.47 
150 10 x 15 15.08 33.52 62.07 
Table 4-4: Values of filtrate volumes from Vivid Plasma Membrane GX with 45 µL 
of blood with a filter area of 150 mm
2
 
 
Due to these findings, it is important to relate the amount of blood being used 
and the dimensions of the filter paper.  Since the assays would likely be handling 
plasma or serum volumes less than 10 µL, it should be noted that coming from a 
starting blood volume between 40 and 50 µL, a filter area of 100 mm
2
 should be 
sufficient in not only extracting that amount of filtrate, but making sure that the port to 
allow the filtrate to enter the chip is sealed due to the filter cake.  For this, either the 
Vivid Plasma Membranes GX or GR are suitable with a total filter area of 100 mm
2
 
based on concerns for the filtrate volume. 
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4.1.3.  Blood Cell Observations 
                 
                     
Figure 4-6: Microscopic view of using Vivid Plasma Membranes for blood filtration 
(top left: membrane GX – 5X, top right: membrane GX – 20X, bottom left: membrane 
GR – 5X, bottom right: membrane GR – 20X).  The dark channel represents whole 
blood and the four light channels represent filtrate 
 
Based on microscopic observations, it has also shown that there were no 
amounts of RBC in all but two of the filtrate samples. The reason for the amounts of 
RBC in the filtrate was based on sample mixing due to a bad microchip. Other than 
that, it was shown that there were hardly any traces of RBC in the filtrate. The redness 
in the samples explained above was caused by hemolysis either due to the age of the 
blood, or the RBC during filtration. As stated previously, even though there were trace 
amounts of redness in each filtrate, due to the force trying to obtain another 2 µL after 
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about half the possible plasma was recovered, there was no sign of RBC’s anywhere 
after filtration. This satisfies the second focus of the study. 
To show that there was filtrate in these samples, figure 4-7 shows a 
microscopic sample of what happens when there is a tear in the membrane.  Blood 
cells do rush into the channel, but not at the amount found in the control channel with 
whole blood. 
            
Figure 4-7: Microscopic view of using Vivid Plasma Membranes for blood filtration 
with blood cells entering the channel (left: membrane GX – 5X, right: membrane GX 
– 20X)   
 
4.1.4.  Plasma vs. Serum Tests 
 
Figure 4-8: Centrifuged extracted filtrate with ethanol for plasma/serum tests (left), 
fibrin remaining after serum extraction (right) 
 
83 
 
 
Figure 4-9: Centrifuged serum with ethanol for plasma/serum tests.  Note that the 
middle vial had no ethanol added to it 
 
Concerning the presence of fibrinogen, 10% ethanol by volume was added to 
each filtrate sample and frozen overnight to allow for coagulation. Each sample was 
then centrifuged for a half hour to see if there was sediment. The results of this shown 
in figure 4-8 has shown that there was significant coagulation and sediment for each 
individual filtrate. In comparison, figure 4-9 shows the same experiment performed in 
serum.  In figure 4-8, there is a more noticeable amount of precipitate and it is more 
tannish-red than white, as shown in figure 4-9.  Furthermore, in figure 4-9, the middle 
vial is serum without any ethanol added and it is similar to the serum with ethanol 
added.  Therefore, it can be said that each sample was plasma, not serum. In order to 
make it so that these filters release serum instead of plasma, further research has to be 
conducted in order to design a filter that separates serum from plasma. 
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4.1.5. Creation of a Blood Separation Chip 
Figure 4-10: First Prototype of blood-separation chip 
 
In terms of the chip design, the first design, pictured above in figure 4-10, was to be a 
two layer chip.  The bottom layer consisted of the channels used to direct the fluid, 
while the top layer consisted of an open filter at the top.  The dimensions for this chip 
are shown in the schematic.  The filter was to be held into place using a thin layer of 
glue.  While testing, this prototype, there was one main fault with this design.  This 
was caused by the glue on the filter.  The glue seeped throughout the filter, which 
made it so that the blood could not flow through the filter and into the chip.  Because 
of this, a new prototype had to be created. 
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Figure 4-11: Second Prototype of blood-separation chip 
 
This new design consisted of three layers.  The bottom layer is just a flat 
PDMS layer, the middle layer is where all the channels are located and the top layer us 
where the filter is held.  The plasma asher is used to bind all three layers.  The 
channels will be bound as normal, but the filter holder will be bound to the top of the 
chip, with the filter in between the both of them.  In this scenario, the filter holds up 
pretty well and blood flow is not obstructed.  An example of the prototype can be 
found in section 4.1.1 with the figures depicting the blood separation.   
 
Figure 4-12: Modification of second prototype of blood-separation chip 
 
Over the course of this project, this design has been modified in order to 
maximize the effects of blood separation.  For example, in the first update, a second 
inlet channel was added in order to effectively filter out more blood from both sides of 
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the filter paper
[23,24]
.  A second update makes the filter paper circular in order to not 
allow white area and to cover the filter completely with blood
[23,24]
.  These two adages 
will be implemented with the new sequential loading chip being used to detect CRP 
with whole blood. 
4.2.  Removal of IgG 
4.2.1.  Indirect Measurement of IgG 
 
Figure 4-13: Representation of indirect IgG capturing with varying incubation times 
 
The first method used in the removal of IgG was to detect IgG that remained in 
the plasma. Based on the results of these tests, it was determined that the evidence in 
finding the amount of depleted IgG was insufficient. There was a good amount of IgG 
depletion during the early stages with shorter incubation times; however, the 
concentration was shown to be rising as the incubation time elapsed. There not a large 
amount of change between 0 and 2 minutes, but around 5 minutes, there was a huge 
spike in the amount detected and in the opposite direction. There are numerous factors 
that can explain this phenomena happening, which include improper mixing of the 
antibody before the tests and additional proteins/antibodies in the solution. This can be 
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caused by improper binding either to the protein A or the channel and during the wash, 
where improper binding can wash into the solution. Another issue is at larger 
incubation times, protein A can become over-saturated with IgG that it cannot handle 
all the binding and can break off from the glutaraldehyde. The nanodrop does not 
include these factors in its measurement and therefore, will count these rogue agents 
as a part of its total concentration. Because of these reasons, this method of indirectly 
measuring IgG is not useful. A direct measurement of IgG has to be helpful as to how 
well IgG can attach to protein A. Because detection antibodies labeled with FIT-C are 
used in the ELISA, and since protein A has a high affinity to IgG, these antibodies are 
able to attach to protein A and one can be able to use these antibodies to see how well 
they attach to protein. 
4.2.2. Capturing and Direct Measurement of IgG 
 
Figure 4-14: Representation of direct IgG capturing with varying incubation times 
 
In these experiments, the capturing of IgG was performed with the focus how 
effectively IgG binds to protein A. In the following graphs, a similar trend occurs. 
From the start of the experiment to about 2 to 3 minutes, there is a steady increase in 
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the signal of the IgG. However, after this time frame, the signal stays constant. 
However, after 5 – 6 minutes, the signal declines. From the data, this is what can be 
made from it. First, the protein has a rapid rate of capture and it can readily capture 
IgG. However, as expected, there is a limit as to how much antibody can be on the 
protein. This is apparent between 2 and 5 minutes, where the detection is relatively 
level and the same within that time frame. One other thing to keep aware of is that the 
longer the incubation time is (> 6 minutes), the signal decreases. The main reason for 
this being that there the protein can become over-saturated when there are too many 
antibodies on the protein that the protein can likely fall off the glutaraldehyde and out 
of the detection area. 
This is extremely important because once the experiments use serum or 
plasma, it is necessary to remove a great amount of IgG and later on, albumin, so 
knowing how long it takes in order for the protein to become saturated is important. 
Based on these experiments, the optimal time to remove IgG successfully up to 
saturation would be between 3-5 minutes based on the layout of this chip. To be on the 
safe side, it will be the most ideal to have the incubation time set at 5 minutes, which 
would make sure that the majority of the IgG that will be able to attach to the protein 
can be achieved without fear of it breaking away and causing a disruption in the 
detection area.  
Based on this information, one can see how well IgG can readily attach to 
protein A. But how does this help in CRP detection? Both antigens are found in serum 
so it would be best to see how well they can CRP be detected in a buffer that also 
contains IgG. To do this, two variables will have to be considered: First, how 
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incubation time can affect detection. For these trials, multiple incubation times were 
used, which ranged from 0 minutes to 5 minutes. Second, how IgG concentration can 
affect detection. For these trials, IgG concentration varied between 0X to 4X the 
concentration of CRP in solution. This should give an idea as to how well CRP can be 
detected before serum, which contains a larger amount of IgG, can be used. 
4.2.3.  CRP Detection with IgG in Buffer 
 
Figure 4-15: Representation of CRP detection with IgG present with dependence on 
incubation time 
 
 
Figure 4-16: Representation of CRP detection with IgG present with dependence on 
IgG concentration per CRP concentration 
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In these experiments, the capturing of IgG was performed with the focus of 
two variables: the change in incubation time and the change in IgG concentration. 
Based on the results of these graphs, two things can be said. First, as incubation time is 
increased with the IgG concentration the same, the signal also increases. This is to be 
expected since as less IgG is in the detection area, the less interference it causes, 
which means that the CRP signal will be greater. Second, as IgG concentration 
increases, with the incubation time kept constant, the signal also decreases. This is 
based on the fact that there is so much IgG in the system and a limited amount of 
protein A on the channels.  There is a lot more interference in the detection area, 
which attributes to the drop in absorbance. This is helpful because in these 
experiments, the ratio to the amount of IgG to CRP varied between 0:1 and 4:1. In 
human blood however, this ratio is much higher than that of the buffer. Because of 
this, there has to be a way to increase the amount of signal that is comparable to that of 
buffer. 
There are various ways to try to increase the signal such as increasing the 
concentration of protein A and the surface area of the incubation channels.  However, 
it is assumed that the channels are fully concentrated in protein A and in order to 
increase the surface area, the chip would have to be redesigned completely.  However, 
based on the structure of the chip and the dimensions, there is a large amount of space 
utilized for the storage and movement of the fluid compared to the amount of fluid 
used. Because of this, multiple incubation areas can be utilized for the capture of even 
more IgG. The reasoning for this being that up until a certain incubation time (5-7 
minutes), the incubation area will become saturated with IgG that there will still be a 
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significant amount of antibody in the detection area that interference will occur. To 
make it so that this does not happen, multiple IgG capture areas will be integrated in 
order to see if there is a rise in protein A detection. The amount of detection areas will 
vary between 0 and 3, based on the limitations of the design of the chip. 
4.2.4.  CRP Detection in Buffer with Multiple Incubation Areas 
 
Figure 4-17: Bar graph of 10 µg/mL CRP detection in Buffer with 2X the 
concentration of IgG mixed with 0 – 3 incubation areas 
 
 
Figure 4-18: Bar graphs of 10 µg/mL CRP detection in Buffer with and 4X the 
concentration of IgG mixed with 0 – 3 incubation areas 
 
The data above shows the detection of CRP with multiple incubation areas. 
Note that only 3 incubation areas are used due to the amount of liquid and the 
limitation on the chip design. Based on these results, it shows that as the number of 
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incubation areas increase, the intensity detected will also increase. This is to be 
expected since the amount of IgG has been depleted due to the multiple incubation 
areas, which allows for less interference in the detection phase. One thing to be aware 
is that the highest IgG:CRP ratio used here is 4:1. One has to take into account the 
amount of IgG is a lot greater in that of serum and that albumin will also cause 
interference. So even though this data is high, it still cannot compare to a real world 
use as with serum, as shown in the upcoming experiments. 
4.2.5.  CRP Detection in Serum with Multiple Incubation Areas 
 
 
 
Figure 4-19: Bar graphs of 10 µg/mL CRP detection with IgG removal in specified 
removal areas 
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The graphs on the previous page show the same experiments above, but with 
serum instead of buffer.  Note that the light source runs on batteries, which explains 
the low CRP in PBS signal.  The above chart shows two experiments with serum with 
a CRP concentration of 10 µg/mL and with incubation areas that vary between 0 and 
3.  For the most part, there is a noticeable increase in intensity as the number of 
removal areas increase.  However, once the third incubation area is added, there is no 
noticeable rise in intensity.  It is not as easy to see with the second chart, as that there 
is an increase with the additional incubation area, but in the first chart, it is noticeable 
as that these two values are identical.  This may stem from the fact that because the 
amount of IgG is decreasing, the fact that there could be just too little that it either 
makes no difference in the actual assay, or that at every 5 minute incubation areas, 
there is just too little IgG left in solution that grabs on to the protein.  Regardless of 
this, it would be beneficial to observe this with other concentrations. 
 Figure 4-20: Bar graph of 100 µg/mL CRP detection with IgG removal in specified 
removal areas 
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Figure 4-21: Bar graph of 5 µg/mL CRP detection with IgG removal in specified 
removal areas  
  
In the case with 100 µg/mL concentration of CRP in serum, this follows suit as 
previously stated.  However, with 5 µg/mL concentration of CRP in serum, there is a 
different trend that shows.  The experiment follows the same pattern up to 2 IgG 
removal areas, but once the third removal area is reached, there is an issue because this 
value is a lot lower than that of 2 areas.  This can be from the fiber optics not receiving 
a signal, or that something happened to the detection area that did not allow the 
ELISA to function properly.  Regardless of this, it seems that the highest levels of 
detection occur with two IgG removal areas.  The following graphs give a comparison 
to how well CRP is detected at these three concentrations, and would allow seeing the 
difference in intensity for all three concentrations.   
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Figure 4-22: Line plot of CRP detection comparison with 2 IgG removal areas 
 
Figure 4-23: Bar graph of CRP detection comparison with 2 IgG removal areas 
 As shown in the graphs, blue represents detection of CRP in PBS, green 
represents CRP detection in serum without any IgG removal and red represents CRP 
detection in serum with two IgG incubation areas.  This was performed with 3 CRP 
concentrations: 5, 10 and 100 µg/mL.  In terms of both the bar graph and the line plot, 
there was a significant increase across all concentrations with IgG removal.  However, 
the amount detected was still considerably low compared to the amount found in PBS.  
This means that there is interference caused by albumin in the sample.  For this reason, 
it is safe to assume that the removal of IgG is prevalent, however, the fact that albumin 
still has to be removed has to be brought to attention. 
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4.3.  Introduction of Albumin Removal 
4.3.1. Order of Incubations 
 
Figure 4-24: Bar graph representing how order of removal is affected 
 
Once it was discovered that the removal of IgG was effective, the integration 
of anti-albumin IgG had to be considered. The first issue of this is in what order 
should the removal be (albumin → IgG or IgG → albumin). The reasoning for having 
the removal of albumin first is that there is more of it in serum than IgG, whereas the 
reasoning for the removal of IgG first is that IgG in serum can cause interference and 
can break away the IgG already used in capturing albumin. To perform this task, two 
runs were produced where CRP was detected in its normal fashion and the integration 
of protein removal was used. Each run was different as to the order of the removal of 
the protein. The first run consisted of the albumin removal first, followed by IgG 
removal, whereas the second run was the opposite: IgG removal followed by albumin 
removal. Intensity measurements were performed after each removal stage to see how 
well the CRP can bind in the detection area. A negative control which contained no 
removals and a positive control containing CRP in buffer were also used as a 
reference.   
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The results on the previous page show that when the albumin was removed 
first, there was as slight increase in signal.  There was also a slight increase when the 
IgG removal came later.  However, when the IgG was removed first, a higher signal 
was present, that basically was about the same as the signal obtained when albumin 
was removed, followed by IgG.  A stronger signal was emitted when the albumin was 
removed after the IgG.  Compared to the CRP in PBS detection, it was still not up to 
that level, but a stronger signal was found.  The results from this experiment show that 
the preferred order for HAP removal would be the removal of IgG, followed by the 
removal of albumin.  This follows the same reason as in Godfrin and Franzblau
[23,24]
.  
Figure 4-30 on the next page shows the completed chip with the areas highlighted for 
each fluid and where the areas for IgG and albumin removal would be.  Keep in mind 
that even though one area is highlighted for each removal process, the number of 
incubation steps in each area will vary based on the experiment. 
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Figure 4-25: Microfluidic chip including blood separation and areas where IgG and 
albumin removal zones are located 
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4.3.2. Introduction of Albumin Removal Areas 
 
Figure 4-26: Bar Graph representing the addition of albumin removal areas 
 The graph above shows the comparison as more albumin removal areas are in 
place.  The first experiments were performed with 1 IgG removal site, followed by an 
increasing amount of albumin removal areas, from zero to three, including one with 
just serum without any removal and one with CRP in PBS.  The first experiments were 
performed with a CRP concentration of 10 µg/mL, represented the red bars.  The 
initial response was that this performed well because the signal increased with the 
number of detection areas.  However, a second experiment was performed with 5 
µg/mL concentration of CRP and even though the signal also increased, the difference 
between the two concentrations was too small.  This means that if one was to measure 
a CRP in this manner, for a specific intensity, the intensity range for those two 
concentrations would be too small to tell.  Compared to the example of CRP in serum, 
there needs to be a wide range of intensity values for these two concentrations 
 To solve this, two more experiments were performed to see the reasoning 
behind this.  Based on the highest experimental results (1 IgG and 3 albumin areas), an 
additional removal area was added to both experiments (one had 1 IgG and 4 albumin, 
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and the other had 2 IgG and 3 albumin).  Based on these experiments, there now was a 
noticeable difference between the two concentrations.  Each produced a high signal 
and each concentration was close to that of the buffer.  This can be tied in with the 
previous experiments, where even with one round of IgG removal; there was still a 
large amount of IgG remaining in the solution.  Because of this reason, and that the 
intensity increased during this round of experiments, the new flow method for the 
removal of IgG and albumin will be 2 IgG removal areas, followed by 3 albumin 
removal areas. 
4.3.3. CRP Detection in Serum 
 
Figure 4-27: Linear comparison of CRP removal with 2 IgG and 3 Albumin removal 
areas for 5, 10 and 100 µg/mL 
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Figure 4-28: Bar comparison of CRP removal with 2 IgG and 3 Albumin removal 
areas for 5, 10 and 100 µg/mL 
 
The above graphs show the results of the serum tests with this new protocol. In 
this run, 3 different concentrations of CRP were added to the CRP free serum: 5, 10 
and 100 µg/mL. Each of the graphs show that a different amount of CRP can be easily 
identified based on whether or not serum or buffer is used. This is shown based on the 
different color lines on the graph. From here, we can see that a different value/range 
can be associated with each amount of CRP that is added.  
One other thing to note is that the difference in adsorption between 5 and 10 is steeper 
than that of 10 and 100. This means there is a greater difference in whether or not 
serum has 5 or 10 versus whether or not serum has 20, 50 or 100. For this reason, it is 
essential to see if values can be associated with values between 10 and 100. 
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Figure 4-29: Linear representation of CRP detection in Buffer, Serum with high 
abundant protein removal and Serum without High abundant protein removal 
 
 
Figure 4-30: Bar representation of CRP detection in Buffer, Serum with high 
abundant protein removal and Serum without High abundant protein removal 
 
Based on the diagrams above, there is still no change in intensity at 50 and 
even at 25. However, there is a slight drop when the 15µg/mL level is reached. It is at 
this point where an accurate measurement of CRP can be determined. It can also be 
seen that the detection area is fully concentrated, which means that no more CRP can 
be added to increase the signal. Because of this, one can see that the CRP detection 
area is idea for identifying samples of CRP at low concentrations, but not ones with 
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high concentrations. However, his can signify a good yes-no marker on whether or not 
a person has a high risk of cardiovascular diseases, but not an extent as to how the risk 
factors are. 
CRP 
Concentration 
(µg/mL) 
Signal in Serum  
(no removal)  
Signal in Serum  
(IgG and Alb. 
Rem) 
Signal in Buffer 
0.7 1300 2166.4 2373 
1 1840 2563.5 2685 
2.5 3017.6 4747 5156.4 
5 6007 9004.2 10316.43 
10 6959 11486.4 12067.53 
15 7215.75 11779.2 12467.53 
25 7384 12088.6 13223.25 
50 7618.5 12989.4 13894.83 
100 7570 13010.6 13811.9 
Table 4-5: Signals of varying concentrations of CRP in Serum (with and without IgG 
and albumin removal) and in Buffer  
 
 The following table depicts values obtained when the assays are performed 
with different combinations.  The second column represents the signal in serum with 
no albumin or IgG removed (represented by the green line in the graph), the third 
column represents the signal in serum with IgG and albumin removed (represented by 
the red line in the graph) and the fourth column represents the signal in buffer 
(represented by the blue line in the graph).  These numbers represent the signal 
emitted at specific concentrations.  These vales show what has previously been stated, 
but in a numerical format.  This shows the rise in signal compared to the rise in CRP 
concentration and how it varies between the three solutions.  This still shows the same 
issue that once higher CRP concentrations are met, the signal becomes more linear due 
to the design of the detection area and the incubation time in said area.   
Also, it shows where this change from a rise to a linear plot likely occurs. This 
was shown to be around 10 – 15 µg/mL for all three curves.  From this, a table can be 
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made where these two areas should meet.  This was based on dividing the graph into 
two sections and adding a quadratic trend line on the left side and a linear trend line on 
the right.  The graph showing one example is below and the table with the list of 
values is also below.  
 
Figure 4-31: Plot representing where the change of signal in concentration occurs 
(trend lines for serum with stops) 
 
Type of Curve Eq. for Left Side Eq. for Right Side Concentration (@ 
Intensity) 
Serum w/out 
Stops 
Y = 1809x + 560.51 Y = 5.5865x + 
7126.1 
6.224 µg/mL 
(@7161) 
Serum w/ Stops Y = 1804.1x + 
695.75 
Y = 16.538x + 
11609 
6.122 µg/mL 
(@11710) 
Buffer Y = 1870.3x + 
824.5 
Y = 17.541x + 
12391 
6.243 µg/mL 
(@12500) 
Table 4-6: Concentrations indicated where a rising signal turns more linear 
 
 This was based on the fact that the signal started to become concentrated 
around 10 µg/mL.  As a result of this, it was shown that with the increase of 
concentration, the signal started to become stagnant around 12000.  This was easily 
associated with CRP concentrations less than 10 µg/mL.  This was not due to the 
removal of HAPs, but more to do with the detection area itself.  The time taken to 
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capture CRP in the detection area was five minutes.  This was based on the previous 
experiments where at this time, there surface was already concentrated with CRP that 
no further binding could occur.  This method worked well for CRP concentrations 
under 10 µg/mL but over 10 produced this linear correlation whereas the concentration 
of CRP increased, the signal would either increase slightly, or not at all.  Perhaps the 
signal would be better if the incubation time was increased, but with the fact that the 
detection site can become saturated with CRP, this would be unlikely.  The best 
solution to see that there can be an increase in signal would be to increase the surface 
area of the detection area to accommodate this problem.  This method could be 
investigated further in order to see if this holds true.  In the meantime, it can be said 
that at CRP concentrations under 10 µg/mL, this method is preferred, but at or greater 
than 10 µg/mL, there is a high signal, but no clear and concise differences between 
concentrations, especially at concentrations over 25 µg/mL. 
4.3.4. CRP Detection in Blood 
 
Figure 4-32: Graphical Analysis of CRP detection in whole blood compared to the 
serum results 
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After a few experiments in which a normal blood sample was used, a number 
of conclusions can be reached. First, the filter filtered of the plasma well. This meant 
that there was adequate amount of plasma in the channel during the experiment. Also, 
there was an absence of not only red blood cells, but also hemoglobin. This allowed 
the plasma to be a clear liquid, or a light tan liquid, which eliminates the obstruction 
caused by the blood cells. 
Also, the points above on the graph were based on a trend line with the red line 
as the basis for the trend line.  This line is a rough estimate as to how far outside the 
previous experiments were.  This graph however does not take into account a point 
where no signal occurs.  For this, a second plot was created at a CRP concentration 
that is close to 0 µg/mL (around 800 for intensity). 
 
Figure 4-33: Graphical Analysis of CRP detection in whole blood compared to the 
serum results with an estimate point at a CRP concentration of 0 µg/mL 
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In this graph, there are two considerable differences in the trend lines.  The 
first is that two different concentrations of CRP in blood are given.  The table on the 
next page highlights the two differences. 
Graph Signal Emitted CRP Plasma 
Concentration 
CRP Blood 
Concentration 
4-37 9416.875 5.2323 µg/mL 2.8254 µg/mL 
4-37 9629.125 5.4570 µg/mL 2.9468 µg/mL 
4-38 9416.875 4.7377 µg/mL 2.5584 µg/mL 
4-38 9629.125 4.8526 µg/mL 2.6204 µg/mL 
Table 4-7: Values of CRP in whole blood based on experiments and figures 4-32 & 4-
33 
 
Even though the values represented in figure 4-33 are less than that of figure 4-32, 
they do represent the curve better since they are more likely to be found on the red line 
than in the figure 4-32.  This makes this second figure more ideal in estimating the 
value of CRP in blood.  However, the first graph is better at estimating values greater 
than that of 5 µg/mL concentration.  For this reason, in order to accurately see what 
kind of plot can be obtained from these experiments, the two equations created from 
the trend lines were set in order to solve for the intersecting point that was accurately 
depicted on the plots.  From this, it was shown that the two trend lines intersected at a 
concentration of 3.856 µg/mL at an intensity of 7816.  Any values lower than this was 
fitted with the trend line form figure 4-33 and values greater than this was fitted with 
the trend line from figure 4-32. 
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Figure 4-34: Representation of possible CRP detection in Serum  
 
 The graph above shows the possibilities of the detection of CRP as each 
specific concentration is associated with an intensity value.  However, these values are 
for serum alone, which was in the detection area.  In order to see the values of CRP in 
blood, all the serum values would have to be multiplied by 0.54 since 54% of the total 
volume of blood is serum.  The graph for the blood is shown below, which is nearly 
identical to that of serum, but with a different X-axis.  The two black dots represent 
the two experiments with blood being used as a fluid. 
 
Figure 4-35: Representation of possible CRP detection in Blood 
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The following table on the next page represents the intensity values associated with 
the graph at various CRP concentrations. 
Intensity CRP in 
Serum 
(µg/mL) 
CRP in 
Blood 
(µg/mL) 
Intensity CRP in 
Serum 
(µg/mL) 
CRP in 
Blood 
(µg/mL) 
1605.66 0.5 0.27 9668.31 5.5 2.97 
2337.37 1.0 0.54 10090.20 6.0 3.24 
3197.06 1.5 0.81 10453.49 6.5 3.51 
4142.88 2.0 1.08 10762.37 7.0 3.78 
5136.75 2.5 1.35 11021.05 7.5 4.05 
6144.37 3.0 1.62 11233.74 8.0 4.32 
7135.25 3.5 1.89 11404.64 8.5 4.59 
8008.91 4.0 2.16 11537.95 9.0 4.86 
8631.87 4.5 2.43 11637.89 9.5 5.13 
9183.60 5.0 2.70 11708.65 10.0 5.40 
Table 4-8: Values of CRP in serum and whole blood based figure 4-40 
 On the graph, it is worth noting that all CRP concentrations in blood greater 
than 5.5 tend to converge at 12000.  Based on the previous experiments with serum 
only, the signal can get over 14000, but this requires a blood CRP concentration 
greater than 10 µg/mL.  However, from the introduction and the literature review, a 
high risk of cardiovascular disease occurs at 3.0 µg/mL concentration of CRP in blood 
(5.56 µg/mL in serum), this chart works well in the acceptable range of an individual 
with either a low or a moderate risk of cardiovascular disease.  For more extreme 
cases however, it is still functional, but there is known error due to the small spacing 
between the intensity values and CRP concentration.  Therefore, according to the table 
and chart, a reading of under 4000 means that a patient has a low risk of 
cardiovascular disease, a reading between 4000 and 10000 signifies a moderate risk 
and a reading over 10000 signifies a high risk.  According to figure 4-40, the blood 
samples gave off a reading of about 9500, which translates to a CRP blood level of 
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2.87 µg/mL concentration of CRP in blood (5.3 µg/mL concentration of CRP in 
serum), which translates to a moderate risk of cardiovascular disease. 
Since there is no definitive method of checking to see if removal of IgG and albumin 
has occurred in the channel, it would be best to detect the amount of CRP in the 
plasma and then compare it to the amount taken by the graph made in the previous 
experiments. In this case, the fiber optics recorded a signal for two measure 
measurements of blood of 9416 and 9629, which correlates to a CRP plasma 
concentration of 4.78 µg/mL and 4.91 µg/mL, respectively. In order to obtain the 
blood concentration, since the mass of CRP is constant and adding cells increases the 
volume, a good estimate would to take the concentrations and divide by the amount of 
plasma in blood (54%). This will give CRP blood concentrations of 2.58 µg/mL and 
2.65 µg/mL respectively. 
This shows that it is in the normal range of serum as in the previous tests.  
However, one thing of noting is that fibrinogen could still be in the plasma. This could 
still cause some interference within the detection area and/or the incubation areas. In 
order to see if this experiment is performed well, this has to be taken into account. 
This will be talked about in more detail in the upcoming section. Other than this, it 
was shown that the plasma was filtered well and that a respectable signal could be 
found with the addition of blood in the detection of CRP. 
4.3.5. Limit of Detection 
 This section will explain the different methods for limit of detection that were 
used in this thesis.  The first method implemented was the use of direct observation.  
Using the experimental curve with the IgG and albumin removal, it was found that the 
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lowest limits in which CRP that can be detected in which there was a persistent 
increase in intensity was at 0.7 and 1.0 µg/mL.  This was shown in figure 4-34.  
Averaging these two values together gave a limit of detection of 0.85 µg/mL CRP in 
serum, or 0.46 µg/mL CRP in blood. 
 The second method implemented was the signal to noise method of 
determining limit of detection.  The four lowest values that were detectable were 
plotted and a linear trend line was also plotted in order to show the correlation 
between these values.  The standard deviation was also calculated for all the points 
and this was placed with the slope in equation 1 in chapter 3.  The result of this was a 
limit of detection of 0.7 µg/mL CRP in serum and 0.39 µg/mL in blood.  Using 
equation 2, the limits of quantification for both serum and blood respectfully were 
2.12 and 1.17 µg/mL.  The graph displaying the slope is shown below in figure 4-36. 
 
Figure 4-36: Trend line for limit of detection using signal-to-noise 
 The final method implemented was performed using the limit of blank.  In this 
method, assay tests were recorded with no CRP or antibody signal.  The mean and 
standard deviation was recorded and placed into equation 3.  The result of this was a 
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limit of blank of 0.82 µg/mL.  This was placed into equation 4 with the standard 
deviation of the lowest measurement (0.7) and a limit of detection was found to be 
1.10 µg/mL for serum and 0.61 µg/mL for blood.  The limit of quantification was 
found using equation 6 to be 3.31 µg/mL for serum and 1.82 µg/mL for blood.  Table 
4-9 summarizes the methods and values obtained for LoD and LoQ.  The discussion 
about the limit of detection will be addressed in chapter 5. 
Method LoD Serum LoD Blood LoQ Serum LoQ Blood 
Observation 0.85 µg/mL 0.46 µg/mL 2.55 µg/mL 1.38 µg/mL 
Signal:Noise 0.70 µg/mL 0.39 µg/mL 2.12 µg/mL 1.17 µg/mL 
Limit of Blank 1.10 µg/mL 0.61 µg/mL 3.31 µg/mL 1.82 µg/mL 
Table 4-9: Summary of limits of detection and quantification for blood and serum 
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CHAPTER 5 
 
CONCLUSION 
 
5.1.  CRP Detection 
Based on the results of the previous experiments, there are a number of 
conclusions that can be made. The first conclusion is that minute amounts of blood be 
effectively filtered and have no trace of blood cells anywhere.  This is due to the 
construction of the filter membrane in that it is very hydrophilic and has pores large 
enough to allow plasma to pass through and keep blood cells out.  Also, there was no 
sign of either blood cells escaping or hemolysis occurring.  This means that all of the 
filtrate entering the chip was plasma.  This by itself eliminates the majority of objects 
that can cause obstruction with the ELISA in the detection area.  Because of this, a 
chip was created that was able to incorporate blood filtration by using separation 
membranes. 
In addition to this, it is possible to detect CRP in any medium, including 
buffer, serum and whole blood. It is even possible to detect it without the extraction of 
small proteins. However, because of the interference between the capture antibodies 
and high abundance proteins, it was shown not only to be more difficult, but there is 
no variance between different amounts, as compared to detecting CRP with buffer. It 
is also worth noting that protein A can effectively capture human IgG in serum. One 
thing though that has to be pointed out is that there is a limit as to how well protein A 
can hold on to IgG. Usually over 5 minutes of incubation time, the protein becomes 
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too saturated with antibody that the antibodies start to fall off the protein or the protein 
breaks off completely from the channel. This should explain why the signal is lower at 
incubation times over 5 minutes. This was one of the reasons why multiple incubation 
areas had to be included on the chip. The other reason being that the amount of IgG in 
serum is far greater than that of CRP (coupled with the amount of human albumin). In 
order to obtain a better signal, a method of removal of more proteins/antibodies has to 
be used. 
Based on the design of the chip, two incubation areas were originally created: 
one for IgG removal and one for albumin removal. The channels in the chip between 
the filter and the detection area can hold about 50 microliters of fluid at one time. 
Since 5 microliters of serum are only needed for each experiment, it would be best if 
multiple incubation areas were introduced. This would be performed for both the IgG 
and albumin incubation areas. In the following experiments, it was shown that the 
signal for CRP did increase with each additional incubation area, but it is also 
important to know that the rise in signal between 2 and 3 areas is lower than between 1 
and 2. It is best to say that there should be at least two incubation areas just for IgG 
removal. Also, before any experiments are performed with albumin, it is safe to say 
that there should be at least 2 incubation areas for albumin based on the fact there is a 
greater concentration of albumin than there is of IgG. 
The next experiments involved seeing whether or not removal of IgG or 
removal of albumin would come first, based on this assessment, it was determined that 
the removal of IgG would come first because there would not be any interference 
between the IgG in the serum and the IgG already on the protein A. This is based on 
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the graphical data, where there was a higher final signal with IgG then albumin than 
the other way. From the previous experiments, it was then time to test the effects of 
albumin with one base sample (10 µg/mL concentration of CRP). This first 
experiment increased the amount of albumin detection spots, which came after 1 IgG 
incubation area. The results showed that as the amount of incubation areas increased, 
the signal in the system also increased. The same theory applied when a lower 
concentration was used (5 µg/mL). The experiment revealed that the signal also 
increased. However, when the two results were compared there was no clear 
separation in the intensities. There was a difference in the intensities, but it would not 
be considered great. In order to make sure that this is functional, there has to be a large 
enough gap between 5 and 10 µg/mL of CRP. One of the reasons for this being that 
there is only one IgG incubation area. This causes interference not only in the 
detection area, but also with the anti-albumin IgG. Because of this, a second 
experiment was performed, with 2 IgG and 3 albumin incubation areas, and 1 IgG and 
4 albumin areas. 
It was also shown that with concentrations of 5 and 10 µg/mL of CRP, there 
was a distinct difference in the levels in intensity. This difference in intensity was 
between 1500 and 2500 for 5 and 10 µg/mL. This was provided that there had to be 2 
IgG removal areas, followed by 3 albumin removal areas.  Because of this, it would be 
essential to remove as much IgG in serum before albumin can be removed. For this to 
occur, at least two IgG incubation areas have to be established in order for this 
interference to be mitigated.  
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As a comparison between the two previous tests, a higher concentration was 
performed (100 µg/mL). The results of this test showed that there was a rise in signal 
with the increase in concentration. However, the rise in concentration was not as high 
as compared to the lower concentrations. The reason for this being either the 
incubation time in the detection area is too low or the detection area is too 
concentrated with CRP. Because of this, it would be ideal to see what the maximum 
concentration that the detection area can hold. As it turns out, with different dilutions, 
it was shown that a decrease in the signal occurred at15 µg/mL in serum. This is not 
very high considering that this is around the lowest concentration in which the CRP 
level is in the “danger zone”. Because of this, this detection system can inform the 
user whether or not his CRP level is too high, but not to the extent of how high it can 
go. However, it can give the level of CRP in a healthy person accurately. 
The results of the previous experiments resulted in a curve that can be used as 
a correlation between intensity and CRP concentration. This is shown as the red line in 
the graphs in chapter between the blue line representing CRP in buffer (positive 
control) and the green representing CRP in serum without protein removal (negative 
control).  As shown in the graph, the red line is very close to the blue line, which 
means that the process of IgG and albumin removal before the detection of CRP 
worked well. Compared to the line for CRP in serum without any removal, it is on a 
level about 2 times that. Is it possible to achieve a higher signal compared to the 
previous experiments, yes, but that will require another incubation area (either a third 
for IgG or a fourth for albumin), and even then, this does not factor in other proteins in 
serum. Even with the extra incubation area, the intensity would only go up by a few 
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hundred. The important thing is that there is a reasonable curve that can be used to 
detect an amount of CRP in serum, even though it can only accurately detect 
concentrations less than 15 µg/mL. 
As for the tests with whole blood, the experiments worked well from top to 
bottom. There was an ample amount of blood that was filtered well into the chip 
without any blood cells entering or rupturing. The plasma did go through all 5 
incubation areas in the chip and CRP was detected (there was a detection signal 
emitted) in the detection area. One thing to point out is that the signal shows a 
concentration, compared with a trend-line that was less than 5 µg/mL concentration. 
The addition of a 2.5 µg/mL test has shown that there was a decrease in intensity by 
about 3000. However, with tests at 1 µg/mL, the decrease was around 1200, with an 
addition 500 decrease around 0.7.  This shows that while it is possible to detect low 
amounts of CRP, at concentrations under 1 µg/mL, it becomes more difficult due to 
the relative amount of CRP compared to IgG and albumin.  While this test shows that 
it is possible to detect CRP in whole blood, there are still three issues that have to be 
dealt with. First, the blood that was used was from one source. If multiple sources 
were tested, one could see that there could be varying patterns between the different 
blood types. It is not as easy as inserting a fixed concentration of CRP because one 
would have to account for the CRP that is currently in the blood. Second, this is CRP 
detection from a planned detection system. If it could be possible, an actual 
measurement of CRP would have to be performed to see if this method would hold 
water. Finally, the previous tests used serum as a medium for CRP. This new test used 
plasma as a medium. The main difference between the two is the presence of 
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fibrinogen. Fibrinogen is not as abundant as albumin, but it is a larger protein and it 
can cause blood to coagulate when it is outside of the human body. One set of future 
experiments could be to insert a sixth incubation area that removes fibrinogen and see 
if the CRP detection changes.  
 From the results of these experiments, a few advantages and disadvantages can 
be pointed out.  The first advantage is that not only is CRP detectable in serum and 
blood, but it is within the area of using CRP in a buffer solution with the same 
detection.  This means that a wide range of signals that are normal can be found and 
there can be different absorbance values associated with them.  The second advantage 
is that blood that was either not de-coagulated with EDTA or diluted worked in the 
system.  This means that the system can be used outside of a laboratory setting where 
a prick on the finger for blood extraction can be performed.  One final advantage is 
that this can qualify as an LOC – POCT device, in which patient care can be 
performed on the spot and the amount of blood that can be obtained is less than 50 µL 
per patient. 
 However, there are a few disadvantages to this process.  The first of which 
being the time taken to perform the assay.  It takes on average between 50 and 60 
minutes to perform the assay, with the majority of the time spent on IgG and albumin 
removal.  It is true that the majority of the IgG and albumin can be removed within 2 - 
3 minutes per incubation, but this experiment used 5 minutes as a time in order to 
effectively fill the channel surface effectively with IgG or albumin.  If a 2 – 3 minute 
incubation time is used, it might make the time elapsed half of what this experiment 
calls for (20 – 30 minutes).  A second disadvantage is the detection area.  As 
119 
 
performed in the experiment, a titration curved was created for the detection of CRP in 
serum and blood.  Unfortunately, any blood CRP concentration greater than 5 – 6 
µg/mL kept the curve stationary, meaning that the same signal was still going off.  
Because of this, there is no way to determine the extent of detection for high CRP 
patients without a simple yes or no.  In order to fix this, either a better detection area 
has to be created, or another incubation area time has to be utilized.  One final 
disadvantage is that multiple tests still have to be performed on a patient.  This is due 
not only due to the fiber-optic signal, but also that CRP levels can vary from person to 
person within a few days.  Because of this, multiple readings have to still be 
implemented in order to obtain a good reading.  Despite these disadvantages, this 
method has shown that for normal CRP levels, this method of CRP detection from 
whole blood is ideal. 
 In terms of the limit of detection, it has been shown that this system is able to 
detect minute amounts of CRP in whole blood (< 0.5 µg/mL in whole blood).  
However, both the signal-to-noise and the limit of blank methods display two different 
values.  This is due in part to the signal achieved due to the blank.  Without a chip in 
place in the system, the level of intensity is around 800.  This is fine for the method of 
signal-to-noise because it assumes a intensity of 700 at no CRP concentration (see 
figure 4-41), but in the case of limit of blank, it has been shown that with a blank, 
there is still an intensity level of 1900 that has been detected, with a standard deviation 
of around 150.  The lowest experimental level is at 0.7 µg/mL and the intensity values 
have shown have a value of around 2100 and a standard deviation of around 300.  
With the calculations, it was shown that the limit of detection was doubled using the 
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limit of blank.  As a comparison, a second signal-to-noise ratio was conducted, as seen 
in figure 5-1.   
 
Figure 5-1: Signal-to-noise LoD calculation with emphasis on the blank point 
This time, this calculation was based on the blank measurement.  The result showed 
that LoD for serum and blood were the same as with the LoB method (1.11 µg/mL & 
0.61 µg/mL respectfully).  Because of the blank intensity being that high, this was 
shown in the LoD calculations. 
 As a comparison for this project, it would wise to take a look at the results 
from Godfrin
[23]
.  In his set up, only there was only one incubation area for each HAP 
removal.  These incubations was only for 7 minutes each, whereas the incubations for 
this report were for only 5 minutes based on the protein A experiments.  Also, his 
included a blocking step where BSA was used to eliminate any non-specific binding, 
whereas this project did not incorporate it, since it relied more on the protocol from 
Li
[22]
 and Franzblau
[24]
.  Furthermore, the CRP incubation time was longer than the 
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one used in this report (10 min as compared to 5 minutes).  Because of this, the 
majority of time used in CRP detection in Godfrin
[23]
 whereas the majority of the time 
was used in HAP extraction.  The table below highlights the times needed to perform 
each step. 
Incubation Step Time via Godfrin (min) Time via Pytka (min) 
Capture Antibody 7 7 
Blocking w/ BSA 5 0 
IgG Removal 7 (1 @ 7min) 10 (2 @ 5 min) 
Albumin Removal 7 (1 @ 7 min) 15 (3 @ 5 min) 
Sample (CRP) 10 5 
Detection Antibody 5 5 
PBST 5 5 
Rinse, Pumping & 
Detection 
4 8 
Total 50 55 
Table 5-1: Comparison between CRP detections based on the Godfrin
[23]
 and Pytka 
systems 
 
 Even though these differences apply, the system used in this report was only 5 
minutes longer than the one used by Godfrin.  Knowing that less than 5 minutes was 
an acceptable time for the incubation, if this was implemented, it amount of time for 
the process would decrease by about 20%.  Also, it would be ideal to look at the 
comparisons graphically, which are shown in figures 5-2 to 5-4. 
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Figure 5-2: Comparison of CRP detection in buffer graphs between the Godfrin
[23]
 
project (top) and this project (bottom) 
 
 The first comparison is the CRP detection in PBS buffer.  Based on the results 
of these graphs, it was shown that both graphs are similar not only in shape, but also in 
the intensity values.  Based on this, both graphs can be used as a bench mark for a 
comparison with serum and blood. 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
0.1 1 10 100
In
te
n
si
ty
 (
co
u
n
ts
) 
CRP Concentration (µg/mL) 
Comparison of CRP Detection in Buffer 
123 
 
 
 
Figure 5-3: Comparison of CRP detection in serum graphs between the Godfrin
[23]
 
project (top) and this project (bottom) 
 
 In the serum tests, there are a few key factors to point out.  First of all, the 
Godfrin test used a diluted serum (10:1 PBS:Serum) in order to test the functionality 
of the system
[23]
.  This report, on the other hand, did not use diluted serum, which 
means that the normal IgG and albumin concentrations in serum were kept intact.  
Even with this modification, it was still shown that the rise in intensity in the Godfrin 
experiments were not as great as the experiments in this report.  This could be partially 
based on the amount of HAPs still in the serum.  There was a rise in the intensity as 
concentration increased, but compared to the values to the bottom graph, it was not 
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buffer curves.  The bottom graph, on the other hand, matched almost exactly the buffer 
curves.  Table 5-2 on page 118 shows the percentages of CRP detected in serum 
compared to the buffer curves for both experiments. 
 
 
Figure 5-4: Comparison of CRP detection in blood graphs between the Godfrin
[23]
 
project (top) and this project (bottom) 
 
 For the results based on whole blood tests, keep in mind that the CRP 
concentration in serum is larger than that of whole blood.  This is due to the removal 
of cells that contribute to 45% of the total volume in blood.  This is important because 
the Godfrin tests used blood doped with a certain CRP concentration
[23]
, whereas this 
project estimated the CRP concentration by multiplying the concentration CRP in 
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serum by 0.55.  Because of this, only the lower end values for the Godfrin graph apply 
here.  The Godfrin graph shows a rise in intensity based on the CRP concentration, but 
it still was smaller than that in diluted serum (see figure 5-2) for each concentration.  
The blood values obtained in this project used the assumption the only difference 
between the serum and blood graphs were the loss of 45% of the blood volume.  Thus, 
taking a look at both graphs, up to 5 µg/mL concentration, there is a substantial rise in 
concentration in both graphs, but the Godfrin plot is too low compared to the plots in 
this project.  Tables 5-2 and 5-3 shows the specific CRP concentrations of both 
projects and compares them to that of the concentrations for each one in buffer. 
Godfrin Project Pytka Project 
Conc. C (Se) C (Bu) % Det. C (Se) C (Bu) % Det. 
0.5 405 2200 18.4% 2166 2373 91.3% 
1.0 510 2250 22.7% 2564 2686 95.5% 
5.0 700 7500 9.33% 9904 10316 96.0% 
10.0 930 14000 6.64% 11486 12067 95.2% 
Table 5-2: Comparison of detectable CRP in serum amounts and percentages detected 
for both projects 
 
Godfrin Project Pytka Project 
Conc. C (Blood) C (Buffer) % Det. C (Blood) C (Buffer) % Det. 
0.5 490 2200 22.3% 2337 2373 98.5% 
1.0 450 2250 20.0% 4100 4300 95.3% 
5.0 590 7500 7.87% 11600 12000 96.7% 
Table 5-3: Comparison of detectable CRP in blood amounts and percentages detected 
for both projects 
 
The Godfrin plots can only detect normal CRP in the intensity range of 450 – 
600.  This system on the other hand, can detect CRP in the intensity range of 1600 - 
12000.  This means that because of the high range, there is a small window of error 
between two distinct concentrations (for example, a 1.0 µg/mL difference in 
concentration).  Even though there is still error in this new system, it only varies about 
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0.5 µg/mL compared to 1.0 µg/mL.  Even though the CRP could be detected 
accurately with a concentration less than 5.5 µg/mL concentration in blood, this is still 
within the range of normal CRP levels in blood.  This difference is due to the amount 
of HAPs still in the serum during CRP detection.  This was shown in the amount of 
CRP recovered in each of the experiments.  The Godfrin experiments only recovered 
about 20% of the available CRP, and then decreased for each additional concentration.  
Whereas this project saw the percentage of captured CRP did not drop below 90%.  
This was due to the addition of multiple incubation areas in the chip.  Because of this, 
a better method of accurate detection of CRP in whole blood was possible. 
One final thing to point out is the comparisons of the limit of detection.  The 
method used in the Godfrin experiments was a variation of the limit of blank.  In this 
case, the LoD was found by taking the average signal at the blank and adding it to 
three times the standard deviation of the blank.  Using this method, this LoDs in this 
thesis were 0.93 µg/mL and 0.50 µg/mL for serum and blood respectfully.  In the 
Godfrin thesis, the same LoDs were at were 0.14 µg/mL and 4.54
[23]
.  The reasoning 
for the smaller LoD in serum is that, again, diluted serum was used for the 
experiments, and that the zero concentration intensities were a quarter of the 
experiments in this thesis.  As for the blood LoD, because of the amount of HAPs still 
in the system, it was not accurate in low concentration areas.  This is the reason for the 
high LoD for blood compared to the method in this thesis.  Because of this, it was 
shown that the addition of multiple HAP incubation areas not only could accurately 
capture and detect low amounts of CRP in blood, but also detect amounts less than 0.7 
µg/mL in blood. 
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5.2.  Further Work 
Even though the previous experiments performed well and had shown that 
CRP can be detected with whole blood, there are a few more experiments that can be 
performed in order to make the system better. The first experiment could be the 
addition of a fibrinogen incubation area. As discussed previously, the blood plasma 
tests were assumed that the fluid behaved similarly to serum, when in actuality, the 
main difference is that serum does not include fibrinogen. Fibrinogen is a relatively 
large protein that is used in clotting and solidification of blood. The reason that this is 
an issue is that fibrinogen can act like albumin in that it can cause interference in the 
detection area. Even though there is not a large concentration of it, in comparison to 
albumin, it is a larger protein and it can cause more havoc. If there was any 
interference due to fibrinogen in the chip, the intensity would be a lot lower than what 
it should be. In order to get a better estimate as to the level of CRP in a sample of 
blood, it might be essential to include a fibrinogen incubation area either before or 
after the albumin incubation area. 
The next experiment would be the addition of various samples of blood. Each 
individual has a different level of CRP in their blood and the previously experiments 
only used one type of blood. With multiple samples, it would be efficient to see where 
these samples lie on the curve in order to show how well various CRP levels can be 
detected in blood. One other issue is the lack of an official CRP measurement. The 
previous experiments were an estimate as to how much CRP is in the blood, but the 
accuracy of this system cannot be verified until an official measurement can be 
obtained for comparison. 
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Even with those experiments being performed, there is a possibility for future 
work. The first possibility is the integration for automation. The previous experiments 
were done manually with either a syringe or a syringe pump. There have been attempts 
to integrate this into an automated system. A previous Master's and PhD project 
included developing machines that perform this automation
[22,24]
. This new method 
would involve rewriting a code that would enable the fluid to move automatically and 
account for the multiple incubation areas. 
The second possibility would integrate a better detection system for CRP 
detection. The main system used for detection is by way of fiber-optics. While it is a 
good method for detection, there are various short comings associated with using 
fiber-optics. These include polishing the optic wires for better detection, the fact that 
they can easily break and be expensive to repair and replace, and are bulky for a 
portable system.  One good detection system would be the use of a charge-coupled 
device (CCD).  Previously, CCDs were tested as a measurement for detection when it 
comes to immunoassays
[60]
. A CCD acts much like a camera where a snapshot of the 
detection area is taken and that photo is analyzed using imaging software 
processing
[80]
. This method is less bulky and cheaper to maintain than fiber-optic 
cables. The help of a CCD can be beneficial for more accurate and more sensitive 
detection. 
A third possibly would be a new method of chip design and creation. 
Typically, chips take on average 1 – 3 days to create, with an additional 1 – 2 weeks to 
create the molds. Also, with the proximity of volatile chemicals and the fact that the 
molds could be damaged, a better chip could be constructed. One method is the use of 
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paper as a substitute for PDMS. Channels can be made in the paper which would 
allow fluid to travel through it
[81]
. Also, special areas can be set up for incubation and 
detection
[81]
. It would be cheaper to produce the chips on paper and in a shorter time. 
Finally, no fiber optics will be used in detection. The main source of detection will 
come in the form of image processing. The only downside is that fluids cannot be 
stored on a paper chip like a PDMS chip can. But small vials can be used for each 
reagent. With that aside, a paper-based chip would be useful for the next step in better 
tuning this current chip. 
One final future project would be the detection of other antigens in the blood. 
There are many different proteins found in human blood and each protein has a 
specific function associated with it. In addition, various antibodies have been created 
for capturing and detecting these antigens. They can be integrated in the chip in order 
to determine how much of a specific antigen does this person possess. An example of 
an antibody that has been created to detect and attach to a specific protein will be 
discussed in the next section.  With these advancements, it would be possible not only 
to better detect CRP in blood, but also other proteins and viruses that could be 
detrimental to human life.  In conclusion, a better method of detection C – reactive 
protein from whole blood using lab-on-a-chip methods was found by using filter 
membranes for blood filtration and the introduction of protein A and multiple 
incubation areas for the removal of high abundance plasma proteins.  This method not 
only produced a high array of signals, but was also accurate in detection.  
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 SECTION 2  
 
CREATION OF A RECOMBINANT ANTIBODY AGAINST TAU PROTEIN 
 
CHAPTER 6 
 
INTRODUCTION 
 
 6.1. Alzheimer's Disease 
 One of the most common ailments that can affect a large percentage of the 
older generation is Alzheimer's disease.  Alzheimer's is a neuron-degenerative disorder 
characterized by memory and cognitive loss, dementia and a rapid reduction in brain 
matter[82].  According to the Alzheimer's Association, there are currently more than 5 
million Americans with a form of Alzheimer's and a new case developing every 67 
seconds.  It is the 6th leading cause of death in the United States with approximately 
500,000 individuals dying each year[83].  Currently, there is no cure for Alzheimer's 
and no method of either prevention or of slowing the disease.  If trends like this 
continue, by 2050, the amount of patients with Alzheimer's would triple from 5 
million to just over 13.8 million[83]. 
 The basic methods of detection of Alzheimer's include determination of 
memory loss, difficulty completing ordinary tasks, problems with speaking and 
writing, misplacement of goods and mood changes, to name a few[84].  But this only 
helps in determining whether or not someone has Alzheimer's, not a method of early 
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detection.  This has to be performed by various tests in the blood and in the spinal 
cavity[85].  While there is no set method to detect Alzheimer's early on, there are 
relationships in body functions that can relate if whether or not a patient could be 
diagnosed with Alzheimer's early on. 
6.2. Tau Protein 
 One such relationship is the interaction of Tau protein.  Tau is a rod-like protein 
found in the brain and the spinal column that helps to stabilize other proteins known as 
microtubules[82] and by relaying messages throughout the body.  Tau performs these 
tasks by undergoing a process known as phosphorylation, which allows the protein to 
interact with phosphates and break up and send messages to other parts of the 
brain[86,87].  However, if too much of this occurs, the brain area can start to degenerate 
and exhibit symptoms of Alzheimer's based on CAT scans of different patients[88].  It 
has recently been discovered that tau may be the culprit of the main effects of 
Alzheimer's disease[85].  Because of this, there have been new developments as to how 
tau can be detected. 
6.3. Antibodies against Tau 
 One method of the detection of tau protein would be the use of antibodies that 
attach to tau[89,90].  This was explained in the first section where CRP was detected 
using antibodies.  These antibodies can be used for immunoassays in order to 
determine the risk of Alzheimer's based on the concentration of phosphorylated tau 
(pTau)[89].  However, tau is a long protein with little known antibodies, especially in 
places where phosphorylation can occur[91].  Because of this, it would be ideal to 
create antibodies specifically to bind to those areas of tau.  The most common method 
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to create antibodies is to inject antigens from multicellular organisms and extracting 
them[92].  However, since using multicellular organisms is a huge liability, there has to 
be another method in which antibodies against tau can be extracted.  Fortunately, there 
is a method called phage display which uses a known antibody library packed into 
phage, which is a virus, which can attach to tau antigens.  In this method, the phage 
injects the antibody library into bacteria and from there, antibody fragments can be 
produced in the bacteria[93].  Even though these fragments are more basic than IgG, 
they still contain the necessary parts that can bind to tau.  The upcoming sections will 
explain why an antibody for Tau has to be found and how using bacteria and phage 
display, these antibody fragments can be created. 
6.4. Phage Display 
 Antibody phage display allows the generation of e.g. human antibodies in 
vitro. In antibody phage display, an antibody fragment, in this work the single chain 
fragment variable (scFv), is displayed on the phage surface and the corresponding 
genetic information for this scFv is encoded on a phagemid which is packaged in the 
phage particles. Therefore, the genotype and genotype are coupled.  In the phagemid, 
the scFv gene fragment is fused to the phage gene III (gIII), encoding phage protein III 
(pIII). This allows the expression of a fusion protein: scFv::pIII. During phage 
assembly in E. coli, the fusion protein will be incorporated in the phage particle and 
the phagemid will be packaged in the phage resulting in an antibody phage[92-95]. 
Antibody fragments can be selected by a process called panning. An antibody phage 
library (HAL7/8 in this work) can be incubated with the desired target molecules (Tau 
peptides in this work). The non-binding antibody phage will be washed away and the 
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bound antibody phage particles will be eluted. E. coli will be infected with the eluted 
phage particles and with the help of helper phage; new antibody phage particles will 
be produced. These amplified phage particles will be used in a next panning on the 
desired target to further increase the fraction of target specific antibodies. These 
panning rounds will be performed 3-4 times[94,95]. 
Single bacteria colonies, infected with the antibody phage particles of the last 
panning round, will be cultivated in micro titer plates and soluble monoclonal 
antibodies will be produced. These monoclonal antibodies fragments will be tested by 
ELISA to identify monoclonal binders.  Subsequently, the scFv encoding gene 
fragments can be analyzed by DNA sequencing to identify unique binders and for 
further analysis. Finally, these antibody fragments can be recloned in any antibody 
format (e.g. IgG) for further production and biochemical analysis[94,95]. 
6.5. ELISA 
 In order to test if these antibodies are beneficial, assays have to be completed 
in order to make sure that these antibodies bind to the specific proteins.  The tests 
performed are known as Enzyme-linked Immunoassays (ELISA).  As explained in 
chapter 2, these tests use a series of antibodies to capture proteins and antigens and a 
second set of antibodies to detect said proteins and antigens.  A substrate is then used 
to detect these antibodies[12].  Multiple types of ELISAs exist, which, as explained in 
chapter 2, include direct (where a protein is unknown and antibodies can detect it), 
indirect (where the antibodies are unknown, and the protein is known), sandwich 
(where an antibody specific to a certain antigen is first placed onto the bottom of a 
well), and competition (where competing proteins/antibodies are used to “compete” 
134 
 
with the main ELISA).  These types can be integrated into two main ELISA 
experiments: screening ELISAs, where different clones can be found, and titration 
ELISAs, where the overall strength of detection is found[92].  These two experiments 
can be integrated in order to create an antibody that can easily detect tau protein. 
6.6. Objective 
 The focus of this investigation is the creation of two recombinant antibody 
fragments that attach to two specific types of tau as a biomarker for Alzheimer's: 
phosphorylated tau (tau with phosphate groups attached (pTau)) and non-
phosphorylated tau (tau without phosphate groups attached (Tau)).  These two 
antibody fragments are beneficial in that they would be able to attach not only to 
healthy tau, but also tau that may be a factor in Alzheimer's disease. 
 The first task of the project is the creation of the fragments.  This will be 
performed by the use of phage display.  This method will reveal the proper fragments 
that will attach to the protein.  Even though only a small antibody fragment would be 
obtained, it is a cost effective and safer procedure than obtaining IgG 
(immunoglobulin G) from a multicellular organism.  Plus, these same fragments have 
all the proper sequencing that is normally found in IgG in which it attaches to the 
antigen.  This sequencing is what allows the antibody to attach to the protein.  Using 
phage display, one antibody fragment can be obtained from a library of different 
antibody possibilities by injecting DNA into bacteria and creating multiple colonies.  
After three or four panning rounds, one antibody fragment for both Tau and pTau will 
be obtained. 
 The second task of the project is the detection and strength of the antibody 
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fragments.  This is where the ELISAs will come into play.  Using ELISA, these 
extracted antibody fragments will be detected and checked if they are able to bind to 
the antigens.  This process is crucial because it has to be made certain that different 
antibodies can be created.  Also, there will be many clones that can attach to the 
protein.  Therefore, tests will have to be performed to check if these fragments are 
identical and are able to bind well.  This will be performed again by ELISA in order to 
see the limits of concentration that these antibodies can be detected.  Also, since there 
are many clones, these fragments will have to be sequenced.  This means that the DNA 
structure has to be checked to see if either multiple clones have the same structure, or 
that multiple different clones are able to attach to the same protein.  This is important 
because there can be an instance where two antibodies, with different sequences can 
still attach to the same protein. 
 The end result for this investigation will be the creation of two distinct 
antibody fragments that will be able to attach to a section of tau: one that attaches to 
pTau and one that attaches to Tau.  These two antibody fragments will be useful to 
diagnose an early onset of Alzheimer's.  Since tau is a long protein (350-450 amino 
acids)[91], and since there are antibodies that can already attach to parts of tau, this 
project will focus on one section of tau that is prone to phosphorylation and does not 
have an antibody associated with it.  With this method, it can be possible to in the 
future, use this antibody as a diagnostic tool and to map out the entire protein in a 
cost-effective manner, in order to see which antibodies are able to attach to it. 
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CHAPTER 7 
 
REVIEW OF LITERATURE 
 
 7.1. Alzheimer's Disease 
 One of the most debilitating diseases today is Alzheimer's disease.  Alzheimer's 
disease is classified as a dementia usually associated with problems with memory and 
behavior[82].  Dementia is described as a neurological ailment that is associated with 
memory lost.  While older patients do experience some sort of memory loss, it can 
only be described as dementia if this memory loss affects normal everyday activities.  
This not only includes loss of memory, but also problems in communication, the 
ability to stay focused and a lower sense of judgment and reasoning[84].  Alzheimer's is 
the most common form of dementia, with roughly 5 million affected people and a new 
case every 67 seconds.   Each year, more than 500,000 Alzheimer's patients die and at 
current trends, the number of Alzheimer's patients will triple to approximately 13 
million by 2050[83].  With these numbers, it is important to see how large of a factor 
Alzheimer's will be in the upcoming decades. 
 There are various known symptoms for Alzheimer's that affect patients.  
According to the Alzheimer's Association, there are 10 warning signs as to check 
whether or not a person has Alzheimer's.  These 10 signs are listed on the next page[84]. 
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1: Memory loss that disrupts daily life 6: New problems with words in speaking 
or writing 
2: Challenges in planning or solving 
problems 
7: Misplacing things and losing the 
ability to retrace steps 
3: Difficulty completing familiar tasks at 
home, work or leisure 
8: Decreased or poor judgement 
4: Confusion with time or place 9: Withdrawal from work or social 
activities 
5: Trouble understanding visual images 
and spatial relationships 
10: Changes in mood or personality 
Table 7-1: The 10 signs of Alzheimer’s disease[84] 
 One known issue that is important is that currently, there is no known cure for 
Alzheimer's.  Most patients that have been diagnosed with Alzheimer's will die due to 
complications with Alzheimer's.  Not only that, but there is no known method to either 
prevent or to slow down the process[96].  This means that at this time, once a patient is 
diagnosed with Alzheimer's there is no efficient method to help slow down the time 
length from diagnosis to death.  Due to this issue and the fact that more people will 
develop Alzheimer's in the upcoming years, it is important that there is a method to 
detect and try to treat Alzheimer's early on before these 10 factors quickly come into 
play. 
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 7.2. Known Alzheimer's Factors 
 
Figure 7-1: Comparison between a normal and Alzheimer’s affected brain [88] 
 The figure above shows a sketch of a human brain.  The left side shows a 
normal fully functioning brain, while the right side shows a brain based on the effects 
of Alzheimer’s.  The most noticeable trait is the difference in size and in structure.  
The Alzheimer’s brain is noticeably smaller in size and shows more rapid decay.  This 
was demonstrated back in 1906, when Dr. Alois Alzheimer noticed that one of his 
patients was suffering from dementia and had issues with rapid memory loss, 
unpredictable behavior and the need to be depended on others for normal everyday 
activities.  When this patient died, he examined this person’s brain and found that the 
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overall size had reduced and, especially in the cerebral cortex and hippocampus, 
where learning and memory takes place and large gaps or ventricles[88].  This can be 
seen in the cat scans below in figure 7-2. 
 
Figure 7-2: CAT scans of a healthy and Alzheimer’s affected brain[88] 
Currently, it is unknown as to what causes this decay in the brain, but there are several 
factors that associate with this.  Some of these factors include beta amyloid, a protein 
found in plaque areas around the brain[97,98], and tau protein, known tubules, in which 
fragments can be found the blood and spinal fluids of patients[99,100].  Even though 
there is no known concrete evidence that these two proteins cause Alzheimer's, they 
are still regarded as a links into how the disease is formed and what is happening in 
the brain area.  The upcoming sections will explain the proposed roles of both beta 
amyloid and tau in Alzheimer's. 
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7.3. Beta Amyloid 
 Beta Amyloid (aβ) is a protein that commonly shows in patients that have 
Alzheimer's.  This protein is a relatively short protein (consisting of about 40 amino 
acids) and is often the result of proteolysis, or protein breakdown, of the large 
Amyloid precursor protein (APP)[101,102].  There is little known about the function of 
APP, but there has been research to suggest that to bind proteins and/or cells together, 
and that it helps to direct the migration of neurons during early development[103].  
Other theories suggest that APP is used in the formation and repair of synapses, which 
join nerve cells and transmit neurons[104,105].  Whatever the function of APP has in the 
body, it breaks down to form aβ.  However, in patients that exhibit all the symptoms of 
Alzheimer’s, one noticeable trait is that plaques of aβ are found in the brain regions.  
This is from the result of the breakdown of APP and that certain forms of aβ proteins 
can coagulate into obscene proportions[102,106].  Below is a diagram that shows this 
result. 
 
Figure 7-3: Sketches of neurons in a healthy brain vs. neurons in an Alzheimer’s 
brain.  Note the abundance of aβ plaques in the brain affected by Alzheimer’s[107] 
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 The breakdown of APP to aβ performed formed by cleaving a portion of the 
APP into smaller structures around 40 amino acids in length[102].  There are two 
common forms of aβ that APP can break down into: aβ40, the most common form and 
aβ42, the form most prevalent in Alzheimer's.  The 40 and 42 recognition only 
corresponds to the length, or number of amino acids.  Also, aβ is made up of a chain of 
hydrphobic and hydrophilic areas in both the middle and ends of the protein.  Aβ 
attaches readily to each other in its hydrophobic areas but since aβ40 is a smaller 
molecule, there is a maximum amount copies it can attach.  Aβ42 has two more amino 
acids on it, which are hydrophobic.  While there can be mutations, where some 
hydrophilicity can occur in this area, for regular aβ42, these are all hydrophobic.  
Because of this hydrophobicity, more aβ42 can aggregate and form larger clusters, 
which can send the brain into a “repair mode”.  This can explain the aβ plaques found 
on Alzheimer's patients as well as lessening of the brain matter.  These reasons show 
how important aβ is to the study of Alzheimer's[106]. 
Figure 7-4: Differences between aβ40 and aβ42 aggregation.  Notice that aβ40, 
bottom, cannot aggregate more than four times its size, while aβ42, top, can aggregate 
to greater proportions[108] 
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 7.4. Tau Protein 
 However, there is another protein that is now factoring into the possibility of a 
probable cause of Alzheimer's: Tau Protein.  According to Stoothoff, “tau was first 
discovered in 1975… as a protein that co-purified with microtubules through cycles of 
assembly and disassembly and was called tau for its ability to induce tubule formation. 
[109]” The role of tau protein will be explained later on in section 7.5.  Right now, here 
is general description of the structure of tau.  Tau is a long rod-like protein that is 
located in the brain and nervous system, mostly found in the neurons[91,100].  There are 
6 main isoforms of Tau based on the number of binding domains and inserts.  The 
binding domains, known as repeats, are located in the C- (carboxyl) terminal of the 
protein and are positively charged, which allows it to bind to any microtubule, which 
are negatively charged.  The number of domains can vary between 3 (3R) or 4 (4R), 
where the second domain is missing from the 3R.  In terms of location on the protein, 
this report will explain in terms of length based on the number of amino acids.  These 
domains are located at a length at amino acid 166 in the case of the shortest isoform 
and at amino acid 244, in the case of the longest isoform.  The more domains the 
protein has, the better it is at stabilizing microtubules.  Also, there are inserts located at 
the N- (amino) terminal, which help send messages to the C-Terminal.  The number of 
inserts can range from zero to two (0N, 1N and 2N). These inserts are located at amino 
acid 45[91,100].  A diagram of an isoform of tau, the longest, and a table explaining all 6 
isoforms of tau can be found on the next page. 
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Figure 7-5: Tau Protein showing the locations of the domains (pink) and inserts 
(red)[91] 
 
Tau Isoform # of Domains # of Inserts Protein Length (# 
of Amino Acids) 
Tau 0N/3R 3 0 352 
Tau 0N/4R 4 0 383 
Tau 1N/3R 3 1 381 
Tau 1N/4R 4 1 412 
Tau 2N/3R 3 2 410 
Tau 2N/4R 4 2 441 
Table 7-2: Different tau isoforms[91] 
 Based on this table, the lengths for each tau isoform vary between 352 amino 
acids for the shortest isoform to 441 amino acids for the longest isoform.  Also, it can 
be seen that each binding domain consists of 31 amino acids and each insert consists 
of 39 amino acids[91].  Furthermore, it is worth noting that all forms of tau contain the 
same 352 amino acids that are on the shortest isoform.  The only variation is the 
amount of domains and inserts[91].  The diagram on the next page shows all six 
isoforms of tau and the locations of these variations.  The inserts are located at the 2nd 
and 3rd exons, or sections.  The orange represents the first insert and the green 
represents the second insert.  The black bars on the right represent the domains.  The 
pink is where this change in the number of domains occurs.  In this case, all changes 
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occur at the second domain (from the left). 
 
Figure 7-6: Differences in the tau isoforms[91] 
 Tau protein is an interactive protein, in which it regulates and stabilizes 
microtubules.  It does this by interacting with tubulin, which forms microtubules in the 
brain[91,110].  To clarify, tubulin is a group of globular proteins, which are globe-like in 
appearance, that come together to form microtubules.  There are 5 known types found 
in the human body: alpha-, beta-, gamma-, delta- and epsilon tubulins, with the most 
common being the alpha and beta types[111].  The process in which this happens is 
known as phosphorylation and it will be explained below. 
 7.5. Phosphorylation  
 Phosphorylation occurs when phosphate groups (PO4) attach a protein, which 
can alter the specific function or role of the protein.  In this method, certain biological 
processes can be altered without needing to create or destroy more proteins[112].  
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Enzymes or molecules known as kinases are responsible for phosphorylation of 
proteins, which can change the entire structure and function of the protein.  Kinases 
only add phosphate groups to three amino acids: serine (S) (HO2C2H(NH2)CH2OH), 
threonine (T) (HO2C2H(NH2)CH(OH)CH3) and tyrosine (Y) 
(HO2C2H(NH2)CH2(C6H4)OH)
[113].  
 
Figure 7-7: Phosphorylation occurring at serine (left), threonine (center) and tyrosine 
(right)[113] 
 
Phosphorylation is what is known as a regulatory process, in which multiple 
vital actions can occur in the body[87,114,115].  This also include the removal of 
phosphate groups, known as dephosphorylation[115].  Some examples of where protein 
phosphorylation is essential in the human body include the regulation of the activities 
of enzymes and the interactions between different proteins[115].   In the larger scale, 
these regulations and interactions include various metabolic processes, gene 
regulation, cell cycle control, transport in the cell and cell adhesion[115].  In short, 
protein phosphorylation is an important regulatory process in the human body. 
In the case with tau protein, phosphorylation is performed in order to promote 
the assembly of and regulate the stabilization of microtubules[91,109].  Microtubules are 
hollow cylinders that have a diameter of about 24 nm made up of tubulin[110,116,117].  
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They are involved in various processes, which include cell division, and are utilized in 
the structure and transport throughout the cell[118].   Because microtubules are essential 
to the human body, in order to help stabilize these tubes, tau is brought in and how it is 
stabilized depends on the phosphorylation of tau[91].  The amount of phosphate groups 
on Tau depend on how stable the microtubule is.  The more phosphate groups on the 
protein, the less stable the tubule is[91,109].  This process is a relatively common process 
in the body and it actually allows the formation of new protein tubes.  However, one of 
the main factors that Tau is a link to Alzheimer's is known hyper-phosphorylation, 
which will be explained in the upcoming section.  Below is the process in which tau 
helps assemble and stabilize microtubules. 
 
Figure 7-8: How unphosphorylated tau (left) and phosphorylated tau (right) help 
stabilize molecules[118] 
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7.6. Hyperphosphorylation and the Focus on Tau Protein for   
Alzheimer’s 
 
 One of the main reasons why tau protein is a link to Alzheimer’s is the process 
of hyperphosphorylation.  This is when phosphate groups attach to the Tau at a faster 
pace and break down microtubules at a quicker pace.  This in turn causes aggregation 
of filaments which in turn forms neurofibrillary tangles, one of the key components to 
the disease[91,118-120].    This breakdown can be so rapid that, because of the inability to 
stabilize microtubules, this can result in the decrease of brain matter, as attributed to 
figure 7-1.  This theory of the hyperphosphorylation of tau has only been researched in 
the last twenty years and it has only been since recently that more evidence suggests 
this[121].  This can be better shown in figure 7-9.  Figure 7-9 displays tau with the 
known phosphorylation sites.  There are about 100 known sites, with 1/3 to 1/2 of 
them being sites for normal brain activity (green).  The remaining sites show where 
phosphorylation and Alzheimer’s have a connection with tau (red and blue)[91]. 
Figure 7-9: Phosphorylation sites on tau for normal brain activity (green), 
Alzheimer’s activity (red) and both (blue)[91] 
 
However, 20 years ago, this was not the case.   Previously, the focus of source 
of Alzheimer's has been the fact that aβ plaques could be found on patients.  This 
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created the assumption that aβ was the main suspect in causing Alzheimer's[121,122].  
This shift in the focus from aβ to tau comes in large part due to how Alzheimer's is 
first detected and study as the disease progresses.  In most cases, it is easier to see that 
aβ can be found in increasing numbers as the person develops Alzheimer's.  However, 
that is not the case with Tau, in that Tau is the driving force for the cognitive decline, 
which will result in memory loss[121,122]. 
 According to Dr. Melissa Murray of the Mayo Clinic in Jacksonville, FL, “Tau 
can be compared to a train track that brain cells use to transport food, messages and 
other vital cargo throughout neurons...In Alzheimer's, changes in the tau protein can 
cause the tracks to become unstable in neurons of the hippocampus, the center of 
memory.  The abnormal tau builds up in neurons, which eventually leads to the death 
of these neurons[122]”.  This means that because of the affected tau not being the 
stabilizers that they are, this is the cause of the loss of cognition and memory. 
 This was performed by studying at least 3,500 brains, in which 1 out of 3 were 
Alzheimer's confirmed.  Each brain varied as to what stage of dementia it was in when 
the patient died, so that it could give a time-line of brain degeneration.  Each brain was 
not only looked at for tau severity, but also for amyloid severity.  The results showed 
that it was tau, not amyloid, that predicted the onset of cognitive decline, duration of 
the disease and the deterioration of mental health.  Also, when the research looked at 
amyloid, it was discovered that the brain-specific amyloid observed a signal from the 
brain scans, and not the amyloid in vessels.  Furthermore, this did not correspond to 
tau pathology, as similar brains with similar tau effects, which led to Alzheimer's, did 
not lead to similar amyloid effects.  It was found that some brains with a large amount 
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of tau influence had only a small amount of amyloid influence, and vice versa.  This 
can show that amyloid can be found in individuals even if they have not experienced 
cognitive decline.  Based on this reasoning, it should be pointed out that tau is now a 
major influence in Alzheimer's[122]. 
 However, one cannot overlook amyloid as a cause as well.  There has been 
research to suggest that beta amyloid can be a factor in hyperphosphorylation of 
tau[121,123].  Research has suggested that amyloid can cause an excessive flow of ions 
into neurons.  This in turn can activate kinases that would undergo phosphorylation on 
tau[121].  One such kinase is known as AMPK (5’ adenosine monophosphate-activated 
protein kinase).  AMPK normally responds to stresses that deplete essential supplies, 
including low glucose and heat shock by direct phosphorylation of a number of 
enzymes[124].  Because of this, it can be said that beta amyloid can play a large role in 
the development of Alzheimer’s.  But in terms of finding a source and early detection, 
it is more reasonable to take a look into the hyperphosphorylation of tau protein.  
7.7. Antibodies for Detection against Tau 
 Now that it is clear that tau is the main factor in cognitive degeneration, it is 
important to find a method of early detection of rogue tau.  As explained in the 
previous part, there exists assays that can detect proteins by use of specific 
antibodies[19,20].  Because of this, antibodies can be created that will help in capturing 
tau.  There have previous antibodies that have been created that have been used to 
detect certain areas of tau protein[90,91].  This is shown in figure 7-9 with yellow 
arrows.  These arrows represent the different antibodies that already have been created 
in order to attach to tau protein[91]. These antibodies can be helpful in the identification 
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of tau protein in terms of both its phosphorylated and unphosphorylated forms.  
However, there have not been advances in terms of the number of antibodies created.  
Tau is a long protein and there are certain sections of it that are not associated with an 
antibody[91].  Because of this, there has to be a method of creating antibodies for all 
parts of tau. 
There are numerous methods to create and extract different forms of antibodies 
from organisms.  Some of the most popular organisms to use are mice, goats and 
monkeys[92].  However, this project is more concerned about seeing how antibodies 
can attach to tau protein.  Because of this, and the severe liability risks of using 
animals as test subjects, it is not recommended that live animals would be used.  
Instead, another method has to be implemented.  This method uses bacteria/E. coli in 
order to create antibodies.  This was because of the availability of bacteria, the ease of 
working with it and the relatively cheap cost of using it.  However, because such a 
simple one-celled organism is used in the creation of antibodies, these antibodies will 
be known as antibody fragments and would be the simplest form in which it still can 
detect tau[92].  Even though they cannot be properly be used in normal immunoassays, 
they are nevertheless important because they create the foundation for an antibody 
library and are the basic entities that attach to the desired antigen[92].  This will be 
further explained in section 7-9. 
7.8. Reasoning for an Antibody against Tau Protein. 
 Since Tau is one of the proteins that were linked to Alzheimer's disease, it 
would be good to create antibodies in order for it to be used in immunoassays as a 
biomarker.  This is done by connecting the antibodies to the surface of the protein via 
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the amino acids on both the protein and the antibody[92].  The diagram on the next page 
shows the model of the longest Tau isoform (Tau 4R 2I) at 440 amino acids long.   
 
 
Figure 7-10:  Diagram of tau protein where the specific antibodies will be created[91] 
 The two inserts are at sections 2 and 3 and the domains are located at sections 
10, 11 and 12, were the second domain is the difference between 3R and 4R.  The 
numbers at each amino acid spot indicates where phosphorylation can occur.  Green is 
during normal brain activity, while red is observed with patients with Alzheimer's.  
Blue indicates both and black is unknown.  Based on this diagram, there have been 14 
known antibodies that have been discovered, based on the yellow lines.  The majority 
of these occur at the front and the back of the protein.  For example, antibody T46 
corresponds with the amino acids from the 420 to the 441 area (S422, T427, S443 & 
S436)[91].  While there have been some antibodies that have been discovered, the 
majority of the sites do not have an antibody associated with it.  For this reason, this 
project will focus on finding antibodies for the first binding domain (1R).  This 
domain is common in all tau isomers and is located on 256-262 range.  The peptide, or 
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protein section, that this project will focus on will be the area from 251 to 270, where 
known phosphoylation occurs at S258 and S262. 
7.9. Types of Antibodies 
 For the basis of this project, the antibodies that are the main end product are 
known as single-chain variable fragments (scFvs).  This form of antibody fragment is 
the smallest form of immunoglobulin that still retains its function in antigen-
binding[125].  These small antibody fragments consist of a heavy chain (VH) and a light 
chain (VL), which are connected together by a peptide linker 
[92,125].  Compared to 
immunoglobulin (Ig) antibodies, they are about 1/6 in size (scFv ~ 25 kDa, IgG ~ 150 
kDa)[92,125,126].   However, they are still able to attach to antigens as well.   If one takes 
a look at the structure of an IgG antibody, one would notice the tips of the branches 
are where the antibody would bind to the antigen.  These branches are known as the 
variable fragment region (Fv).  This is similar to the scFv in that the same two chains 
are used in order to attach the antibody to the antigen.  The only difference between 
the two in structure is that the scFv includes a linker, which allows the two chains to 
act as a single chain in name, whereas the Fvs are two separate chains that are located 
on the tips of the IgG.  Nevertheless, both the scFv and the Fv regions of the IgG 
contain the same genetic sequence that allows them to bind to the same antigen.  This 
is shown below in figure 7-11. 
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Figure 7-11: Diagran showing the difference between the IgG (left), Fv regions (top 
right) and scFv (bottom right) antibodies/antibody fragments[126]   
 
Other types of antibody fragments include the antigen-binding fragments (Fabs)[93,127], 
dimetric single chain variable fragments (di-scFvs)[128] and single domain antibodies 
(sdAbs or VHH)[127-129].  Even though these examples are important in antibody 
construction, they do not hold relevance in this report because they were not fully used 
this study.  Instead, scFvs were produced in order to find antibody fragments that were 
specifically designed to attach to tau protein.  The upcoming sections will explain the 
use of recombinant antibodies and the method used to create them: phage display. 
7.10. Recombinant Antibodies and Phage Display 
 Because of the previously described methods used in order to create antibodies, 
a new method of antibody creation has to be performed.  In the last 20+ years, a new 
method of creating recombinant antibodies has become popular.  Some of the benefits 
of creating recombinant antibodies are that these experiments are performed with the 
use of animals, which means a reduced risk of contamination due to the disease that 
the antibodies are being built for, they can be modified to be created for a specific 
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organism in mind and they can be designed to be modified for uses that would 
normally not occur naturally, for example, targeting cancer cells[92].  One of the most 
common methods is the use of phage display.  In phage display, phages, a virus, help 
to select and replicate antibodies for a specific protein[92,94,95,130].  An example of a 
phage and its structure is shown below. 
 
Figure 7-12: Diagram of phage with scFv fragment[131] 
 A single scFv fragment is displayed on the surface of the phage and the 
corresponding genetic information is encoded on a phagemid and packed inside of the 
phage particle.  In the phagemid, the scFv fragment is fused to the phage gene III 
(gIII) which encodes phage protein III (pIII).  This then allows the expression of a 
fusion protein: scFv:pIII.  The fusion protein will be incorporated in the phage particle 
and the phagemid will be packaged in the phage during phage assembly.  This results 
in an antibody phage[94,95,130-132].  The method of phage display is explained below on 
the next page. 
The first step of phage display is the in vitro selection of antibody phage 
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particles.  This is what is known as panning[94,95].  In this step, antigens in which are of 
importance, in the case of this thesis, tau peptides are attached to a well of a micro titer 
plate.  An antibody phage library, in this case, HAL7/8, is incubated with these desired 
peptides.  The antibody phage of importance binds to the peptide, while the unbound 
phage is washed away.  The bound phage then goes through a process, known as 
elution, in which the phage is collected.  This phage then infects an E. coli culture.  
Here, the phage is amplified in the cell and new antibody phage is produced with the 
help of helper phage.  This new antibody phage will then be used in a new 
panning[94,95].  The reason for this is that each antigen is likely to be attached to the 
micro titer plate using a biotinylated linker, which is attached to streptavidin, which is 
in turn coated on the plate.  This allows for better binding between the antigen and 
phage than having the antigen bind to the well due to the fact that the antigen is more 
intact.  Because of this, there might be some phage that will actually bind with the 
streptavidin and the linker.  By performing multiple sets of panning rounds, an optimal 
amount of phage and antibody that binds directly to the desired antigen will be found 
and a high concentration of it will be produced[92,94,95,130-132].  Each run through of this 
process is known as a panning round.   A diagram highlighting a panning round is 
found in figure 7-13 on the next page. 
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Figure 7-13: Diagram describing an example panning round[131] 
 In most cases, 3-4 panning rounds would have to be performed in order to 
obtain a satisfactory amount of antibody phage.  During the final round (either the 3rd 
or 4th), soluble monoclonal antibodies will be produced. These antibodies will be 
tested via ELISA (enzyme-linked immunosorbent assay) in order to identify positive 
monoclonal binders.  Furthermore, the scFv encoding gene fragments can be analyzed 
via DNA sequencing in order to determine unique binders and the antibody fragments 
can be recloned into any antibody format (IgG) for further production and biochemical 
analysis[92,94,95,130]. 
7.11. ELISA and DNA Sequencing 
 Once an appropriate number of clones have been created, the next step is to 
make sure that there are active binders for each antigen.  To test this out, an ELISA 
(enzyme-linked immunosorbent assay) is performed.  Back in chapter 2, the different 
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types of ELISAs were pointed out.  These were a direct ELISA (where the antibody is 
attached to an unknown antigen on the bottom of a well), an indirect ELISA (where an 
unknown antibody is attached to the antigen), a sandwich ELISA (where the antigen is 
attached to a capture antibody before being detected) and a competition ELISA (where 
the ELISA is in direct comparison to a competing ELISA)[59].  These ELISAs share a 
basic construct: an antibody is used to detect an antigen and that antibody is detected 
via a substrate[12,133].  Because of the amount of clones that will be made based on the 
phage display, it would be a good idea to find scFv fragment that can attach to tau by 
using an ELISA.  This can be performed in order to narrow down the amount of clones 
that have been made, in order to find an antibody fragment that will properly attach to 
tau.  This is what is known as a screening ELISA.  In this screening ELISA, clones are 
picked out and the scFvs are extracted from the E. coli culture.  These fragments are 
then placed in a micro titer plate with the antigen already in place.  After the fragments 
have incubated and attached to the protein, detection antibodies are applied and 
incubated for some time.  The substrate is then applied and clones are then taken into 
account based on the signal given off.  This is due to the color change in substrate.  
The darker the color, in most cases, the higher the signal[12,59,133,134].  From there, 
clones that have shown to emit a high signal can be removed.  An example of a 
screening ELISA is found on the next page. 
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Figure 7-14: Diagram of the steps for a screening ELISA.  Top represents a well with 
a desired antigen signal, bottom represent no antibody signal[134] 
 
 
Figure 7-15: Example of a completed screening ELISA.  Note that the dark blue well 
represents a strong signal[135] 
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 Sometimes even the screening ELISA can produce more clones than needed as 
well.  This means that there might be multiple clones with the same structure.  If this is 
the case, it would be necessary to perform a BStN digest.  This digest is a type of 
electrophoresis by using an agarose gel.  In this digest, fragments are separated and 
sorted by size through a gel by the use of an electric field[136-138].  Because each 
fragment has a different make up and a different size, they can flow through the gel at 
different speeds.  The larger the particle, the slower it will move through the gel[136-
138].  This will create bands in the gel when exposed to UV light.  Based on these 
bands, it can be determined what would be the makeup of these fragments.  Similar 
fragments should look the same under the light, while different fragments should have 
bands[136-138].  From there, the number of possible clones can be further lowered.  An 
example of this digest is shown below. 
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Figure 7-16: Example of a BStN1 digest[139] 
 Once a suitable number of clones have been found, the next step would be to 
create titration curves for these fragments.  This is in order to make sure that not only 
these fragments are able to attach to their specific antigens, but also to find out the 
strength of each antibody fragment.  This is performed by using a titration ELISA[140].  
In this ELISA, the concentration of antigen or antibody fragment is decreased along 
the length of the micro titer plate.  When substrate is then added to the wells, the color 
should gradually become lighter as the concentration of antigen or antibody fragment 
decreases[140,141].  An example of this can be found in figure 7-17.  From this, the 
overall strength of the antibody or antigen can be determined and how much of each 
would be needed in order to produce a successful signal. 
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Figure 7-17:  Example of a titration ELISA[141] 
 Once both ELISAs are performed and there are clones that have been chosen 
based on these two ELISAs, these fragments are then broken up through a process 
known as DNA sequencing.  This allows the DNA strand on the fragment which 
attaches to the antigen to be read in order to figure out its binding structure.  One of 
the most common methods is known as the Sanger Method[142].  In this method, the 
fragments are broken into plasmids.  These plasmids are then denatured by using heat.  
This turns the plasmids into single strand structures of DNA.  Next, a primer, or a 
chain of 3 nucleotides is added to the ends of each strand.  The strands of DNA are 
then separated into one of four tubes containing dideoxynucleotides, one for each of 
the four bases: adenine, thymine, cytosine and guanine.  Each tube also contains DNA 
polymerase, which attaches the nucleotides to the DNA.  In each tube, the nucleotides 
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will attach to the strands until the specific nucleotide for that tube attaches to it.  From 
there, the four tubes will go through gel electrophoresis, in which each strand is 
separated and the sequence can be read from top to bottom[142].  An example is shown 
below in figure 7-18 
 
Figure 7-18: Example of DNA Sequencing using the Sanger Method[142] 
 
 Since this process is more involved, for the purposes of this project, the DNA 
sequencing will be performed offsite.  The main goal for this however is to see how 
the antibody fragments attach to the tau and if there are multiple fragment clones that 
attach, either more than one clone with the same structure, or more than one clone 
with different structures.  From DNA sequencing, it will be determined how these 
fragments can attach to the desired proteins.  In the upcoming sections, the procedure 
for these experiments will be presented. 
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CHAPTER 8 
 
METHODOLOGY 
 
8.1 Phage Display 
  8.1.1. Panning using Agar Plates 
 To begin with the experiments, it is important to mention the tau that was used.  
The tau peptides that were used are located in the area shown in orange in figure 8-1. 
 
Figure 8-1: Tau protein with DNA sequence with peptide area highlighted in orange 
and phosphorylation sites in red[98]. 
 
 Above is the sequence for tau protein, length 441.  The box highlighted in 
orange shows where on the tau the peptides used for this project come from.  This 
peptide is located between amino acids 251 and 260.  It is 20 amino acids in length 
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and has phosphorylation areas at site 258 (S) and 262 (S).  These are of importance 
because they are phosphorylation areas in which Alzheimer’s is prevalent.  In this 
project, two types of peptides will be used: a peptide without phosphate groups at 
those sites (Tau) and a peptide with phosphate groups at both sites (pTau).  Also, two 
forms of each peptide will be used in these experiments.  The reason for this being that 
micro titer plates coated with streptavidin will be used to carry out the phage display 
and the ELISA for the peptides to attach to the well rather than capture the fragments.  
For this reason, each peptide will be attached to one of two biotinylated linkers.  The 
reason that two linkers will be used is that each linker has its own set of amino acids 
connecting between the biotin and the peptide.  Because of this, it is possible for the 
phage/scFv to attach to the linker.  Because of this, each peptide will either have what 
will be known as linker 1 (L1) or linker 2 (L2).  With multiple panning rounds, each 
round will alternate between the two linkers so that no phage/scFv that attaches to the 
linker will be detected.  The following table lists the four different peptides that will be 
used. 
Peptide 
Number 
Name Linker Sequence 
1 Tau L1 eBio-bAbAbAbAbA- PDLKNVKSKIGSTENLKHQP 
2 Tau L2 eBio-GGSGGS- PDLKNVKSKIGSTENLKHQP 
3 pTau L1 eBio-bAbAbAbAbA- PDLKNVKpSKIGpSTENLKHQP 
4 pTau L2 eBio-GGSGGS- PDLKNVKpSKIGpSTENLKHQP 
Table 8-1: Peptides used in project with sequence (p – phosphate group) and linkers 
 There are four total experiments for this project, each with the same 
procedures.  The only difference between them is the types of peptides being used.  
The first two experiments focus on obtaining an scFv fragment by alternation.  This 
will be performed with Tau only for experiment 1 and pTau only for experiment 2.  In 
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these experiments, peptides 1 & 2 (Tau L1 & Tau L2) and peptides 3 & 4 (pTau L1 & 
pTau L2) will alternate for each panning round.  In experiment 1, peptide 1 will be 
used in rounds 1 & 3 while peptide 2 will be used in round 2.  The same can be said 
for peptides 3 & 4 in experiment 2 (peptide 3 for rounds 1 & 3, peptide 4 for round 2).  
This method will not only make sure that only the selected phage at the end of the 
experiments will only bind to the peptide, but also with the additional third round, be 
in greater numbers.  With this method, a scFv clone can be found that only attaches to 
the peptide. 
 The other two experiments focus on competition.  This will be performed with 
the L1 peptides for experiment 3 and the L2 peptides for experiment 4.  In these 
experiments, pTau peptides are in competition with the Tau peptides with the same 
linker.  This means that before the phage comes in and attaches with pTau, some of the 
phage that either attaches to Tau or the linker will be removed.  This is done in order to 
find phage that will attach to pTau at a simpler rate due to the fact that less phage is 
located in the solution.  This can be reversed in order to locate phage for Tau with 
pTau in competition, but for these experiments, only phage against pTau will be 
considered. 
  8.1.2. Panning using Agar Plates 
 The first part of this project is to perform the panning rounds in order to 
retrieve the scFvs used for detection.  There were two different methods used to 
perform the panning rounds.  The first and easier method is to use agar plates to 
cultivate E. coli cultures to extract scFvs.  To perform this experiment, a total of three 
panning rounds were performed to maximize the amount of cultures created.  In this 
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experiment, this procedure was taken from the protocol “Panning Ab-libraries: 
Panning mit biotinylierten Oligopeptiden (Panning with biotinylated oligopeptides)” 
developed by Michael Hust of the Institute of Biotechnology, TU Braunschweig, 
Braunschweig, Germany[143] (see appendix B.1 for a English translation).  To begin the 
first round of panning, 1 well of a NUNC Streptavidin plate (Item no: 436014, Lot no: 
123305, Roskilde, Denmark) was coated with 1 µg (1µL) of tau peptide diluted in 150 
µL of PBS (Phosphate Buffer Saline).  This was used as the coating well, which was 
used as the main site for the phage to antigen binding.  A second well was coated with 
350 µL 2% mPBS (PBS + milk powder).  This was the pre-adsorption well, which was 
used to remove phage that bound either to the streptavidin or to other antigens.  This 
plate with these wells was stored overnight at 4°C without shaking.  Diagrams 
showing the steps are found below in figure 8-2. 
 
Figure 8-2: Diagrams showing the panning process with the Streptavidin on the well 
(left), addition of 2% mPBS for blocking (center) and the addition of biotinylated tau 
peptide (right) 
 
In conjunction with this, a 50 mL 2×YT-T (Yeast Extract Tryptone Medium 
with 20µg/mL tetracycline) overnight culture inoculated with E. coli XL1blueMRF' 
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(LOT#00016047973 (Patrick Droste), Institute of Biotechnology, TU Braunschweig, 
Braunschweig, Germany) was also prepared and incubated overnight at 37°C at 250 
RPM (INFORD Thermotron High Temperature Shaking Incubator, Rose Scientific 
LTD, Edmonton, AB, Canada).  This was the first bacterial culture that was used to let 
the phage attach itself to the E. coli.  After incubation of the bacteria culture, 40 ml of 
2xYT (Yeast Extract Tryptone Medium without tetracycline) was inoculated with 
37°C overnight culture.  From there, the optical density (OD) was measured.  To 
ensure that optimal growth occurred, the solution was inoculated until the OD reached 
0.1.  It was then incubated at 37°C and at 250 RPM and measured for OD until the OD 
reaches 0.5.  This process took about 1.5 hours. 
 While this process was going on, the incubation and phage sorting on the 
streptavidin plate was being performed.  These incubation steps were performed on a 
shaker at room temperature.  The first step was to wash the wells three times with 350 
mL with 1X PBS with 0.05% Tween (PBST) using a microplate washer.  The washer 
that was used was a TECAN Columbus microplate washer (Männedorf, Switzerland).   
Afterward, the pre-absorption wells were coated with 350 µL Panning block (2% 
mPBS + 2% BSA), while the coating wells were coated with 350 µL 2% mPBS.  It 
was then incubated for one hour.  The next step was to remove the panning block from 
the pre-absorption wells and add 150 µL Panning block with 5X1011 clones of the 
antibody phage library to it.  This was performed with the HAL 7/8 library and the 
total volume of the library added was between 4 and 6 µL.  An additional 5 µL phage 
was added to the well to eliminate further binding to the streptavidin.  This was then 
incubated for one hour.  Afterwards, the panning block and phage were removed from 
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the pre-absorption wells and placed in separate vials to be used in the next part.  The 
wells were then washed three times with 350 mL with 0.05% PBST.  After this, the 
phage was then added to the coating wells incubated for two hours.  The wells were 
then washed ten times with 350 mL with 0.05% PBST.  This was to remove all signs 
of possible excess phage and leave only phage that stuck to the antigen.  After 
washing, 200 µL Trypsin was added to re-suspend the phage in solution.  This was 
incubated at 37°C for 30 minutes (Memmert Incubator, Memmert, Schwabach, 
Germany).  The phage was then collected to be eluted and coated on agar plates.  
Figure 8-3 highlights the addition of phage into the wells. 
 
Figure 8-3: Diagrams of wells with phage entering and binding to the tau peptides 
(left) and after removal of unbound phage (right) 
 
 The next part is to create and grow the bacteria cultures that will create the 
scFvs.  For this part, two sections will be performed.  The first is to create the main 
culture.  For this step, 100 µL Phage was added to 20 mL 2YT Medium and incubated 
at 37°C for 30 min.  After incubation, this solution was centrifuged (Eppendorf 
Cenrtrifuge 5810 R, Eppendorf, Hamburg, Germany) at 4000 RPM for 10 minutes.  
169 
 
The supernatant was then decanted and the remaining pellet was re-suspended with 
250 µL 2YT medium.  This solution was spread on a 15 cm 2YT-AG agar plate and 
incubated overnight at 37°C.  
 The second section was the elution of the phage.  For this section, 10 vials 
were set up it create the dilutions.  In five of these vials, PBS was added: two with 900 
µL, one with 990 µL, one with 60 µL and one with 10 µL.  After this was performed, 
10 µL of a positive control (pHAL14-HT186-D11) was added to a sixth vial.  Once 
this was completed, 10 µL Trypsin + Phage was added to the vial with 990 µL PBS.  
This dilution was 1/100 of the original.  From there, two more dilutions were made.  A 
second dilution was created when 100 µL of the first dilution was added to 900 µL 
PBS, which created a 1/1000 dilution.  A third dilution was also created when 100 µL 
of the second dilution was added to 900 µL PBS, which resulted in a 1/104 dilution.  
From there, 10 µL of each dilution was added to three more reaction caps, creating a 
further drop in dilutions.  To perform this, 10 µL was taken from the 1/104 dilution to 
create a 1/106 dilution, 10 µL was taken from the 1/1000 dilution to create a 1/105 
dilution and 10 µL was taken from the 1/100 dilution to create a 1/104 dilution.  From 
there, the incubated XL1 culture is then added to these vials.  The following vial had 
50 µL added to it: the 1/104 dilution, the 1/105 dilution, the 1/106 dilution, the positive 
control and the vial with 10 µL PBS.  An additional 60 µL was added to an empty vial.  
After this, the following vials were incubated for 30 minutes at 37°C:  the 1/104 
dilution, the 1/105 dilution, the 1/106 dilution, the positive control, the 60 µL XL1 
culture, the 60 µL PBS and the 50 + 10 µL XL1 + PBS.  After incubation, the three 
elutions were then spread on three separate 10 cm 2YT-AG agar plates, while the 
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remaining four were added drop wise onto a fourth plate.  These plates were then 
incubated overnight at 37°C. 
 After incubation, each plate was checked for bacterial growth and all colonies 
on the small plates were counted (see appendix B.3 for total counts).  After this step, 
the amplification of the phage began.  In this stage, the scFvs are extracted from the 
bacteria and are placed inside phage again for another panning round.  To begin with, 
the 15 cm plate was washed with 5 mL 2YT-AG (2YT Medium + 1:1000 ampicillin + 
1:20 glucose) medium.  From there, the suspension was mixed with a 40 mL solution 
of 2YT-AG Medium until the OD of the solution was at 0.1.  The remaining 
suspension was stored at 4°C.  This solution was then incubated at 37°C at 250 RPM 
until the final OD was around 0.5.  Depending on the solution, this could take between 
2 and 5 hours.  This is because during incubation, there is some bacterial growth, then 
decay and then growth again.  Once the solution reaches an OD of 0.5, 5 mL (~ 2.5 X 
109 cells) was extracted and  infected with a 1:20 ratio of M13K07 (5 X 1010 pfu) 
helper phage.  This was then incubated twice: once for 30 min at 37°C without 
shaking and again for 30 min at 37°C at 250 RPM.  Once incubation was complete, 
the culture was then centrifuged at 4000 RPM for 10 minutes.  After, the supernatant 
was decanted, the pellet was re-suspended with 1 mL 2YT medium and the total 
solution is added to 30 mL to 2YT-AK (YT Medium + 1:1000 ampicillin + 1:1000 
kanamycin) medium.  This was incubated overnight at 30°C at 250 RPM.  After 
incubation, the solution was filtered and stored in separate vials.  This ended the first 
panning round[143]. 
 The remaining panning rounds (second and third) were performed in a similar 
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fashion as the first with some notable exceptions.  First, different antigens were used 
during each panning round.  This will be explained later on in the procedure.  Second, 
the antibody library that was placed in the pre-adsorption well was from the previous 
panning round.  This amount was 150 µL that was added without panning block.  This 
was for both the second and third rounds.  Third, the final was increased after 
complete incubation.  The number of total washed in the final wash was the round 
multiplied by 10 (first round: 10 washes per well, second round: 20 washes per well, 
third round: 30 washes per well).  The final variation was during the elution step.  This 
step occurs normally as before, except with one additional part: amplification.  In this 
part, 9 vials were used to create amplification.  In four vials, 990 µL PBS were added 
and in two additional vials, 900 µL PBS were added.  In the first 990 µL vial, 10 µL 
Trypsin + Phage was added to create a dilution that was 1/100 of the original.  From 
there, five more dilutions were made.  A second dilution was created when 10 µL form 
the 1/100 dilution was added 990 µL PBS, which resulted in a 1/104 dilution.  This 
was repeated with the remaining 990 µL PBS vials resulting in a 1/106 dilution and a 
1/108 dilution.   Then 100 µL was added from the 1/108 dilution to a 900 µL PBS vial, 
creating a 1/109 dilution and that was repeated with the last 900 µL vial to create a 
1/1010 dilution From there, 10 µL of each dilution was added to three more reaction 
caps, creating a further drop in dilutions.  To perform this, 10 µL was taken from the 
1/1010 dilution to create a 1/1012 dilution, 10 µL was taken from the 1/109 dilution to 
create a 1/1011 dilution and 10 µL was taken from the 1/108 dilution to create a 1/1010 
dilution.  From there, 50 µL incubated XL1 culture is then added to these vials.  Then 
three 10 µL samples of each were dropped on a 10 cm agar plate and incubated 
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overnight at 37°C.  The following day, each sample was counted for bacteria 
cultures[143]. 
  8.1.3. Panning using Micro Titer Plates 
 Using micro titer plates during the panning rounds is seen as a faster method 
than the straightforward method of using agar plates for panning.  During the first 
panning round, the same methods used to find phage for scFvs up to when the bacteria 
are added to the phage.  Instead of using different sized agar plates, the bacteria 
cultures were placed in small amounts in micro titer plates for growth and cultivation.  
In this experiment, this procedure was taken from the protocol “Panning Ab-Libraries: 
Panning in Immunotubes (MTPs)” developed by Michael Hust of the Institute of 
Biotechnology, TU Braunschweig, Braunschweig, Germany[144] (see appendix B.2 for 
an English translation).  To perform this, the exact same procedure for the first 
panning round was used (see 8.1.2. Panning in Agar Plates) until it was time to 
perform the elution.  To perform the elution, 50 µL of Phage was added in one well of 
a micro titer plate, along with 130 µL of 2YT-XL1 Culture.  This was then incubated 
at 37°C for 30 min.  Added to the well after incubation was 20 µL of 10XGA (2YT + 
1:20 Glucose + 1:1000 Ampicillin) medium to the culture.  This was then incubated 
overnight at 37°C at 850 RPM (LabNet VorTemp 56 Shaking Incubator, LabNet, 
Edison, NJ). 
 Amplification of the phage was also different than in the previous experiments.  
To begin amplification, 5 µL overnight culture was added to 180 µL 2YT-AG medium 
in one well in a new micro titer plate and 10 µL was added to 180 µL 2YT-AG 
medium in a second well in that same plate.  This was then incubated at 37°C and 850 
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RPM.  The remaining culture was stored at 4°C.  The OD was then found and 
recorded.  This was found by using a TECAN Sunrise microplate reader (Männedorf , 
Switzerland).  However, in previous experiments, the OD was measured at a 
wavelength of 600 nm.  In this experiment, the wavelength was measured at 620 nm.  
To find the optimal OD, the following measurement had to be used: an OD620 between 
0.3 and 0.4 is around an OD600 between 0.4 and 0.5.  The incubation time varied 
between 1.5 and 2.5 hours.  After incubation, 10 µL M13K07 helper phage was added 
to each well and the cultures were incubate at 37°C without shaking for 30 min and at 
37°C and 850 RPM for 30 min.  Each culture was centrifuged at 4000 RPM for 10 min 
and the supernatant was decanted.  180 µL 2YT-AK medium was added per well and 
the cultures were incubated overnight at 30°C and 850 RPM.  The next day, the 
cultures were centrifuged for 10 min at 4000 RPM.  100 µL of supernatant were 
collected in vials and were used in the next round of panning, where the 100 µL of 
supernatant was added to the pre-adsorption wells as in the previous experiment.  This 
was repeated during the second round of panning.  However, the third round of 
panning, agar plates were used again during the colony growth for use in the 
upcoming screening ELISA.  This procedure was shown in the previous section[144]. 
 8.2. ELISA and scFv Detection 
  8.2.1. Screening ELISA 
 During the Screening ELISA, the scFv clones go through a process where they 
are attached to a piece of antigen and and then detected with detection antibodies to 
see if they attached to the antigen and how strong the signal is.  In all ELISA 
experiments, the procedure was taken from the protocol “ELISA” developed by 
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Michael Hust of the Institute of Biotechnology, TU Braunschweig, Braunschweig, 
Germany[145].  To begin this section, cultures were picked from the cultivation plates 
from the panning round and placed in a well of one of two 96 well Costar micro titer 
plates (Corning Inc., Corning, NY).  Each well was filled with 180 µL 2xYT-AG 
Medium.  In total, 92 wells had a clone culture, 2 wells (H3 & H6) were left blank for 
the negative control and 2 wells (H9 & H12) had a positive control (pHAL14-HT186-
D11) inside.  Each plate was incubated overnight at 37°C at 800 RPM.  There were 
two plates that were used because of the amount of colonies that were found after the 
third panning round.  After incubation of the micro titer plates, a second set of plates 
were used for bacterial growth of the overnight cultures.  In these plates, 170 µL of 
2YT-AG Medium along with 10 µL of the overnight culture was added per well.  The 
remaining clones were stored at 4°C.  These new plates were incubated at 37°C at 800 
RPM for 2 hours.  After incubation, the solutions were centrifuged at 4000 RPM for 
10 minutes.  The supernatant was then decanted and a solution of 180 µL 2YT-AI 
(2xYT Medium + 1:1000 ampicillin + 1:20000 IPTG (Isopropyl β-D-1-
Thiogalactopyranoside)) medium per well.  These plates were incubated overnight at 
30°C and 800 RPM. 
 At the same time, the ELISA plates were set up.  For one micro titer plate that 
had picked colonies inside the wells, 2 ELISA plates were used during the run.  One 
plate was used as the positive control, where there the antigen used in the phage 
display will be used in the experiment to see if the scFv bound to the antigen.  The 
other plate contained no antigen and was used to see if that scFv bound to the 
streptavidin.  Both ELISA plates were coated with streptavidin, (100 µL at a 
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concentration of 2 µg/mL), except for the positive controls, wells H9 & H12, which 
were coated with 100 µL of 1 µg/ml MucI.  These plates were then stored overnight at 
4°C to allow for coating of the wells. 
 After the overnight incubation for the ELISA plates, the streptavidin was 
discarded and both plates were blocked with 350 µL of 2% BSA in 0.1% PBST.  This 
was incubated for one hour.  Then the plates were washed three times with 0.05% 
PBST.  The next step was to add 100 ng of the tau antigen in 100 µL PBS to each well 
of the one of the plates.  This was added for all wells, except for the positive controls, 
where 100 µL hMucI was added to wells H9 & H12.  This plate was used as the 
positive control during the ELISA.  In the other plate, only 100 µL of PBS was added 
to each well, except again for the two wells used as the positive control.  This plate 
represented the negative control during the ELISA.  Both plates were incubated for an 
hour and washed three times with 0.05% PBST. 
 During this part of the experiment, the overnight cultures were centrifuged at 
4000 RPM for 10 minutes.  After centrifugation and the ELISA plate washing, the 
scFv clones were transferred to the ELISA plates.  This was performed by adding 50 
µL of 2% BSA in PBS and transferring 50 µL of the scFvs into those ELISA plates, 
making sure that the clone in a given well went to the same well in the ELISA plates.   
Both plates were incubated for an hour and washed three times with 0.05% PBST.  
After washing, 150 µL of 9E10 primary antibody (goat anti myc antibody, 1:1000) in 
2% BSA in PBS were added to each well in both plates.  These plates were then 
incubated for an hour and washed three times with 0.05% PBST.  Afterwards, 150 µL 
of a secondary antibody (goat anti mouse with a tag, 1:1000) in 2% BSA in PBS was 
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added to each well.  These plates were incubated one last time for one hour and 
washed three times with 0.05% PBST. 
 The last step was to perform the detection of the ELISA.  For this, a TMB 
(3,3’,5,5’-Tetramethylbennzidine) mixture was used to detect the antibodies.  To 
perform this detection, 100 µL of a 20:1 ratio of TMB-A:TMB-B was added to each 
well.  From there, the detection began when the colors of the wells changed from clear 
to blue.  The darker the blue, the more concentrated the scFvs are in the well.  In order 
to make sure that the experiment worked, all the positive control wells had to be blue, 
all the negative control wells had to be clear and the wells on the positive control plate 
had to be blue, while the wells on the negative control plate had to be clear.  The first 
signs of detection in the plates were found within the first five minutes.  After 20 – 30 
minutes, the reaction slowed down and the background started to come into play.  At 
this point, the experiment detection was stopped by adding 100 µL of Sulfuric Acid in 
each well.  This turned the solution from blue to yellow and allowed the experiment to 
stop so that the OD of each well could be measured.  To measure the OD, the plate 
was placed in an ELISA reader (TECAN Sunrise) and the reader was set to measure 
the OD at a wavelength of 450 nm, but have a reference wavelength at 620 nm.  After, 
the plates were read, the results were graphed and clones that worked well in the 
experiment were chosen based on two factors: intensity and high positive:negative 
ratio[145].  Once the clones are chosen, they are grown overnight in 5 mL 2YT medium.  
After incubation, 80 µL of culture is added to a sterile vial, along with 20 µL of 
glycerol, mixed together and stored at -80°C for further use in experiments.  Diagrams 
explaining the process are shown in figure 8-4. 
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1 2 3 4  
5 6 7 8  
Figure 8-4: Diagram showing the ELISA steps (1: coating of streptavidin, 2: blocking 
with 2% BSA in PBS, 3: addition of tau, 4: addition of scFv clones, 5: primary 
antibody, 6: secondary antibody, 7: TMB, 8: sulfuric acid) 
 
8.2.2. BStN Digest. 
 After the screening ELISA, the clones that gave off a high signal and aspect 
ratio were chosen to be sequenced for possible antibodies.  However, some screening 
ELISAs can display multiple positive clones.  These clones can be reduced by 
selecting a minimum OD level in the ELISA.  However, at times, there can be 
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upwards to 20 clones within a given OD range.  When this happens, it is necessary to 
perform a BStN Digest.  This digest breaks down the scFvs into smaller components 
and sorts the components based on mass.  It is used to find out if there are any 
identical clones in the system.  Once the digest is performed, the number of possible 
binders is greatly reduced because it can be shown that for multiple picked clones, 
they have the same structure and DNA makeup. 
 To perform the digest, the procedure is broken up into four parts: breakdown of 
scFvs, building of the separation gel, separation of the scFvs and optical detection.  To 
begin the experiment, the scFvs have to be broken down.  This starts with a master 
mix to use in the Thermal Cycler (MJ Research PTC 200, MJ Research, St. Bruno, 
QC, Canada) in order to perform a polymerase chain reaction (PCR).  Each clone 
needs the following amount of these ingredients to be in the vial for breakdown: 
 2 µL of 5X GoTaq Flexi Buffer 
 0.4 µL of Magnesium Chloride 
 0.2 µL of Deoxynucleotide Triphosphates (dNTPs) 
 0.5 µL of MHgIII_r Primer 
 0.5 µL of LacZpro_f Primer 
 0.05 µL of GoTaq Polymerase 
 6.35 µL of distilled water 
 A small amount of scFv is scraped and placed inside a vial with the master 
mix.  From there, the PCR is activated and the following program is used during the 
process: 
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1. 95°C for 2 minutes 
2. 94°C for 20 seconds 
3. 56°C for 15 seconds 
4. 72°C for 90 seconds 
5. Repeat steps 2 – 4 a total of 29 more times 
6. 72°C for 3 minutes 
7. End program at 16°C 
 From there, 3 µL of solution is transferred to a second vial that contains the 
following: 
 0.5 µL of 10X Nuclear Extraction Buffer 2 (NEB2) 
 0.5 µL of 10X Bovine Serum Albumin (BSA) 
 0.2 µL of BstNI (10 U/µL) 
 0.8 µL of distilled water 
From there, the PCR is activated and the following program is used during the 
process: 
1. 60°C for 1 hour 
2. 65°C for 10 minutes 
3. End program at 16°C 
 At the same time the agarose gel has to be assembled.  To assemble the gel, the 
following procedure is used.  In a clean glass molding, the following mixture is added 
in two parts.  It is added until about halfway, hardened, and completely filled: 
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 1.55 mL of distilled water 
 3.2 mL of 30% Acrylamid mix 
 1.2 mL of 5X Tris/Borate/EDTA (TBE) buffer 
 60 µL of 10% Ammonium Persulfate (APS) 
 2.4 µL of Tetramethylethylenediamine (TEMED) 
 Both the chemicals used for the PCR and agarose gel came from New England 
Bio Labs in Ipswich, MA.  Slots are added during the making of the top layer, so that 
the clones are easily inserted inside the gel.  Once the samples have been prepared and 
the gel has been hardened, the digest is then able to begin.  1 – 2 µL of dye is added to 
each sample to where each line in the digest is and to give an estimate as to where the 
samples have traveled down the gel.  In total: 5 – 7 µL of sample was added to each 
well as well as a 4 µL sample of marker it show where the size of each particles is 
separated along the gel.  To run the experiment after all the samples have been loaded, 
the gel and casing is attached to a container, which is filled with 1% TBE Buffer 
solution.  An electrical charge runs through the gel at 300V and 50mA for 45 minutes 
in order to pass the samples through the gel.  After 45 minutes, the gel is removed, and 
added to a petri dish with 40 µL of Ethidium Bromide (c = 10 µg/mL) 100 mL TAE 
(Tris/Acetate/EDTA) Buffer and incubated at room temperature for 15 minutes.  This 
constitutes the developing stage so that the lines can be easily seen.  After 
development, the gel is placed in a UV scanner, where ultraviolet rays allow the bands 
to be seen inside the gel.  From there, one would be able to decipher which clones are 
identical and which ones had some abnormalities in the DNA structure.  From there, 
the total number of possible clones can be decreased based on similar structures, as 
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one will be able to see by way of DNA sequencing. 
  8.2.3. Titration ELISA 
 During the titration ELISA, each clone is placed into two different tests on the 
same ELISA: to make sure that the scFv only binds to its proper antigen and that the 
limit of detection for each scFv clone is found.  The procedure for this ELISA is 
similar to that of the screening ELISA, except for some differences during the addition 
of the scFv clones and the antigens used to attach to the scFvs[145].  The experiment 
starts with a 96 well micro titer plate, where 4 wells per clone is filled with 180 µL of 
2xYT-AG medium.  Each culture is reused from cryotubes that were prepared earlier 
after the screening ELISA for each specific binder and each culture was placed in the 
filled wells.  One of the wells had a positive control inside so that it was to be shown 
that the experiment functioned properly.  This plate was incubated overnight at 37°C 
at 800 RPM. 
 After overnight incubation overnight a second 96 well micro titer plate is used 
for the growth of the clones. 170 µL of 2YT-AG medium is added to the same 
locations as the first plate.  10 µL of the overnight culture is then added per well.  This 
plate is then incubated at 37°C at 800 RPM for 2 hours.  Once incubation is 
completed, the plates are spun down and the supernatant is decanted.   180 µL of 2YT-
ASI medium is added per well and the plates are incubated overnight at 30°C and 800 
RPM.  At the same time, the ELISA plates are being prepared.  The Costar ELISA 
plates are coated with 100 µL Streptavidin (100ng/well), except for one well, which 
was coated with 100 µL of MucI (1µg/well) to be used as a positive control.  The 
plates are incubated for 1 hour at room temperature.  From there, the Streptavidin is 
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discarded and each well was blocked with 2% BSA in 0.1% PBST.  These plates are 
then stored overnight at 4°C. 
 The following day, the plates are washed three times with 0.05% PBST.  At this 
point, the antigens added to the plate.  Each antigen was added so that there was one 
antigen per row.  For each clone, two rows are used for the antigen the scFv should 
bind to, one row is used for the antigen that the scFv should not bind to and one row 
does not have antigen, in order to see if there was binding to the streptavidin.  In each 
well with antigen, add 100 ng of antigen is added to 100 µL of PBS.  In the rows 
where no antigen is added and the well with the positive control, only 100 µL of PBS 
is added.  The plates are then incubated for 1 hour and washed three times with 0.05% 
PBST.  In the meantime, a 96 well micro titer plate is used per ELISA plate for the 
transfer of scFvs.  In each well, 100 µL of 2% BSA in PBS is added.  The overnight 
culture is spun down and the supernatant is transferred in the following way: 100 µL 
of supernatant for a specific clone is added to each well in the first column of that 96 
well plate.  After mixing, 100 µL of mixture in the first column is transferred to the 
second column.  After mixing, 100 µL of mixture in the second column is transferred 
to the third column.  This process is repeated for each column until the last column is 
reached.  Then, starting with the second to last column, 100 µL of mixture is 
transferred from the micro titer plate to its exact column on the ELISA plate.  This is 
done by transferring the second to last column, then the third to last column, and so on 
until the first column is transferred.  This is done so that the results can be as accurate 
as possible.  In the last column of the ELISA plate, 50 µL of 2% BSA in PBS is added, 
as well as 50 µL of the overnight culture for the positive control.  These plates are then 
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incubated at room temperature for 1.5 hours and washed three times with 0.05% 
PBST.   
 The remaining steps are the same as for the screening ELISA.  After washing, 
150 µL of 9E10 primary antibody (goat anti myc antibody, 1:1000) in 2% BSA in PBS 
were added to each well in both plates.  These plates were then incubated for an hour 
and washed three times with 0.05% PBST.  Afterwards, 150 µL of a secondary 
antibody (goat anti mouse with a tag, 1:1000) in 2% BSA in PBS was added to each 
well.  These plates were incubated one last time for one hour and washed washed three 
times with 0.05% PBS. 
 The last step was to perform the detection of the ELISA.  For this, a TMB 
mixture was used to detect the antibodies.  To perform this detection, 100 µL of a 20:1 
ratio of TMB-A : TMB-B was added to each well.  From there, the detection began 
when the colors of the wells changed from clear to blue.  The darker the blue, the more 
concentrated the scFvs are in the well.  In order to make sure that the experiment 
work, all the positive control wells had to be blue, all the negative control wells had to 
be clear and the wells on the positive control plate had to be blue, while the wells on 
the negative control plate had to be clear.  The first signs of detection in the plates 
were found within the first five minutes.  After 20 – 30 minutes, the reaction slowed 
down and the background started to come into play.  At this point, the experiment 
detection was stopped by adding 100 µL of sulfuric acid in each well.  This turned the 
solution from blue to yellow and allowed the experiment to stop so that the OD of 
each well could be measured.  To measure the OD, the plate was placed in a machine 
and the reader was set to measure the OD at a wavelength of 450 nm, but have a 
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reference wavelength at 620 nm[145].  If the experiment worked, the intensity would 
fade from left to right in the two rows where the antigen that is supposed to attach to 
the scFv, while the other rows would give off no signal.  From there, the best shown 
clones would be then chosen to be sequenced to show the DNA structure and to see 
any common areas in the structure or if they were identical. 
  8.2.4. DNA Sequencing 
 The final step for the whole experiment is the DNA sequencing.  In this part, 
the structure of each scFv is found and one can see if there is more than one clone that 
can be used to detect antigens.  To begin with the sequencing, an overnight culture is 
first made by inserting a small amount of culture for a specific clone in a test tube 
filled with 5 mL of 2xYT-AG medium.  This test tube is incubated overnight at 37°C 
at 250 RPM.  The following day, the overnight culture is poured into a 1.5 mL reaction 
cap, one milliliter at a time and centrifuged for 1 minute at 10X g (Eppendorf 
Centrifuge 5415 D, Eppendorf, Hamburg, Germany).  The supernatant is discarded 
and the process is repeated until all the culture is used up and the pellet remained in 
the reaction cap.  The next part of the experiment used the peqGOLD Plasmid Mini 
Kit (PeqLab, Erlangen, Germany) in order to extract the DNA.  The first step is to 
suspend the pellet completely in 250 µL of Solution I, which is mixed with Rnase.  
Then 250 µL of Solution II is added and the cap is gently inverted until a clear lysate 
formed.  After that, 350 µL of Solution III is added and the cap is again gently inverted 
until a white precipitate formed.  The cap is then centrifuged for 10 min at 10X g.  The 
resulting supernatant is then transferred to a peqGold membrane (~750 µL) and 
centrifuged for 1 minute at 10 X g.  After centrifugation, 750 µL DNA Wash Buffer, 
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which was mixed with ethanol, is added to the membrane and centrifuged for 1 minute 
at 10 X g.  This last step is repeated one more time.  Then the membrane was dried by 
centrifugation for 2 minutes at 10 X g.  Following drying, 100 mL of elution buffer is 
added to the membrane, centrifuged for 1 minute at 5X g and collected in a clean 
reaction cap.  This elution is stored at 4°C. 
 To prepare the elution for sequencing, new reaction caps containing the 
plasmids must be sent to a GATC Biotech AG (Konstanz, Germany) for sequencing.  
These reaction caps had to contain a plasmid concentration between 30 and 100 
ng/µL, while the total volume had to be equal to 30 µL.  To obtain this precise 
concentration and volume, elution buffer was added to the specific volume of plasmid 
to obtain the desired concentration at 30 µL of solution.  The caps were shipped and in 
a few days, the sequencing came back as a downloadable note file, which could be run 
on VBASE2 (www.vbase2.org) to give the proper sequence for each scFv clone 
Multalin (multalin.toulouse.inra.fr/multalin/) in order to see if multiple clones were 
similar to each other, but how they lined up against each other. 
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CHAPTER 9 
 
FINDINGS 
 
 9.1. Non-phosphorylated-Tau Protein 
  9.1.1. Screening ELISA 
Figure 9-1: Screening ELISA for Tau 
 The main objective for obtaining results with non-phosphorylated Tau is to 
show what type of scFvs can be created with a version of Tau that was not only 
healthy and did not immediately show the possible effects of phosphorylation, but also 
that there was a baseline for detection, that strands of Tau could be found and not 
render the experiment obsolete.  After three panning rounds, 92 E. coli samples from 
were collected, cultivated, had all possible amounts of scFvs extracted, and underwent 
a screening ELISA.  The results are as follows:  Out of a possible 92 potential clones, 
37 clones had an OD greater than or equal to 0.3.  However, two of these clones also 
had a positive signal:negative signal under 5.  The reason that there needs to be a 
A1 A7A4 A10 B1 B4 B7 B10 C1 C4 C7 C10 D1 D4 D7 D10 E1 E4 E7 E10 F1 F4 F7 F10 G1 G4 G7 G10 H1 H4 H7 H10
0
0,2
0,4
0,6
0,8
1
Tau L1/L2
Tau [100 ng/well]
Streptavidin [100 ng/well]
position (scFv clone)
A
4
5
0
n
m
 -
 A
6
2
0
n
m
187 
 
positive:negative ratio over 5 is that there is only streptavidin in the wells of the 
negative control.  This is to make sure that the scFvs will ONLY attach directly to the 
antigen and not anywhere else, including the streptavidin.  Out of the possible 35 
clones, that could be of use, 31 had an OD greater than 0.5.  However, to further show 
that the amount of scFvs can be maximized, 11 had an OD greater than 0.8 and only 4 
had an OD greater than 1.0.  To show which clones were the best during this ELISA, 
all clones that exhibited an OD greater than 0.8 were used in the following BStNI 
digest. 
A10 B3 C1 C2 D7 D8 
D12 E4 E7 G9 H7  
Table 9-1: Chosen clones for BStN digest for Tau 
  9.1.2. BStN Digest 
Figure 9-2: BStN Digest of Tau clones from A10 through H7 
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 The use of the BStNI digest is to determine if there are any differences in the 
makeup of each clone.  Each scFv component is broken up into smaller fragments and 
separated an agarose gel using electrophoresis.  During the experiment, each 
component is separated based on mass (the greater the mass, the higher up in the 
column it would be), with a band showing the location of each particle.  Although the 
bands cannot be seen in the gel directly, they can be detected via UV light.  For this 
experiment, 11 clones were prepared and separated in the aforementioned gel.  As a 
result of this separation, there were 5 different sets of bands that could be used to 
differentiate each scFv (A10-C2-D12-G8, B3-E1, D7-D8, D12-E7, H7, with C1 not 
displaying any signal).  However, in some cases, there seemed to be different 
variations of intensities that corresponded with each clone, as shown with clones E7 & 
G8.  Also, on some of the clones, there appears to be an extra band near a specific 
group of bands, which could mean an error in the process of splicing or a totally 
different clone altogether.  This was shown for clones D12 and E1, for example.  
Because of these bands, 6 clones will go through DNA sequencing and a titration 
ELISA. 
A10 C1 D7 E4 E7 H7 
Table 9-2: Chosen clones for Titration ELISA and DNA sequencing for Tau 
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  9.1.3. Titration ELISA 
Figure 9-3: Titration ELISA of Tau against Tau (linkers 1&2), pTau (linker 1) and 
Streptavidin for clones A10 and C1 
Figure 9-4: Titration ELISA of Tau against Tau (linkers 1&2), pTau (linker 1) and 
Streptavidin for clones D7 and E4 
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Figure 9-5: Titration ELISA of Tau against Tau (linkers 1&2), pTau (linker 1) and 
Streptavidin for clones E7 and H7 
 
 The purpose of the titration ELISA is to determine the intensity of specific 
concentrations of each scFv clone, or the limit as to how intense the detection is.  In 
this experiment, with the binders for non-phosphorylated tau, we see that the most 
concentrated samples for 4 clones show a standard OD of between 1.0 and 1.4.  Only 
one clone had one peptide at an OD of 0.4 and one clone had both peptides at around 
0.2 at the maximum concentration.  Because of this, these clones are not well fit to be 
used for further experiments involving Tau.  What is also worth noting is that the 
detection signal is still strong (similar OD), even at 1/8 the concentration of scFvs.  
After this is when the signal becomes weaker with decreasing concentration.  
However, at an OD at 0.2, the intensity of this decreasing OD lessens and becomes 
more gradual towards an OD between 0.03 and 0.1.  This occurs at an scFv 
concentration 1/64 – 1/128 the size of the original concentration.  Therefore, we can 
see that based on this observation, these scFv clones have a limit of detection at 1/128 
the original concentration, with a high amount of detection starting at 1/8 the original 
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concentration.  Because of this, all six clones will be sequenced: A10, C1,D4, E4, E7 
& H7. 
  9.1.4. DNA Sequencing: 
 With the DNA sequencing, the pattern of each attaching points on the scFvs for 
both the heavy chain and the light chain are found and the antibody library can be 
made for that specific scFv that attaches to the non-phosphorylated Tau.  For this, it 
was ideal to base the clone selection from a CDR comparison (due to an IP relevance, 
the CDR comparisons cannot be shown, but the structure of the scFvs for both Tau and 
pTau will be presented in section 9.5).  Based on the results of the sequencing, only 
three clones had full heavy and light chains that were similar: A10, C1& E4.  Clone 
E7 had the same heavy chain, but no light chain, which made it unsuitable for further 
study.  The other two clones, D7 & H7, were sequenced, but also had unfavorable 
results.  Clone D7 had a sequence that was completely different than the other three 
clones, while clone H7 was missing completely.  It was later re-sequenced, but the 
light chain sequence was also missing.  Also, it is important to note that even though 
the light chain was missing for two of the clones, the heavy chain was still identical in 
sequence as with the three best clones.  In terms of choosing a clone, it was 
determined that based on the ELISAs and sequence, that clone E4 will be used as the 
biomarker against Tau..  However, even though clone D7 did not have a high signal in 
the titration ELISA, because of the difference in the CDR comparison, this could be a 
second possible candidate for the scFv against Tau. 
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 9.2. Phosphorylated-Tau Protein 
  9.2.1. Screening ELISA 
Figure 9-6: Screening ELISA for pTau 
 The main objective for obtaining results with phosphorylated Tau is to show 
what type of scFvs can be created with a version of tau that was phosphorylated.  This 
is because unlike non-phosphorylated tau, this type of tau is known as a signaler for 
Alzheimer’s disease.  After three panning rounds, 92 E. coli samples from were 
collected, cultivated, had all possible amounts of scFvs extracted, and underwent a 
screening ELISA.  The results are as follows:  Out of a possible 92 potential clones, 29 
clones had an OD greater than or equal to 0.6.  None of these clones had low positive 
to negative control ratio, meaning that it is with the upmost confidence that these 
clones will only attach to the antigen and not the streptavidin.  Out of these possible 29 
clones, that could be of use, 16 had an OD greater than 0.8, with the majority of these 
clones within the same OD range.  These clones were used in the following BStNI 
digest. 
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A2 A5 B7 B8 
B9 B10 C3 C6 
C12 E3 E11 F3 
F5 G7 H4 H5 
Table 9-3: Chosen Clones for BStN Digest for pTau 
  9.2.2. BStN Digest 
 
Figure 9-7: BStN Digest of pTau clones B7 through H5 
 
 For the BStNI digest, 16 clones were prepared and separated in an agarose gel.  
As a result of this separation, there were 5 different sets of bands that could be used to 
differentiate each scFv (B7-B8-B9-B10-C3-C6-G7-H4, C12-E3, E11-F3, F5 & H5).  
However, like in section 9.1.2, in some cases, there seemed to be different variations 
of intensities that corresponded with each clone (C6 and G7 for example).  Because of 
these bands, 10 clones will go through DNA sequencing and a titration ELISA. 
A2 A5 B3 B10 C3 
E3 E11 F5 H4 H5 
Table 9-4: Chosen clones for Titration ELISA and DNA Sequencing for pTau 
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  9.2.3. Titration ELISA 
In terms of this round of the titration ELISA, this experiment had to be 
performed twice.  The first time, there was an issue with pTau L1.  The scFvs were 
binding properly to pTau L2 but not to pTau L1.  It was then determined that the 
peptides were old and contaminated during the course of the screening ELISA, with a 
new set of peptides, the screening ELISA could resume and the results shown below 
and on the next page display the actual final product. 
Figure 9-8: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and 
Streptavidin for clones A2 and A5 
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Figure 9-9: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and 
Streptavidin for clones B3 and B10 
Figure 9-10: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and 
Streptavidin for clones C3 and H4 
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Figure 9-11: Titration ELISA of pTau against Tau (linker 1), pTau (linkers 1&2) and 
Streptavidin for clones E3 and E11 
 
 With a new set of antigens, the experiment was a success as the scFv clones 
attached to both antigens (the phosphorylated ones), with the exception of clone B3 
which did not bind to pTau L2.  At the highest scFv concentration possible, the OD 
values ranged between 0.8 and 1.2.  However, there was a slight difference between 
the result in the last experiment and the current experiment.  In the last experiment, as 
the scFv concentration decreased, the OD stayed relatively flat until it the 
concentration reached 1/8 the original.  At that point, the concentration started to 
sharply decreased until it was about 1/64 the original, where it then leveled off.  In this 
experiment, as the concentration started to decrease, the OD also decreased. At the 
original concentration, the OD was between 0.8 and 1.2.   At 1/2 the original 
concentration, the OD was between 0.55 and 1.1.  The OD at 1/4 the concentration 
was between 0.5 and 0.95.  This steady decrease continued until the concentration was 
1/128 the original concentration.  Because of this observation, these scFv clones have 
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a limit of detection at 1/128 the original concentration, but unlike the last experiment 
where there is no increase in signal after 1/8 the concentration, there can be an 
increase in signal as the scFv increases.  Because of this, 10 clones will be sequenced: 
A2, A5, B3, B10, C3, E3, E11, F5, H4 & H5. 
  9.2.4. DNA Sequencing: 
 Based on the CDR comparison, out of the possible 10 clones, only three clones 
were bad.  Clone B3 was missing part of the light chain, which made it unsuitable for 
further study, which explains the titration curve, clone A2 was missing the light chain 
and clone E11 was missing completely. On the other hand, the other seven clones that 
were still intact had identical sequences, meaning that there was only one sequence for 
this antigen.  One other thing to note is that even though some scFvs were completely 
missing the light chain, their heavy chains were identical to the rest of the suitable 
clones.  Based on these results, it was decided that clone B10 would be used as a 
possible biomarker against pTau. 
 9.3. Phosphorylated-Tau Protein Linker 1 with Competition 
  9.3.1. Screening ELISA 
Figure 9-12: Screening ELISA for pTau L1 in competition with Tau L1 
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 The main objective for obtaining results with phosphorylated Tau is to show 
what type of scFvs can be created with a version of Tau that was phosphorylated.  
However, what is different with this experiment is that competition is used.  During 
competition, a second antigen is used in the panning process.  While the target scFvs 
are being detected in this step, another antigen is being used to remove other scFv's 
that might cause interference.  For this experiment, the main antigen being used for 
detection is phosphorylated Tau with the first linker, with non-phosphorylated Tau 
with the first linker being used as competition.  This is done in order to remove any 
binding to the non-phosphorylated Tau and the linker beforehand.   After three panning 
rounds, 92 E. coli samples from petri dishes with agar were collected, grown and had 
all possible amounts of scFvs have been extracted, a screening ELISA was performed.  
The results are as follows:  Out of a possible 92 potential clones, 5 clones had an OD 
greater than or equal to 0.1.  None of these clones had low positive to negative control 
ratio, meaning that it is with the upmost confidence that these clones will only attach 
to the antigen and not the streptavidin.  However, it should be noted that one clone 
gave off a really high signal compared to the others (> 0.7), and was next to one of the 
positive controls.  This could mean that there might have been a chance for a possible 
contamination.  These 5 clones were used in the following BStNI digest. 
G3 G4 G5 G6 H11 
Table 9-5: Clones chosen for BStN digest for pTau L1 
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  9.3.2. BStN Digest 
 
Figure 9-13: BStN Digest of pTau L1 with competition clones G3 to H11 
 For the BStNI digest, 5 clones were prepared and separated in the 
aforementioned gel.  As a result of this separation, there were 4 different sets of bands 
that could be used to differentiate each scFv.  There is only one pair of clones that 
were similar: clones G5 & G6.  The rest either varied in intensity in the bands (G4) or 
exhibited an extra band that was not common among the other clones (G3).   Also, 
H11, the clone that exhibited a higher peak than the rest, was completely different than 
the others in the digest.  As a result of this, all five clones will be used in the titration 
ELISA and DNA sequencing. 
G3 G4 G5 G6 H11 
Table 9-6: Clones chosen for Titration ELISA and DNA Sequencing for pTau L1 
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9.3.3. Titration ELISA 
 
Figure 9-14: Titration ELISA of pTau with linker 1 with competition from Tau with 
linker 1 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin, without clone H11 
 
Figure 9-15: Titration ELISA of pTau with linker 1 with competition from Tau with 
linker 1 for clone H11 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin 
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 As shown by the titration graphs on the previous page, the experiment 
performed well pTau L2, but not with pTau.  This was explained in section 9.2.3.  
Because of this, new peptides were prepared and the titration was performed again.  
Figure 9-16: Redo of Titration ELISA of pTau with linker 1 with competition from 
Tau with linker 1 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin, without 
clone H11 
Figure 9-17: Titration ELISA of pTau with linker 1 with competition from Tau with 
linker 1 for clone H11 against Tau (linker 1), pTau (linkers 1&2) and Streptavidin 
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 In this second run, it was a success as the scFv clones attached to both antigens 
(the phosphorylated ones).  At the highest scFv concentration possible, the OD values 
for the clones, except for H11, ranged between 0.04 and 0.4.  There was a decline after 
this, but the signal was too weak to consider any further experiments with these 
antibodies.  However, the clone H11, the one that exhibited a high signal performed 
well.  The OD at the maximum concentration was around 0.8, with a steady decrease 
as the concentration also decreased.  At 1/64 the original concentration, the OD started 
to level off towards an OD of zero.  Because of this, only clone H11 underwent DNA 
sequencing. 
  9.3.4. DNA Sequencing: 
 Based on the results of the CDR comparison, clone H11 displayed a complete 
sequence.  Moreover, compared to the previous experiment with no competition, the 
DNA sequence was exactly the same as the other ones sequenced.  Based on this 
observation, this clone can be used with the others as a possible scFv to detect 
phosphorylated Tau. 
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 9.4. Phosphorylated-Tau Protein Linker 2 with Competition 
  9.4.1. Screening ELISA 
Figure 9-18: Screening ELISA for pTau L2 in competition with Tau L2 
 Like back in section 9.3, this screening ELISA encompassed the use of 
competition.  Except this time, the peptides with linker 2 were used.   After three 
panning rounds, 92 E. coli samples from petri dishes with agar were collected, 
cultivated, had all possible amounts of scFvs extracted and underwent a screening 
ELISA.  The results are as follows:  Out of a possible 92 potential clones, 19 clones 
exhibited an OD reading greater than 0.2.  These clones were the best read clones out 
of all the possible clones that were produced.  However, with one of the clones, clone 
F4, the negative control was abnormally higher than what it should have been.  This 
could either be a case where there was contamination in the negative control or there 
was an unknown error during the running of the experiment.  Nether the less, because 
of this error, this one specific clone cannot be used in any further experiments.  
Instead, the other 18 clones can be used for a BStNI digest. 
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A3 A6 B4 C3 C4 D1 
E1 E2 E3 E5 E6 F1 
F2 F3 F4 F5* G5 H1 
H2 H4 H7    
Table 9-7: Chosen clones for BStN digest for pTau L2(*Clone F5 had a higher 
negative signal than positive) 
  9.4.2. BStN Digest 
Figure 9-19: BStN Digest for pTau L2 with competition clones A3 through E1 
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Figure 9-20: BStN Digest for pTau L2 with competition clones E2 through H7 
 In this digest, 18 clones were prepared and separated in the agarose gel.  As a 
result of this separation, most of the clones were similar in band length and distance.  
However, some of the clones did experience a small brightness in the type of band 
(clone E1, compared to D1), while other bands were just a little bit off from what the 
majority of the bands (clone H7 compared to clone H4).  As a result of this digest, 14 
different clones will undergo a titration ELISA and DNA sequencing. 
A3 A6 B4 C3 C4 D1 
E1 E2 F1 F3 G5 H1 
H2 H7     
Table 9-8: Chosen clones for Titration ELISA and DNA sequencing for pTau L2 
 
 
 
 
 
206 
 
  9.4.3. Titration ELISA 
Figure 9-21: Titration ELISA of pTau with linker 2 with competition from Tau with 
linker 2 against Tau (linker 2), pTau (linkers 1&2) and Streptavidin 
 
 Like the last experiments, the scFv clones attached well to the target antigen 
(pTau L2), but not pTau L1.  Not only that, but that same scFv also attached to one of 
the negative controls, Tau L2.  This was the control where the antigen was non-
phosphorylated, but it used the exact same linker as before.  Because of this, it is safe 
to assume that these scFvs somewhat bind to the antigen, but there is binding at the 
linker.  A further titration ELISA was performed but it resulted in similar results, 
except that the OD measurements were lower than before.  Because of these reasons, 
this experiment was not further investigated because the focus is only on scFvs that 
attach directly to the antigen and nothing else. 
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9.5. Titration ELISA Using the Best scFv Clones against Tau, pTau and 
Other Antigens 
 
 In these final experiments, the optimal scFv clones against Tau and pTau  (Tau 
clone E4 and pTau  clone B10) underwent a titration ELISA against not only the forms 
of Tau that were used, but also against other antigens.  In a 96 well ELISA plate, the 
following order was used for each antigen (from top to bottom): Non-Phosphorylated 
Tau – Linker 1 (Tau L1), Non-Phosphorylated Tau – Linker 2 (Tau L2), 
Phosphorylated Tau – Linker 1 (pTau L1), Phosphorylated Tau – Linker 2 (pTau L2), 
Beta Amyloid 42 Fibrils (aß 42), Phosphorylated Fibronectin 1 – Linker 1 (pFN1 L1), 
Phosphorylated Fibronectin 2a – Linker 1 (pFN2a L1), Streptavidin (negative control).  
This is to make 100% sure that each scFv only binds to its own antigen and not any 
others. 
Figure 9-22: Titration ELISA for Tau scFv clone E4 against Tau (linkers 1&2), pTau 
(linkers 1&2),  aβ42, pFN1 (linker 1), pFN2a (linker 1) and Streptavidin 
 
 The ELISA that used the Tau scFv only bound to the non-phosphorylated Tau.  
At the highest concentration possible, the OD measured between 1.3 and 1.55.  This 
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measurement was for the most part constant, even at 1/16 the original concentration.  
At a lesser concentration, OD decreased substantially until it was 1/128 the original 
concentration.  At that point, the OD started to slowly level off towards 0.0.  There 
was no additional binding to any other antigen, with the exception of pTau L2, which 
displayed a small amount of detection.  This might have been caused by linker 
binding, but it is small compared to the binding to the Tau.  In terms of clone D7, this 
titration ELISA was not performed as the signal back in the previous ELISA (see 
section 9.1.3) was not high compared to clone E4. 
 
Figure 9-23: Titration ELISA for pTau scFv clone B10 against Tau (linkers 1&2), 
pTau (linkers 1&2),  aβ42, pFN1 (linker 1), pFN2a (linker 1) and Streptavidin 
 
 The ELISA that used the pTau scFv only bound to the phosphorylated Tau.  At 
the highest concentration possible, the OD measured between 1.4 and 1.6.  This 
measurement was for the most part constant, even at 1/16 the original concentration.  
At lesser concentration, OD decreased substantially until it was 1/1024 the original 
concentration.  At that point, the OD started to slowly level off towards 0.0.  There 
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was no additional binding to any other antigen. 
 To further compliment this, tables 9-9 and 9-10 below shows the fragment 
structure of these three antibodies.  This breakdown for the antibody fragments is as 
follows:  There are two types of chains: heavy and light.  On the heavy chain, there are 
three sections: variable (V), diversity (D) and joining (J).  There are also two types of 
light chains: kappa (K) and lambda (L).  On either the kappa or lambda chains, there 
are two sections: variable and joining.  Fragments can either have a kappa chain or a 
lambda chain, but not both.  The naming scheme uses the above letters and numbers to 
differentiate the segments 
Antibdy Name ALP13-E4 ALP13-D7 
Antibody Type Non-Phosopho-Specific 
Heavy Variable  IGHV5-51*01 IGHV1-46*01 
Heavy Diversity IGHD3-22*01 IGHD5-5*01 
Heavy Joining IGHJ4*02 IGHJ4*02 
Light Variable IGLV3 IGLV1-47*01 
Light Joining IGLJ3*01 IGLJ3*01 
Table 9-9: Structures for the scFvs chosen that bind against Tau 
Antibdy Name ALP13-B10 
Antibody Type Phosopho-Specific 
Heavy Variable  IGHV5-51*01 
Heavy Diversity IGHD1-26*01 
Heavy Joining IGHJ3*02 
Light Variable IGLV2-8*01 
Light Joining IGLJ3*02 
Table 9-10: Structures for the scFv chosen that bind against pTau 
 Some of the similarities between the three fragments include: 
 ALP13-E4 & ALP13-D7: Same joining segments for both the HJ & LJ 
 ALP13-E4 & ALP14-B10: Same HV segments 
 All three fragments have lambda structures for light chains 
Other than these, these three are completely different fragments. 
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CHAPTER 10 
 
CONCLUSION 
 
10.1. Discussion 
 This project effectively found two sets of scFv antibodies that are able to bind 
to a certain Tau peptide.  This was performed effectively by using phage display and 
by harvesting E. coli cultures in order to extract these antibodies.  Because of the 
effects of phosphoylation, which is a side effect of Alzheimer's, these antibodies were 
created in order to bind to both Tau and pTau.  These antibodies were also shown to 
have a high affinity to the antigen and could be detected in small amounts.  Because of 
these reasons, it was shown that creating these antibodies was a success. 
 Furthermore, it was also shown that only one of the same antibodies could be 
formed based on the competition ELISA (pTau L1, not pTau L2).  This is due to the 
fact that there are antibodies that also bound to the linker that were also discovered.  In 
order to mitigate this, a fourth run would have to be performed with the same peptide, 
but with different linkers, so that the proper antibodies could be obtained.  Other than 
this, it was shown that it was possible to obtain two different antibodies for Tau and 
pTau respectfully.  The structures for each was shown in section 9.5, tables 9-9 and 9-
10. 
 As mentioned in the results section, scFv clones for both Tau and pTau were 
found by using different antibody libraries and phage display.  The majority of the 
clones that were tested during the ELISAs performed well, with the exceptions of 
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some clones during the DNA sequencing and the pTau – L2 with competition, where 
the scFvs only attached to the linker.  Based on the results found, scFv clones were 
found that were able to detect pTau antigens and clones were found that detected Tau 
antigens, both with specificity and with a high detection signal.  However during the 
course of these experiments, there were problems that had to be dealt with in order to 
accurately show these results previously shown. 
 The majority of these errors occurred during the panning and the screening of 
the scFvs.  These errors were mostly random errors that were caused by not following 
the protocols properly.  These were either a time-related or temperature-related error 
that resulted in the whole experiment being repeated over again.  For example, if a 
certain experiment was left out too long, the number of E. coli clones were either too 
big or too many.  One other problem occurred with temperatures, especially if a 
certain experiment had to run overnight.  As explained during the procedures, there 
were only three temperatures that each experiment had to be incubated at: 4°C, 30°C 
and 37°C.  While no problems occurred at 4°C, the biggest issue was at 30 and 37°C.  
Incubation at 37°C meant bacteria growth during panning rounds, while 30°C was 
used to breakdown the E. coli to create new phages or to release scFvs into solution.  
However during some experiments, samples that were supposed to be incubated at 
30°C were actually incubated at 37°C.  This was either due to human error, or to other 
experiments being performed in the lab.  This caused problems because there was no 
detection or colonies after each experiment were completed, which meant that all of 
these experiments had to be redone.   
 But one of the biggest errors during each experiment was during the 
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amplification stage.  In this stage, the newly made bacteria colonies had to grow from 
on OD of 0.1 to an OD of 0.5.  This was performed by scraping off the agar plate the 
bacteria and placing between 0.3 and 0.5 mL in a solution of 2YT-AG.  During this 
section, it was important that no agar was also placed in this solution, as it would 
hinder bacterial growth while in incubation.  However, during this sequence there was 
one problem that could cause the experiment to start over again.  In a normal bacterial 
growth, for every half hour elapsed, the OD would double.  For example, at t=0, and 
OD=0.1, at t=0.5h, OD=0.2 and at t=1h, OD=0.4.  However, during this stage, the 
growth was significantly different.  What would happen is that there would be growth 
for the first half hour, but after that, the OD would decrease dramatically.  It would 
decrease to a certain point either just above or just below the original OD.  After that, 
it would remain stagnant for about a few hours, before it would gradually rise up 
again.  Because of this, an experiment that could normally take between 1.5 and 2 
hours, would actually take between 5 and 7 hours depending on the rise in the OD.  
While this phenomenon was normal during the experiments, the problems usually 
occurred when the OD fell below the original OD.  When this happens, it shows that 
there was something wrong with the amplification, which meant that the experiment 
had to be redone.   
 Other errors in panning included measurements with the OD during incubation.  
This was crucial because the growth in OD was not linear with time, but more 
exponential.  At times, if an experiment was being performed where incubation was 
necessary, if the incubation was even 10 or 20 minutes longer than expected, the OD 
would be too high for sufficient bacterial growth due to over-crowding and insufficient 
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supply of food for the E. coli.  However, if an experiment was stopped too short, then 
there would not be enough E. coli to complete the experiment.  To start each 
incubation process, the acceptable OD range had to be in between 0.075 and 0.1, with 
better results at 0.1.  At the end of the incubation, the acceptable range had to be 
greater than 0.45, but no more than 0.65, with 0.5 being in the acceptable range.  But 
since the bacterial growth during this time is not linear, it at times was hard to tell 
when it was appropriate to end this experiment. 
 One other important bit of information during the panning rounds was that two 
different protocols were used during the running of the experiments.  The first 
involved bacterial growth on agar plates, while the second involved bacterial growth 
in micro titer plates.  The first set of experiments was performed using the first 
method.  This method had some positive aspects while performing each experiment.  
For instance, multiple samples after each panning round could be taken.  This means 
that because 100 microliters were needed of phage to run the next experiment, the 
samples were collected in 1.5 – 2.5 mL samples.  This meant that in case the 
experiment went wrong, there was always backup available, so that the experiment did 
not have to start over.  On the other hand, this process was more labor intensive and 
took at times about 6-8 days to complete three rounds.   
 The remainder of the experiments was performed using the method with micro 
titer plates.  This method not only cut back the time needed to create clones by 2 -3 
days, but was also less labor intensive than the previously mentioned method.  
However, the results were not generated until the end of the third panning round.  In 
the previous experiments, agar plates were used to grow bacteria colonies after each 
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panning round.  Since this occurred with larger volumes of solutions, separate vials 
were needed to store the results from the previous experiments.  This was to make sure 
that even if the next panning round was not a success, there was extra phage left over 
to redo the experiment so that it did not have to be started over again.  However, in 
this experiment, because small volumes of phage were used in each experiment, there 
was not any room for error and there were no checks in between to make sure that the 
experiments ran smoothly.  All the results had to be found at the end of the third 
panning round.  If no colonies were present at the end, then the whole experiment had 
to be repeated from the beginning.   
 In the previous experiments, it was shown that scFvs could be made for a 
specific region of Tau Protein, in both phosphorylated and non-phosphorylated forms.  
This is beneficial in that these antibodies can be used as a biomarker.  However, there 
can be more experiments that can further help the project.  These experiments can be 
explained below. 
 10.2. Further Work 
 The first experiment that can be done can be to create an scFv that can detect 
both forms of this peptide of Tau.  As shown in the previous experiments, only the 
scFv made for non-phosphorylated Tau bound to non-phosphorylated Tau and the 
same can be said for phosphorylated Tau.  However, the reverse (Tau → pTau scFv 
and pTau → Tau scFv) cannot work.  This was shown with the final titration curves 
above.  A third antibody can be created that could detect both forms, but this could 
require a larger stock antibody library and more than 4 rounds of panning in order to 
successfully obtain these antibodies. 
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 The second experiment would be to obtain IgG from these scFvs.  This could 
either be performed by engineering the antibodies in a way that would allow for IgG 
creation, or by performing it in the usual manners to obtain IgG.  This would be by 
introducing either the scFv or the peptide into a mammal and then extracting the 
antibodies.  This would be beneficial for performing assays in which tau needs to be 
detected from a fluid and it needs something to attach to.  IgGs work better because 
they have a stabilizer in which they are able to attach to the well, whereas scFvs only 
contain the parts which are supposed to attach to an antigen and maybe a detection 
antibody. 
 One final group of experiments would be to find antibodies for the entire Tau 
protein.  As mentioned in the background, only about a dozen proteins exist that are 
known to connect with certain Tau peptides.  While this project only focuses on one 
specific section, there are many different spots on the protein that have no antibodies 
associated with it.  Because phosphorylated Tau is broken off from the microtubules, 
there are hundreds of peptides in spinal fluid that could be found.  With this many 
different peptides, it should be known that any different amount of peptides could be 
in one solution and it is a lot more difficult to isolate one type.  For this reason, it 
would be better to at least find a few more scFvs that would be able to effectively 
detect all known Tau peptides, both phosphorylated or not. 
Further work will have to be performed in order to effectively either create IgG 
antibodies and completely map the entire protein, but this will happen in the upcoming 
years.  However, it is safe to say that two new antibodies have been discovered that 
would aid in detecting not only Tau protein, but one that is known to undergo 
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phosphorylation.  In conclusion, based on the above experiments and data, two scFv 
antibody fragments have been replicated in order to attach to both Tau and pTau, 
which would aid as a biomarker against Alzheimer's disease.  
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APPENDIX 
 
A.1: Masks for Photo Resists for the Channel – Side Molds 
 
Figure A-1: Photo lithography masks for channel molds 
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A.2: Mask for Photo Resist for the Molds for the Filter Holder 
 
Figure A-2: Photo lithography mask for filter holder mold 
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A.3: Protocol for HAR Photolithography for Silicon Wafer Molds[146] 
Standard Operation Procedure for HAR Photolithography 
 
Experiment Date:_________________ 
 
Hazardous Chemical: Sulfuric Acid, 96% 
 
Hazard Identification: Corrosive. 
Health effects: Causes severe skin burns. Causes severe eye burns. Causes burns of 
the mouth, throat, and stomach. 
Personal protection: Safety goggle, nitrile gloves together with trionic gloves, face 
shield, wet chemical apron, and lab coat should all be worn. 
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk. 
Handling and Storage: Keep container tightly closed in a cool, well-ventilated area. 
Do not store above 23℃. 
Stability and Reactivity: Stable. Avoid exposure to excess heat, combustible 
materials, organic materials, moist air, water, oxidizers, amines, bases. 
 
Hazardous Chemical: Hydrogen Peroxide, 30% 
 
Hazard Identification: Strong oxidizer. Contact with other material may cause fire. 
Health effects: Corrosive to eyes, skin, nose, throat and lungs. May cause irreversible 
tissue damage to the eyes including blindness. 
Personal protection: Safety goggle, nitrile gloves together with trionic gloves, face 
shield, wet chemical apron, and lab coat should all be worn. 
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk. 
Handling and Storage: Keep container tightly closed in a cool, well-ventilated 
area. Do not store above 8℃. Separate from acids, alkalis, reducing agents and 
combustibles. 
Stability and Reactivity: Stable. Avoid exposure to excess heat, combustible 
materials, organic materials, moist air, water, oxidizers, amines, bases, metals. 
 
Hazardous Chemical: Methanol 
 
Hazard Identification: Flammable. 
Health effects: Hazardous in case of skin contact (irritant), of eye contact (irritant), of 
ingestion, of inhalation. Slightly hazardous in case of skin contact (permeator). Severe 
over-exposure can result in death. 
Personal protection: Safety goggle, nitrile gloves, and lab coat should all be worn. 
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk. 
Handling and Storage: Store in the yellow cabinet for the inflammables. 
Stability and Reactivity: Stable. Avoid exposure to excess heat, ignition sources, 
oxidizing agents, metals, and acids. 
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Hazardous Chemical: SU8 Developer 
 
Hazard Identification: Flammable. Flash point is 460℃. 
Health effects: May be harmful if swallowed, inhaled, or absorbed through the skin. 
Readily absorbed through the skin. No significant signs of any health hazard are 
expected to occur through skin absorption. Irritating to eyes and respiratory tract. May 
cause burning, tearing, redness or swelling. Vapor or mist is irritating to the eyes, 
mucous membranes and upper respiratory tract. Prolonged and/or repeated exposure 
can cause gastric or nervous system effects. 
Personal protection: Safety goggle, nitrile gloves and lab coat should all be worn. 
Engineering Controls: Use the fume hood in the Wind Tunnel Lab in Kirk. 
Handling and Storage: Store in the yellow cabinet for the inflammables. 
Stability and Reactivity: Stable. Avoid exposure to oxidizing agents, strong acids, 
and strong alkali. 
 
1st day 
 
1. Cleaning: Add 75ml H2O2 and then 75ml H2SO4 sequentially to form piranha 
solution. The substrate wafer is cleaned in the solution for 15 min (until no bubbles 
are observed on the surface of the wafer) with gentle shaking. The wafer is then 
soaked in distilled water for 5 mins (change to clean water and repeat 2 times ) with 
gentle shaking. 
 
2. Dehydration: Dehydrate the wafer at 200~220 ℃ for a minimum of 30 mins on hot 
plate (No dehydration is needed when using AP300). 
 
3. Adhesion improvement: 
 
Method 1: After cleaning the silicon/glass wafer, spin SU-8 2002 for 25 sec. at 
300rpm and 30 sec. at 3000rpm. The acceleration for low speed is usually set to 
100rpm/sec, 300rpm/sec for high speed. The SU-8 2002 does not spread well on the 
wafer. Repeat for multiple times until a desirable coating is observed. 
Prebake at 65 ℃ for 1 min and softbake at 95 ℃ for 3 min. Over-expose without 
photomask for 2 mins. Postbake at 65 ℃ for 1 min and 95 ℃ for 3 min. (Do not 
develop it afterwards, this contaminates the wafer.) 
Hard bake at 150 ℃ for 30 mins on hot plate. 
 
Method 2: Blow the surface using clean nitrogen. After puddling 2-3ml AP300 on the 
substrate, spin AP300 for 25 sec. at 300rpm and then 30 sec. at 3000rpm. Then, repeat 
the spin coating to air dry the substrate. Make sure to put AP300 in perfectly sealed 
Zip-Loc bag cushioned with nitrogen to protect it against moisture!!! 
 
2nd – 3rd day 
 
Temperature: _______________ Humidity: __________________ 
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4. SU8 preparation: After getting a new batch, loose the cap and heat photoresist at 
an upright position at 50 ℃ in oven for 2 h. Don’t degas the bottle. Don’t pierce into 
the resist as this may induce extra stress. 
 
5. Spin coating: Align the wafer carefully with the chuck of coater. Blow the wafer 
surface from center to edge with N2 gun. Next, spin SU-8 2050 for 45 sec at 300rpm 
then 50sec at 600rpm (130-158 um layer). Remove large edge bead if necessary. 
 
6. Planarization: Then, let it sit perfectly level for 1hr (relaxation time), so the 
photoresist will “smooth out”. SU-8 has good self-planarization property. 
 
7. Softbaking[1]: Make sure the hotplate is perfectly LEVELED before baking 
the wafer. Then, ramp heat from 50 degrees to 95 degrees for 23 min at 2 ℃/min. 
Bake for 3 hr at 95 ℃. Let cool to room temperature at 1 ℃/min. 
 
Step 5-7 can be repeated if higher thickness film needs to be built. Add one extra 
hour for baking at 95C when baking another layer. For instance, bake for 4 h at at 
95℃ when baking the second layer. Bake for 5 h at at 95℃ when baking the third 
layer, etc. 
 
4th day 
 
Optional Step (only for high aspect ratio): 
 
Barrier Coating and Contrast Enhancement 
 
1) Spin coat Barrier Coating 7.5 (ShinEtsuMicroSi, Pheonix, AZ) above the SU-8 at 
1000rpm. Use more than anticipated, as it doesn’t spread well (this also 
prevent substrate from sticking on the photomask. Air dry completely for 5 
min. (enough time to spread at 300rpm, then fast ramp to 3000rpm, 60 s total). 
 
2) Spin on Contrast Enhance Material 388SS (ShinEtsuMicroSi, Pheonix, AZ). Air 
dry completely for 15 min. 
 
8. UV Exposure: The Karl Suss MJB3-Broadband (3.5mW/cm2), 365nm i-line. 
 
Make sure that there is no gap between photo mask and SU-8 surface. The gap would 
result in widening of the patterns due to diffraction! Pay attention to the bubbles which 
may also cause the gap. 
 
UV exposure for 6 mins will work for 400um mold with barrier coat and Contrast 
Enhance Material, only 2min one time with 1 min interval to allow surface cooling. [2] 
 
USE HARD CONTACT. DON’T PRESS SOFT CONTACT BUTTON. 
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Figure A-3: Diagram for UV light exposure for soft lithography mold creation 
 
Tips on adjusting the alignment stage: 
 
 (1) the contact begin around 150 degree, fully contact at 170 degree. This is important 
      to make sure that the wafer is being hold properly, not to loose to cause gap, or 
      not to tight to stick on the photomask. 
 
(2) Hold the outer silver ring when adjusting the stage. CW�lower, CCW�raise. 
 
(3) Use razor to separate the wafer from mask carefully if wafer stick to mask. 
 
Film Thickness:____300 μm____ ____100 μm___ _____50 μm_____ 
 
With CEM and BC: ___Y/N_____ ______________ ______________ 
 
Substrate material:___Silicon_____ ______________ _______________ 
 
Energy dosage required: _________ ______________ _______________ 
 
Estimated exposure time: 2.5+1+2.5 min ____2 min______ ____90 sec_______ 
 
Rinse in water (dissolving the Barrier Coat and lifting off the Contrast Enhance 
Material) and air dry. 
 
9. PEB[3]: ramp heat from 45 to 85 degrees at 2 ℃/min. Held for 40 min at 85 ℃. Let 
it cool gradually to room temperature at 1 ℃/min. 
 
10. Developing: Place the wafer face-down in the glass container. Set the shaker to 
max speed 10 min in developer I (take the wafer out every 5 min and gently blow 
dry with N2), 30 min in clean developer II (take the wafer out every 3 min and 
gently blow dry with N2), and then 1min in IPA. Plasma could be used to clean 
undeveloped residues from the mold. (Make sure use fresh solution for high aspect 
ratio mold.) 
 
Hard bake at 150 ℃ for 30 min (use 1 ℃/min as ramp to heat up and cool down). 
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4th day 
 
11. Channel Fabrication: (5:1 prepolymer/curing agent for high aspect ratio mold) 
 
50+5g PDMS is typically enough for making 4 chips and one substrate for all. 
For high aspect ratio PDMS pattern, more curing agent could be added (e.g. 1:5) to 
the prepolymer. 
 
Pour approximately 6g PDMS on wafer to form the first layer. Degas in the 
vacuum oven. Bake at 60 ℃ for 30mins. 
 
Add another 6g PDMS on wafer to form the second layer. Degas and bake at 60 
℃ for 2.5 h. 
 
For HAR PDMS patterns, degas 1 h for the 1st layer. Degas the 2nd layer as 
usual and bake at 60 ℃ for 4.5 h. 
 
12. Align PDMS to PDMS[4]: Bonding PDMS to PDMS can be done by spray a 
liquid cushion of methanol after plasma treatment at 35psi for 3 mins. Do not do the 
spray near a source of ignition, such as a hotplate. The alignment may be helped 
by using a magnifier. Then, heat it on hotplate at 85 ℃ for 80mins. This method 
allows aligning of different PDMS layers without immediate bonding. 
 
Tips: 
 
[1] Ramped heating reduce the tension in the film during the baking. It’s better to use 
hotplate than oven. Extend prebaking and softbaking time longer, use a Petri dish to 
cover the slide may avoid wrinkles and craters. The actual soft baking time ( e.g 1.5 
hrs) is almost 2 times longer than the suggested soft baking time by the vendor in 
order to make the SU-8 dried completely. 
 
[2] Never illuminate the SU8 for to long periods. Energies of 200 mJ/cm2, heat the 
SU8 at the interface with the photolithographic mask. This heating is responsible for a 
hard skin formation at the surface of the SU8. Therefore, for thick layers and for high 
exposure doses, the illumination should be done stepwise ( expose for 10 to 15 
seconds, leave the system cool down for 60 seconds, illuminate again, etc ...). 
It is important to note that the optimal exposure energy depends on the nature of the 
substrate. 
 
[3] Post exposure baking must be done gradually to prevent micro-cracks of mold due 
to thermal tension. 
 
[4] When aligning two PDMS patterns, grooves must be designed to allow methanol 
evaporates. 
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[5] Cross-linked SU-8 cannot be removed even by Piranha. 
 
[6] The 2nd layer of photoresist will not level dimples on the 1st layer. 
 
Troubleshooting: 
 
1. Dimples. –a sign of surface/thermal tension (a) Caused by surface contamination, 
can be resolved by cleaning in Piranha; (b) Caused by bubbles or residual tension in 
SU-8, can be resolved by heating photoresist at 50 ℃ in oven for 2 h; (c) Presence of 
micro particle in the resist, likely from air; (d) Due to uneven heating of surface, this 
is most unlikely to happen; (e) High humidity won’t cause dimples, we have been 
successful in obtaining “mirrored” film from 20-60% humidity at 25C. 
 
2. Poor adhesion. Generally, glass has very poor adhesion to SU-8. Bare silicon has 
medium adhesion to SU-8. Patterns wider than 200 μm should be fine on silicon. For 
patterns <50 μm, adhesion promoting methods are needed, the following will help (a) 
clean the wafer thoroughly with Piranha, (b) Use AP300, sputtered chromium film, or 
SU-8 2002 as adhesion promoter, (c) over- expose the pattern. 
 
3. Soft mold. (a) It could be that the resist film still “wet”, increasing softbaking or 
PEK time. (b) under-exposure due to insufficient exposing time, less reflective 
substrate, or thicker CEM and BC film. (c) high humidity, SU-8 uptakes moisture. 
 
Written by: Peng Li 
Microfluidic Lab, URI 
Updated on Jun. 29, 2009 
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A.4: Protocol for CRP Detection Tests[147] 
 
Microfluidic Immunoassay Protocol for Detection of C-Reactive Protein 
Experiment date: _________________        Temperature: _______________                                      
Objective:                                                                        
Important Note:          Equilibrate buffer to RT before experiments! 
 Keep the channel wet by sealing Petridish with Parafilm during all processes. 
 Don’t wipe the chip with tissue, always dry it with long-fiber cloth and keep the 
surface free from particle. 
 Always have a negative control and a positive control for each experiment. 
 Make sure the surface isn’t in contact with fluorophores. It causes high 
background. 
 Flush the channels with PBS buffer and then aspirate them between steps.  
Surface Functionalization: 
1. All microchannels are coated with BSA (1.5mg/ml in PBS) for 244 min at RT. 
2. The coated channels are then activated by 0.4% (v/v) glutaraldehyde in pure water 
for 1h at RT. 
3. Protein A (50g/ml in PBS) is incubated with the channel for another 1 h at RT. 
Storage: stored at 4 °C in a buffer consisting of 10 mM Tris, 0.05% BSA, 0.05% 
Proclin 300, and 5% glycerol. 
Immunoassay:             ImmunoChips Functionalized on: ___________________ 
4. Take pre-functionalized chips out from the package. Flush the channels with 1X 
PBS buffer. 
5. Rabbit polyclonal IgG to C-reactive protein (CRP) in Protein A/IgG binding 
buffer with concentrations shown in the table below is injected into channels and 
incubated for 7 min at RT.  
6. Flush the channels with PBS. Then, empty the channel. Make sure it is free of 
residual liquid.  
7. Inject CRP in PBS with concentrations listed in the table into channels. Incubate for 
5 min at RT. 
8. Flush the channels with PBS. Then, aspirate the channel. Make sure it is free of 
residual liquid. 
9. FITC labeled goat polyclonal IgG to CRP in PBS with concentrations shown in the 
table below is injected into channels and incubated for 5 min at RT. 
10. Wash channels by PBST (1x PBS+0.5l/ml Tween 20). Incubate 5 min during the 
wash.  
11. Refill channels with PBS and take image using exposure time 2.5 s and 84%. 
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Schematic of Sandwich Immunoassay 
rIgG to CRP: 1 mg/ml                                (in Binding Buffer). 
CRP: 2.13 mg/ml                                    
gIgG to CRP: 1 mg/ml                                
 
 Concentrations in Micro-channels（
g/ml）  
1 2 3 4 5 
rIg to 
CRP 
     
CRP      
gIg to 
CRP 
     
 
 
Table A-1: Capture antibody, CRP and detection antibody concentrations example for 
immunoassays 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Microscope Setup:   
0. Clean the glass slide and the 5x objective.  
1. Brightness -0.50; Contrast 1.00; G.0.45 1.00. 
2. Use Linearize for histogram (14 bit 16383). 
3. Don’t press White Balance in fluorescence 
mode. (Cyan 1.11 Red, Mag 1.41 Green, Yellow 
0.48 Blue). 
4. 1300×1030 RGB scanned color. 
5. Index set to 0; Black reference enabled. 
6. Best Fit set to 0%, disable Min/Max. 
7. Push lever all the way in; shutter at 1st gear. 
1 5 
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A.5: Example Graphs Taken from Fiber Optics for CRP Detection 
 
 
Figure A-4: CRP detection at intensity = 5274 (concentration ~ 1.3 µg/mL in blood) 
 
 
Figure A-5: CRP detection at intensity = 10256 (concentration ~ 3.4 µg/mL in blood) 
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B.1: Protocol for Phage Display with Agar Plates (Translated from German)[143] 
Panning Ab-libraries: Panning mit biotinylierten Oligopeptiden 
Dissolve the Oliogpeptide in PBS with 5%DMSO. 
Coat 100 ng Streptavidin in 100 µl PBS per Well overnight at 4°C. For each panning 
round coat two wells on two separate Maxisorb Stripes! One well is for the 
biotinylated Oligopeptide binding und second well is for the  pre-incubation of the Ab-
Phage library on top of streptavidin, in order to remove streptavidin binders! 
Alternative: Coat 100 ng biotinylated Oligopeptides in PBS or NaHCO3 Buffer per 
well overnight at 4°C direct on the plate. Check beforehand the Streptavidin-HRP 
Conjugae, if the Oligopeptides bind on the plate! 
Wash with PBST in the 3xELISA-Washer (Program "3 N"), to remove the unbound 
Streptavidin. 
Place 100 - 500 ng biotinylated Oligopeptides in 150 µl PBS in a Streptavidin Well 
geben and incubate for 1 h at RT (not when the Oligopeptides are coated directly on 
the plate!). 
Wash with PBST in the 3xELISA-Washer (Program "3 N"). Fill the wells to 
completely block with 2%MPBST. Incubate at RT for 2 h. 
At the same time, block an empty Streptavidin well (without Antigens) per round with 
Panning block for1 h. (when the Oligopeptides are coated directly on the plate, block 
an empty well with panning block) 
After pre-incubate the Ab-library (1x10
11
-1x10
12
 Ab-Phage, depending on the library), 
or the amplified Phage in the previous panning rounds in 150 µl panning block for 1 h. 
Transfer the Phage from the pre-incubation wells to the wells with the antigen, add 
100 ng streptavidin (competitive assay from the previously used  Streptavidin binders) 
and incubate for 2h at RT. 
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Remove the unspecific bounded phage in the ELISA-Washer (Program "10OBN" with 
Nunc Maxisorbplatte, "10BONS2" with Nunc Maxisorb Stripes). 
Elute the bounded Phagen with 200 µl 10 µg/ml Trypsin for 30 min at 37°C [with basic 
Elution 150 µl 100 mM Triethylamin, 5 min at RT on the shaker (too long of an Incubation reduces the 
infectionality of the phage). Neutralize the Phage with 150 µl 1M Tris HCl pH7.5. With acidic Elution: 
150 µl HCl/Glycin 0,1 M pH 2,2, incubate 15 min on the shaker. Neutralize with150 µl Phosphate 
buffer pH 7,6]. 
Innoculate 50 ml 2xTY-T mit XL1-Blue . Take the colony up O.D.600 0,5. Take 20 ml 
and infect with 190 µl Phage, Incubate for 30 at 37°C. Centrifuge for 10 min at 4000 
rpm (3220xg). 
Titration Setup: 
Infect 50 µl der XL1-Blue Kultur with around 10 µl 10
-2
 -10
-8 
(after each panning 
round) Phage elution. Incubate for 30 min at 37°C and plate up the LB-Amp und 
incubate overnight at 37°C (see Protocol Titration Setup). 
--------------- 
Dissolve the pellet in 250 µl SOB-GA und coat on an SOB-GA Agarplatte (15 cm 
diameter). Incubate overnight at 37°C. 
On the next day, clean the Bacteria off with around 5 ml TY-GA (use Drigalski-
Spatula) and place in a Falcon. 
Innoculate 50 ml 2xTY-GA mit 50-200 µl Bacteria (O.D. 600<0,1). Incubate the colony 
at 37°C until the O.D.is between 0,4-0,5. Infect with 5 ml (~2,5*10
9
 bacteria) 
M13K07 a 1:20 ratio (5*10
10
 pfu) and incubate for 30 min at 37°C without shaking 
and 30 min at 200 rpm. 
Centrifuge the resulting bacteria at 4000 rpm (3220xg) for 5 min and place in Glycerin 
stocks with 20 % Glycerin. 
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In order to remove the glucose, (Phage will not build, if the Lac-Promotor is blocked), 
pellet the bacteria at 4000 rpm (3220xg) for 10 min (Eppendorf 5810R, Rotor A-4-81). 
Carefully resuspend the pellet in about 2xTY-AK  and add in 30 ml 2xTY-AK in a 
100 ml Erlenmeyer flask. Incubate overnight at 30°C and 250 rpm in the shaking 
incubator. 
Centrifuge the bacteria for 10 min at 4000 rpm (3220xg) at 4 °C in a falcon. 
Place the supernatant in a new falcon (if the supernatant is still cloudy, centrifuge the 
suspended bacteria again!) and precipitate the Phage particles with an additional 1/5 
Volume PEG/NaCl. Mix the supernatant and incubate for 1 h on a shaker in ice. 
Centrifuge for 1 h at 4000 rpm (3220xg) (Falcon) and 4 °C. 
Remove the PEG-dissolved efficiently (Tube above roll of papertowels). 
Resuspend the pellet in 500 µl Phage-Dilution Buffer and transfer to a 2 ml cap. 
Centrifuge the rest of the bacteria at 13,000 rpm for 1 min and transfer the supernatant 
to a 2 ml vial and incubate at 4°C or to begin the next panning round. 
Chemicals and  Compounds: 
 PBS pH 7,4 (8,0 g NaCl, 0,2 g KCl, 1,44 g Na2HPO4*2H2O, 0,24 g KH2PO4 
per 1 l) 
 DMSO 
 50 mM NaHCO3, pH 9,6 
 Streptavidn (Applichem) 
 PBST (PBS+ 0,1% Tween 20) 
 2 % MPBST (2 % milk powder in PBST, kept fresh) 
 Panning block (1 % milk powder + 1 % BSA in PBST, kept fresh) 
 10 µg/ml Trypsin in PBS 
 100 mM Triethylamin 
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 Phosphate buffer pH 7,6 (6 mM NaH2PO4, 50 mM Na2HPO4) 
 HCl/Glycin 0,1 M pH 2,2 
 1 M TrisHCl pH 7.5 
 2xTY-Medium pH 7,0 (1,6 % Tryptone, 1 % wheat extract, 0,5 % NaCl) 
 2xTY-T (2xTY + 50 µg/ml Tetracyclin) 
 2xTY-GA (2xTY + 100 mM Glucose + 100 µg/ml Ampicillin) 
 2xTY-AK (2xTY + 100 µg/ml Ampicillin + 50 µg/ml Kanamycin) 
 Mg-solution 2 M (1 M MgCl, 1 MgSO4) 
 SOB Medium pH 7,0 (2 % Tryptone, 0,5 % wheat extract, 0,05 % NaCl, sterile 
after autoclaving, before using 20 mM Mg-solution addition) 
 SOB-GA (SOB + 100 µg/ml Ampicilin + 100 mM Glucose) 
 2 M Mg-Lösung (1 M MgCl2 + 1 M MgSO4) 
 Ampicillin (100 mg/ml Stock) 
 Kanamycin (10 mg/ml Stock) 
 2 M Glucose (filtered sterile) 
 Glycerin 87%, autoclaved 
 PEG/NaCl (20% (w/v) PEG 6000 und 2,5 M NaCl) 
 Phage Dillution Buffer (10 mM TrisHCl pH7,5, 20 mM NaCl, 2 mM EDTA) 
Organisms: 
 VCS-M13 or M13K07 Helper phage or Hyper phage (Kanamycin-Resistance) 
 XL1-Blue MRF' (Tetracyclin Resistance) (Amber Suppressor Mutated (sup E)) 
 Phage bank Glycerol stock 
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Hint: XL1-Blue can be grown up to O.D. 0.5 und then kept on ice until infection (F-
Pili remains at 4°C) 
Materials and  tools: 
 Filtertips 
 50 ml Falcon 
 2 ml screw on vial 
 Immunotubes or Microtiter 8 row plates (250-300µl per well) (Nunc Maxisorb) 
 Microtiter plates or Stripes with bound Streptavidin 
 Petridish 15cm diameter 
 Eppendorf 5810R, Rotor A-4-81 
Work schedule for a panning round: 
Day 0: Antigen coating 
Day 1: Panning, Titration of the eluted phage, overnight growth of the eluted Ab-
phage 
Day 2: Overnight growth and amplification of the eluted phage 
Day 3: PEG-Precipitation of the phage, Titration of the amplified phage + antigen 
coating 
Day 4: Evaluation of the titration, next panning round 
M.Hust 11/16/05 
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B.2: Protocol for Phage Display with Micro Titer Plates (Translated from German)[144] 
Panning Ab-libraries: Panning in Immunotubes (MTPs) 
Coat the well with the antigen (5 µg Protein should be used for the first panning 
round, 0,5-5 µg or a constant 5 µg for the following rounds): Dissolve the protein in 
150 µl 1xPBS or NaHCO3-buffer (preferred) and place in a well. Incubate overnight at 
4°C. (with biotinylated antigens, coat 200 ng Streptavidin in 150 µl NaHCO3-buffer 
overnight at 4°C and wash away the next day the Streptavdin with the Washer and 
incubate the biotinylated Antigen for 45 min at RT in 50 µl PBS).] 
Remove the antigen solution.  
Completely fill in order to block the wells with 2%MPBST. Incubate at RT for 2 h. 
Wash with PBST in a 3xELISA-Washer (Program "3 N"). 
At the same time, block completely an empty well (without antigens) per round with 
panning block for1 h. 
Then pre-incubate 1x10
10
-1x10
12
 scFv-Phage from the library (with HAL7/8 around 
2,5x10
11
), or the amplified Phage from the previous panning round in 150 µl panning 
block for 1 h. 
Transter the phage from the pre-incubation wells into the wells with the antigen and 
incubate for 2h at RT. 
Remove the not or partially bound Phage in the ELISA-Washer (Program "10OBN" 
with Nunc Maxisorb plate, "10BONS2" with Nunc Maxisorb Stripes). The number of 
the washing repeats is based on the number of the panning round (ex. 2x wash with 2
nd
 
panning round). 
Elute bound scFv-Phage  with 200 µl 10 µg/ml Trypsin for 30 min at 37°C. 
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Innoculate 50 ml 2xTY-T mit XL1-Blue. Let the colony grow until  O.D.600 = 0.5. Add 
20 ml and infect with 200 µl eluted scFv-Phage in a 50 mL Falcon, incubate for 30 
min at 37°C for 10 min. 
Centrifuge at 4000 rpm (3220xg). 
Titration setup of the eluted phage: 
Plate 200 µL of the infected bacteria (10
-2
) und plate again 20 µL for the dilution  in 
PBS und around 100 µL (10
-4
 - 10
-6
).  Incubate overnight at 37°C (see protocol 
Titration setup). 
--------------- 
 
Dissolve the pellet in 250 µl 2xTY-GA und spread on a 2xTY-GA Agar plate (15 cm 
diameter). Incubate overnight at 37°C. 
The next day, suspend the bacteria with around 5 ml 2xTY-GA (use Drigalski-
Spatula) and transfer into a falcon. 
Innoculate 30 ml 2xTY-GA in a 100 mL flask with 50-200 µl bacteria (O.D. 600<0,1). 
Let the colony grow at 37°C until the O.D. is around 0,4-0,5. 5 ml (~2,5*10
9
 bacteria) 
infect with M13K07 in a 1:20  ratio (5*10
10
 pfu) incubate for 30 min at 37°C without 
shaking und 30 min at 200 rpm. 
Centrifuge the suspended bacteria at 4000 rpm (3220xg) for 5 min and place in 
Glycerin stocks with 20 % Glycerin. 
This step is common, but not necessary! 
--------------- 
In order to remove the glucose, (Phage will not build, if the Lac-Promotor is blocked), 
pellet the bacteria at 4000 rpm (3220xg) for 10 min (Eppendorf 5810R, Rotor A-4-81). 
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Carefully resuspend the pellet in about 2xTY-AK  and add in 30 ml 2xTY-AK in a 
100 ml Erlenmeyer flask. Incubate overnight at 30°C and 250 rpm in the shaking 
incubator. 
Centrifuge the bacteria for 10 min at 4000 rpm (3220xg) and 4 °C in a Falcon (if the 
supernatant is still cloudy, centruge the suspended bacteria again!). Take twice 1 mL 
supernatant (~1x10
12
 Phagen/mL), store at 4°C, or bzw. Directly add 100 µL + 50 µL 
panning block for the next panning round. Titrate the amplified phage to the control 
(see protocol: Titration steps). 
This step of the process is optional:  
Place the supernatant in a new falcon (if the supernatant is still cloudy, centruge the 
suspended bacteria again!) and precipitate the Phage particles with an additional 1/5 
Volume PEG/NaCl. Mix the supernatant and incubate for 1 h on a shaker in ice. 
Centrifuge for 1 h at 4000 rpm (3220xg) (Falcon) and 4 °C. 
Remove the PEG-dissolved efficiently (Tube above roll of papertowels). 
Resuspend the pellet in 500 µl Phage-Dilution Buffer and transfer to a 2 ml cap. 
Centrifuge the rest of the bacteria at 13,000 rpm for 1 min and transfer the 
supernatant to a 2 ml vial and incubate at 4°C or to begin the next panning round (see 
protocol: Titration steps). 
Chemicals and solutions: 
 PBS pH 7,4 (8,0 g NaCl, 0,2 g KCl, 1,44 g Na2HPO4*2H2O, 0,24 g KH2PO4 
per 1 l) 
 50 mM NaHCO3, pH 9,6 
 PBST (PBS+ 0,1% Tween 20) 
 2 % MPBST (2 % milk powder in PBST, kept fresh) 
 Panning block (1 % milk powder + 1 % BSA in PBST, kept fresh) 
 10 µg/ml Trypsin (Sigma T-0303) in PBS 
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 100 mM Triethylamin 
 Phosphate buffer pH 7,6 (6 mM NaH2PO4, 50 mM Na2HPO4) 
 HCl/Glycin 0,1 M pH 2,2 
 1 M TrisHCl pH 7.5 
 2xTY-Medium pH 7,0 (1,6 % Tryptone, 1 % wheat extract, 0,5 % NaCl) 
 2xTY-T (2xTY + 50 µg/ml Tetracyclin) 
 2xTY-GA (2xTY + 100 mM Glucose + 100 µg/ml Ampicillin) 
 2xTY-AK (2xTY + 100 µg/ml Ampicillin + 50 µg/ml Kanamycin) 
 2xTY-GA Agar plate (2xTY-GA + 1,5% Agar) 
 Ampicillin (100 mg/ml Stock) 
 Kanamycin (10 mg/ml Stock) 
 2 M Glucose (filtered sterile) 
 Glycerin 87%, autoclaved 
 PEG/NaCl (20% (w/v) PEG 6000 und 2,5 M NaCl) 
 Phage Dillution Buffer (10 mM TrisHCl pH7,5, 20 mM NaCl, 2 mM EDTA) 
Material und Tools: 
 Filtertips 
 50 ml Falcon 
 2 ml screw on vial 
 Immunotubes or Micro titer 8 row plate (250-300µl per well) (Nunc Maxisorb) 
 Streptavidin Immunotubes/MTPs/Stripes (Nunc) 
 Petri dish 15cm diameter 
 Eppendorf 5810R, Rotor A-4-81 
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 Tecan Columbus ELISA Washer  
 MTP shaker Vortemp56 (Labnet) oder Thermo Shaker PST-60HL-4 
(Lab4You) 
Organisms: 
 M13K07 Helper phage oder Hyper phage (Kanamycin-Resistant) 
 XL1-Blue MRF' (Tetracyclin Resistant) (Amber Suppressor Mutated (sup E)) 
 Phage bank Glycerol stock 
Hint: XL1-Blue can be grown up to O.D. 0.5 und then kept on ice until infection (F-
Pili remains at 4°C) 
Arbeitsablauf für eine Panningrunde: 
Work schedule for a panning round: 
Day 0: Antigen coating 
Day 1: Panning, Titration of the eluted phage, overnight growth of the eluted Ab-
phage 
Day 2: Overnight growth and amplification of the eluted phage 
Day 3: PEG-Precipitation of the phage, Titration of the amplified phage + antigen 
coating (optional) 
Day 4: Evaluation of the titration, next panning round 
M.Hust 09/12/11 
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B.3: Number of Colonies Obtained for Each Panning Round 
 
 104 105 106 Average* 
Tau Colonies Too Many 153 7 153 X 10
5 
Table B-1: Tau E. coli colonies after third panning round (panning in micro titer 
plates) 
 
 104 105 106 Average* 
Tau Colonies Too Many Too Many 330 ----
 
Table B-2: pTau E. coli colonies after third panning round (panning in micro titer 
plates) 
 
 104 105 106 Average* 
Tau Colonies 31 1 1 20.5 X 10
4 
Table B-3: pTau L1 with competition from Tau L1 E. coli colonies after third panning 
round (panning in micro titer plates) 
 
 104 105 106 Average* 
Tau Colonies 2 0 0 1.0 X 10
4 
Table B-4: pTau L2 with competition from Tau L2 E. coli colonies after third panning 
round (panning in micro titer plates) 
 
* The average values were taken from the average between the 104 and 105 counts.  
This was performed with the formula ((104 coefficient) + 10 x (105 coefficient)) / 2.  
The resulting coefficient is multiplied by 104 to obtain the average result. 
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